{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Exploration of original cases"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "In this notebook we explore the characteristics of the original artificial cases datasets. We aim to answer the following questions:\n",
    "- How many cases are there?\n",
    "- How long are they?\n",
    "- How many unique tokens are there?\n",
    "- Are all of they structured in the same way?\n",
    "\n",
    "We also have some metadata about the cases containing the MeSH terms in it. We will explore the distribution of these terms in the cases."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import os\n",
    "\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "main_path = \"data/1_original/txt\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'A 64-year-old female lifelong smoker with no previous cardiac history presented with a 4-day history of dyspnoea on minimal exertion (New York Heart Association class III). Electrocardiography showed broad complex monophasic ventricular tachycardia (VT) and troponin T was elevated. She was treated initially with intravenous amiodarone and adenosine with no sustained effect.\\n\\nTransthoracic echocardiography showed a severely dilated left ventricle (LV) with a large aneurysm and severely impaired ventricular function. The ejection fraction was less than 10%. Coronary angiography showed a long segment of moderate to severe disease in the left coronary system and a small right coronary artery with no flow limiting disease. Recurrent intermittent episodes of VT became persistent and intractable. Direct current cardioversion was attempted on at least 20 separate occasions, resulting in only transient amelioration of arrhythmia. Percutaneous coronary intervention was undertaken successfully to the left anterior descending artery to reduce ischaemic burden. Multiple defibrillations were required during the procedure. Intra-aortic counterpulsation balloon pump and transvenous pacing were inserted owing to increasing haemodynamic instability of the patient and VT unresponsive to medical treatment.\\n\\nThe patient underwent emergency remodelling of the LV combined with subendocardial resection of the arrhythmogenic scar tissue. LV remodelling was accomplished by insertion of an elliptical patch of porcine pericardium at the junction of the normal myocardium and scar tissue. The operation was guided by three-dimensional transoesophageal echocardiography (TOE).\\n\\nThe immediate postoperative TOE showed an ejection fraction of 67.2% (10% preoperatively) and estimated LV stroke volume of 58.2ml. The patient made an uneventful recovery from surgery with complete resolution of VT. She was discharged home ten days later.\\n\\n'"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "filename = os.path.join(main_path, \"25350173.txt\")\n",
    "content = open(filename, \"r\").read()\n",
    "\n",
    "content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package punkt_tab to\n",
      "[nltk_data]     C:\\Users\\alber\\AppData\\Roaming\\nltk_data...\n",
      "[nltk_data]   Package punkt_tab is already up-to-date!\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import nltk\n",
    "nltk.download('punkt_tab')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Data Exploration"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Amount of data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "There are 1000 clinical cases\n"
     ]
    }
   ],
   "source": [
    "n_cc = len(os.listdir(main_path))\n",
    "print(\"There are {} clinical cases\".format(n_cc))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_txt(path, filename):\n",
    "    total_path = os.path.join(path, filename)\n",
    "    return filename, open(total_path, \"r\", encoding=\"utf8\").read()\n",
    "\n",
    "filename = \"25350173.txt\"\n",
    "\n",
    "def files_to_df(path, extensions=[\"txt\"]):\n",
    "    files = [x for x in os.listdir(path) if x.split(\".\")[-1] in extensions]\n",
    "    data = [extract_txt(path, f) for f in files]\n",
    "    return pd.DataFrame(data, columns=[\"filename\", \"text\"])\n",
    "\n",
    "df = files_to_df(main_path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>filename</th>\n",
       "      <th>text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>25350173.txt</td>\n",
       "      <td>A 64-year-old female lifelong smoker with no p...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>25531204.txt</td>\n",
       "      <td>A 28-year-old man presented to the Emergency D...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>25654384.txt</td>\n",
       "      <td>A 64-year-old female patient with a history of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>25679083.txt</td>\n",
       "      <td>Josephine was a 70-year-old white woman measur...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>25725033.txt</td>\n",
       "      <td>An 85-year-old woman reported sudden onset dys...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       filename                                               text\n",
       "0  25350173.txt  A 64-year-old female lifelong smoker with no p...\n",
       "1  25531204.txt  A 28-year-old man presented to the Emergency D...\n",
       "2  25654384.txt  A 64-year-old female patient with a history of...\n",
       "3  25679083.txt  Josephine was a 70-year-old white woman measur...\n",
       "4  25725033.txt  An 85-year-old woman reported sudden onset dys..."
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\alber\\Documents\\GitHub\\MultiSynDS\\.venv\\lib\\site-packages\\tqdm\\auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n",
      "None of PyTorch, TensorFlow >= 2.0, or Flax have been found. Models won't be available and only tokenizers, configuration and file/data utilities can be used.\n"
     ]
    }
   ],
   "source": [
    "# Include the number of RoBERTa tokens\n",
    "from transformers import GPT2TokenizerFast\n",
    "\n",
    "tokenizer = GPT2TokenizerFast.from_pretrained(\"gpt2\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Token indices sequence length is longer than the specified maximum sequence length for this model (1052 > 1024). Running this sequence through the model will result in indexing errors\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>filename</th>\n",
       "      <th>text</th>\n",
       "      <th>n_char</th>\n",
       "      <th>n_words</th>\n",
       "      <th>n_sentences</th>\n",
       "      <th>n_tokens</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>25350173.txt</td>\n",
       "      <td>A 64-year-old female lifelong smoker with no p...</td>\n",
       "      <td>1932</td>\n",
       "      <td>295</td>\n",
       "      <td>16</td>\n",
       "      <td>419</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>25531204.txt</td>\n",
       "      <td>A 28-year-old man presented to the Emergency D...</td>\n",
       "      <td>3174</td>\n",
       "      <td>573</td>\n",
       "      <td>24</td>\n",
       "      <td>849</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>25654384.txt</td>\n",
       "      <td>A 64-year-old female patient with a history of...</td>\n",
       "      <td>3714</td>\n",
       "      <td>622</td>\n",
       "      <td>20</td>\n",
       "      <td>897</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>25679083.txt</td>\n",
       "      <td>Josephine was a 70-year-old white woman measur...</td>\n",
       "      <td>4772</td>\n",
       "      <td>821</td>\n",
       "      <td>29</td>\n",
       "      <td>1052</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>25725033.txt</td>\n",
       "      <td>An 85-year-old woman reported sudden onset dys...</td>\n",
       "      <td>1915</td>\n",
       "      <td>335</td>\n",
       "      <td>17</td>\n",
       "      <td>492</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       filename                                               text  n_char  \\\n",
       "0  25350173.txt  A 64-year-old female lifelong smoker with no p...    1932   \n",
       "1  25531204.txt  A 28-year-old man presented to the Emergency D...    3174   \n",
       "2  25654384.txt  A 64-year-old female patient with a history of...    3714   \n",
       "3  25679083.txt  Josephine was a 70-year-old white woman measur...    4772   \n",
       "4  25725033.txt  An 85-year-old woman reported sudden onset dys...    1915   \n",
       "\n",
       "   n_words  n_sentences  n_tokens  \n",
       "0      295           16       419  \n",
       "1      573           24       849  \n",
       "2      622           20       897  \n",
       "3      821           29      1052  \n",
       "4      335           17       492  "
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"n_char\"] = df[\"text\"].str.len()\n",
    "df[\"n_words\"] = df[\"text\"].apply(lambda x: len(nltk.word_tokenize(x))).astype(int)\n",
    "df[\"n_sentences\"] = df[\"text\"].apply(lambda x: len(nltk.sent_tokenize(x))).astype(int)\n",
    "df[\"n_tokens\"] = df[\"text\"].apply(lambda x: len(tokenizer(x)[\"input_ids\"]))\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>filename</th>\n",
       "      <th>text</th>\n",
       "      <th>n_char</th>\n",
       "      <th>n_words</th>\n",
       "      <th>n_sentences</th>\n",
       "      <th>n_tokens</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>261</th>\n",
       "      <td>31326486_2.txt</td>\n",
       "      <td>A 52-year-old diabetic woman with a non-ST-seg...</td>\n",
       "      <td>445</td>\n",
       "      <td>76</td>\n",
       "      <td>5</td>\n",
       "      <td>117</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>26512038.txt</td>\n",
       "      <td>We present a case of a 34-year-old man with ac...</td>\n",
       "      <td>511</td>\n",
       "      <td>82</td>\n",
       "      <td>6</td>\n",
       "      <td>137</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>133</th>\n",
       "      <td>30180978_2.txt</td>\n",
       "      <td>A similar case of postpartum cardiomyopathy in...</td>\n",
       "      <td>573</td>\n",
       "      <td>87</td>\n",
       "      <td>6</td>\n",
       "      <td>134</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>29437819.txt</td>\n",
       "      <td>A 67-year-old man with a history of non-ischae...</td>\n",
       "      <td>616</td>\n",
       "      <td>101</td>\n",
       "      <td>4</td>\n",
       "      <td>149</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>28960929_2.txt</td>\n",
       "      <td>A 65‐year‐old man, apparently healthy, was adm...</td>\n",
       "      <td>596</td>\n",
       "      <td>106</td>\n",
       "      <td>6</td>\n",
       "      <td>173</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "           filename                                               text  \\\n",
       "261  31326486_2.txt  A 52-year-old diabetic woman with a non-ST-seg...   \n",
       "11     26512038.txt  We present a case of a 34-year-old man with ac...   \n",
       "133  30180978_2.txt  A similar case of postpartum cardiomyopathy in...   \n",
       "49     29437819.txt  A 67-year-old man with a history of non-ischae...   \n",
       "38   28960929_2.txt  A 65‐year‐old man, apparently healthy, was adm...   \n",
       "\n",
       "     n_char  n_words  n_sentences  n_tokens  \n",
       "261     445       76            5       117  \n",
       "11      511       82            6       137  \n",
       "133     573       87            6       134  \n",
       "49      616      101            4       149  \n",
       "38      596      106            6       173  "
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.sort_values(by=[\"n_words\", \"n_sentences\"], ascending=True).head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>filename</th>\n",
       "      <th>text</th>\n",
       "      <th>n_char</th>\n",
       "      <th>n_words</th>\n",
       "      <th>n_sentences</th>\n",
       "      <th>n_tokens</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>187</th>\n",
       "      <td>30785587.txt</td>\n",
       "      <td>A 51-year-old male, hypertensive patient, a fo...</td>\n",
       "      <td>14524</td>\n",
       "      <td>2649</td>\n",
       "      <td>84</td>\n",
       "      <td>3777</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>531</th>\n",
       "      <td>33544806.txt</td>\n",
       "      <td>Clinical history\\n\\nFour years before the admi...</td>\n",
       "      <td>12664</td>\n",
       "      <td>2206</td>\n",
       "      <td>91</td>\n",
       "      <td>3114</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>139</th>\n",
       "      <td>30226919.txt</td>\n",
       "      <td>The patient is a 60-year-old female with Chaga...</td>\n",
       "      <td>11508</td>\n",
       "      <td>2146</td>\n",
       "      <td>81</td>\n",
       "      <td>3062</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>269</th>\n",
       "      <td>31378248.txt</td>\n",
       "      <td>A 50-year-old man presented to his primary car...</td>\n",
       "      <td>12879</td>\n",
       "      <td>2135</td>\n",
       "      <td>83</td>\n",
       "      <td>2895</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>357</th>\n",
       "      <td>32111708.txt</td>\n",
       "      <td>A 66-year-old multiparous, postmenopausal woma...</td>\n",
       "      <td>12251</td>\n",
       "      <td>2109</td>\n",
       "      <td>92</td>\n",
       "      <td>3011</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         filename                                               text  n_char  \\\n",
       "187  30785587.txt  A 51-year-old male, hypertensive patient, a fo...   14524   \n",
       "531  33544806.txt  Clinical history\\n\\nFour years before the admi...   12664   \n",
       "139  30226919.txt  The patient is a 60-year-old female with Chaga...   11508   \n",
       "269  31378248.txt  A 50-year-old man presented to his primary car...   12879   \n",
       "357  32111708.txt  A 66-year-old multiparous, postmenopausal woma...   12251   \n",
       "\n",
       "     n_words  n_sentences  n_tokens  \n",
       "187     2649           84      3777  \n",
       "531     2206           91      3114  \n",
       "139     2146           81      3062  \n",
       "269     2135           83      2895  \n",
       "357     2109           92      3011  "
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.sort_values(by=[\"n_words\", \"n_sentences\"], ascending=False).head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Axes: xlabel='n_words', ylabel='n_sentences'>"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df.plot.scatter(x=\"n_words\", y=\"n_sentences\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>n_char</th>\n",
       "      <th>n_words</th>\n",
       "      <th>n_sentences</th>\n",
       "      <th>n_tokens</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>1000.000000</td>\n",
       "      <td>1000.000000</td>\n",
       "      <td>1000.000000</td>\n",
       "      <td>1000.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>3731.179000</td>\n",
       "      <td>638.256000</td>\n",
       "      <td>28.116000</td>\n",
       "      <td>888.068000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>1991.746719</td>\n",
       "      <td>342.448611</td>\n",
       "      <td>15.070955</td>\n",
       "      <td>482.138234</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>445.000000</td>\n",
       "      <td>76.000000</td>\n",
       "      <td>4.000000</td>\n",
       "      <td>117.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>2272.500000</td>\n",
       "      <td>385.000000</td>\n",
       "      <td>17.000000</td>\n",
       "      <td>546.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>3467.500000</td>\n",
       "      <td>594.000000</td>\n",
       "      <td>26.000000</td>\n",
       "      <td>827.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>4663.250000</td>\n",
       "      <td>793.250000</td>\n",
       "      <td>35.000000</td>\n",
       "      <td>1104.250000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>14524.000000</td>\n",
       "      <td>2649.000000</td>\n",
       "      <td>132.000000</td>\n",
       "      <td>3777.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             n_char      n_words  n_sentences     n_tokens\n",
       "count   1000.000000  1000.000000  1000.000000  1000.000000\n",
       "mean    3731.179000   638.256000    28.116000   888.068000\n",
       "std     1991.746719   342.448611    15.070955   482.138234\n",
       "min      445.000000    76.000000     4.000000   117.000000\n",
       "25%     2272.500000   385.000000    17.000000   546.500000\n",
       "50%     3467.500000   594.000000    26.000000   827.500000\n",
       "75%     4663.250000   793.250000    35.000000  1104.250000\n",
       "max    14524.000000  2649.000000   132.000000  3777.000000"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>n_sentences</th>\n",
       "      <th>n_words</th>\n",
       "      <th>n_tokens</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>9</td>\n",
       "      <td>410</td>\n",
       "      <td>575</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>19</td>\n",
       "      <td>595</td>\n",
       "      <td>837</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>20</td>\n",
       "      <td>507</td>\n",
       "      <td>734</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>9</td>\n",
       "      <td>456</td>\n",
       "      <td>632</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>11</td>\n",
       "      <td>430</td>\n",
       "      <td>669</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>995</th>\n",
       "      <td>20</td>\n",
       "      <td>502</td>\n",
       "      <td>701</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>996</th>\n",
       "      <td>25</td>\n",
       "      <td>608</td>\n",
       "      <td>860</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>997</th>\n",
       "      <td>17</td>\n",
       "      <td>545</td>\n",
       "      <td>760</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>998</th>\n",
       "      <td>23</td>\n",
       "      <td>477</td>\n",
       "      <td>640</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>999</th>\n",
       "      <td>26</td>\n",
       "      <td>593</td>\n",
       "      <td>821</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1000 rows × 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     n_sentences  n_words  n_tokens\n",
       "0              9      410       575\n",
       "1             19      595       837\n",
       "2             20      507       734\n",
       "3              9      456       632\n",
       "4             11      430       669\n",
       "..           ...      ...       ...\n",
       "995           20      502       701\n",
       "996           25      608       860\n",
       "997           17      545       760\n",
       "998           23      477       640\n",
       "999           26      593       821\n",
       "\n",
       "[1000 rows x 3 columns]"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_ds = pd.read_csv(\"nbs/data/en/ds_en_length.csv\")\n",
    "df_ds"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1500x500 with 3 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "labelsize = 16\n",
    "titlesize = 20\n",
    "\n",
    "fig, ax = plt.subplots(1, 3, figsize=(15, 5), sharey=True)\n",
    "df[\"n_words\"].hist(bins=50, ax=ax[0], label=\"Original\", color=\"blue\", alpha=0.5)\n",
    "df_ds[\"n_words\"].hist(bins=25, ax=ax[0], alpha=0.7, label=\"DS\", color=\"orange\")\n",
    "# df[\"n_sentences\"].hist(bins=50, ax=ax[1])\n",
    "df[\"n_sentences\"].hist(bins=50, ax=ax[1], label=\"Original\", color=\"blue\", alpha=0.5)\n",
    "df_ds[\"n_sentences\"].hist(bins=25, ax=ax[1], alpha=0.7, label=\"DS\", color=\"orange\")\n",
    "\n",
    "df[\"n_tokens\"].hist(bins=50, ax=ax[2], label=\"Original\", color=\"blue\", alpha=0.5)\n",
    "df_ds[\"n_tokens\"].hist(bins=25, ax=ax[2], alpha=0.7, label=\"DS\", color=\"orange\")\n",
    "\n",
    "ax[0].set_xlabel(\"Number of words\", fontsize=labelsize)\n",
    "ax[1].set_xlabel(\"Number of sentences\", fontsize=labelsize)\n",
    "ax[2].set_xlabel(\"Number of tokens\", fontsize=labelsize)\n",
    "\n",
    "ax[0].set_ylabel(\"Frequency\", fontsize=labelsize)\n",
    "\n",
    "ax[0].tick_params(axis='both', which='major', labelsize=labelsize)\n",
    "ax[1].tick_params(axis='both', which='major', labelsize=labelsize)\n",
    "ax[2].tick_params(axis='both', which='major', labelsize=labelsize)\n",
    "\n",
    "fig.suptitle(\"Length distribution of original clinical cases vs discharge summaries\", fontsize=titlesize)\n",
    "\n",
    "fig.savefig(\"img/data_analysis/words_sentences.png\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "|       |   n_words |   n_sentences |   n_tokens |\n",
      "|:------|----------:|--------------:|-----------:|\n",
      "| count |  1000     |      1000     |   1000     |\n",
      "| mean  |   638.256 |        28.116 |    888.068 |\n",
      "| std   |   342.449 |        15.071 |    482.138 |\n",
      "| min   |    76     |         4     |    117     |\n",
      "| 25%   |   385     |        17     |    546.5   |\n",
      "| 50%   |   594     |        26     |    827.5   |\n",
      "| 75%   |   793.25  |        35     |   1104.25  |\n",
      "| max   |  2649     |       132     |   3777     |\n"
     ]
    }
   ],
   "source": [
    "print(df[[\"n_words\", \"n_sentences\", \"n_tokens\"]].describe().to_markdown())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "|       |   n_words |   n_sentences |   n_tokens |\n",
      "|:------|----------:|--------------:|-----------:|\n",
      "| count | 1000      |    1000       |   1000     |\n",
      "| mean  |  539.579  |      19.907   |    752.914 |\n",
      "| std   |   97.6045 |       6.55464 |    147.162 |\n",
      "| min   |  189      |       1       |    243     |\n",
      "| 25%   |  480      |      16       |    667     |\n",
      "| 50%   |  548      |      20       |    762.5   |\n",
      "| 75%   |  602      |      24       |    851.25  |\n",
      "| max   |  829      |      48       |   1172     |\n"
     ]
    }
   ],
   "source": [
    "print(df_ds[[\"n_words\", \"n_sentences\", \"n_tokens\"]].describe().to_markdown())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Patient: Male, 63-year-old\n",
      "\n",
      "\n",
      "Final Diagnosis:\n",
      "• Amyloid light-chain amyloidosis\n",
      "• cardiac amyloidosis\n",
      "• cardiomyopathy\n",
      "• heart failure\n",
      "• primary AL amyloidosis\n",
      "\n",
      "\n",
      "Symptoms:\n",
      "• Aphasia\n",
      "• dyspnea\n",
      "• heart failure\n",
      "• thrombosis\n",
      "• tongue mass\n",
      "\n",
      "Clinical Procedure:\n",
      "• Biopsy\n",
      "• chemotherapy\n",
      "• echocardiography\n",
      "\n",
      "Patient was admitted for newly diagnosed heart failure with high levels of natriuretic peptides and chronically elevated troponin values. During standard treatment, he had experienced transitory aphasia without structural cerebral damage and recovered completely. ECG showed low voltage in the limb leads with a pseudoinfarction pattern in the precordial leads. That finding along with the patient’s clinical presentation (periorbital hematoma, thickened tongue, proteinuria below the nephrotic range, and a decreased glomerular filtration rate) and echo findings were highly suspicious for amyloidosis.\n",
      "\n",
      "Spontaneous echo contrast was detected in the man’s heart cavities, possibly explaining his recent cardioembolic cerebral event despite sinus rhythm. Monoclonal protein–immunoglobulin G (IgG) and lambda light chains were detected on further hematological workup (serum and urine protein immunofixation, serum kappa/lambda free light chain [FLC] ratio). Bone marrow biopsy confirmed the diagnosis of multiple myeloma: 20% CD138+ atypical plasma cells with Congo red-positive amyloid infiltrates. Chemotherapy was started, but unfortunately, the patient died 2 months later from refractory heart failure.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(df[df[\"n_words\"] < 500].text.values[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "30567249.txt\n",
      "A 74-year-old man underwent primary percutaneous coronary intervention (pPCI) for a completely occluded proximal left anterior descending artery. During the procedure, microvascular flow distal to the block could not be established (no-reflow phenomenon) and thus was managed with diltiazem and nicorandil. A follow-up echocardiogram performed on the next day revealed an intraparietal echolucent apicolateral neocavitation corresponding to an intramyocardial haematoma (IMH) along with reduced ejection fraction (EF) of 30% as compared with 45% per intervention. At 1 month follow-up, he went into congestive heart failure with a further decline in EF to 25%. Although the IMH was resolving, left ventricular apex had ballooned out. At 3 months, he was rehospitalised with a storm of ventricular tachycardia and further deterioration in EF with an apical aneurysm, and finally passed away.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "example_1 = df[df[\"n_words\"] < 300].iloc[101]\n",
    "print(example_1.filename)\n",
    "print(example_1.text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "In November 1990, a 25‐year‐old male patient with terminal heart failure due to endomyocardial fibrosis following myocarditis underwent transplantation at our institution using the heterotopic transplant technique. The primary indication for this approach was pulmonary hypertension. The post‐operative course was uneventful.\n",
      "\n",
      "The patient's clinical condition has been monitored in 3‐month intervals since then. The routinely conducted laboratory investigations comprised complete blood count, coagulation, liver and renal function panels, serological examinations, inflammatory parameters, and N‐terminal prohormone of brain natriuretic peptide (NT‐proBNP). Transthoracic echocardiograms were obtained every 6 months or if clinically indicated.\n",
      "\n",
      "The patient was in stable condition at the most recent presentation and had no relevant impairment according to the New York Heart Association functional classification (NYHA I–II). During the assessment of the aerobic capacity, he was able to achieve a 6‐min walk distance of 700 m. An electrocardiogram showed a parasystole with a ventricular rate of the allograft of 85 per minute. The most recent non‐invasive assessment of the allograft using magnetic resonance imaging was performed 6 months before the current follow‐up. The graft showed a normal‐sized left and right ventricles with normal systolic function and no late gadolinium enhancement. The native heart, even though severely impaired and minimally perfused during contrast administration (compared with the graft), showed impaired contractility, however, without signs of intracavitary thrombosis. Due to the different heart rates, ECG triggering and subsequent artefact‐free CMR images could only be achieved for one of the two hearts.\n",
      "\n",
      "\n",
      "The clinical evaluation of the patient delivered no evidence of pulmonary obstruction or restriction. The last radiographic assessment of the lungs showed no signs of congestion or other pathological pulmonary findings.\n",
      "\n",
      "Laboratory assessment revealed normal serum pseudocholinesterase level, thus precluding relevant impairment of the liver's synthetic function. The renal function was slightly reduced (estimated glomerular filtration rate 67 mL/min/m2) according to the NKF classification of chronic kidney disease but stable over the last years. To maintain a well‐compensated volume status, he was taking low‐dose torasemide (5 mg/day).\n",
      "\n",
      "The maintenance immunosuppressive medication was based on cyclosporine A (CsA) with a lower target level due to the prolonged follow‐up and prednisone with a daily dose of 5 mg. Additionally, diltiazem was prescribed as a CsA‐sparing agent (120 mg/day). 5 The mean maintenance trough level of CsA was 107.1 ± 14.5 ng/ml (an average of the last 10 measures). The remaining medication included vitamin D and a vitamin K antagonist. The virological examination revealed negative results concerning the CMV‐DNA, EBV‐DNA, HSV‐1‐DNA, HSV‐2‐DNA, and VZV‐DNA. The percentage of panel reactive antibodies was 7% in the first year and 0% in the following years after HHT.\n",
      "\n",
      "The patient's history since HHT included a knee hematoma while being on heparin, a cholecystectomy, and a partial amputation of a small finger due to trauma.\n",
      "\n",
      "In the years following HHT, the patient underwent at least 30 invasive examinations of the graft's coronary circulation and/or haemodynamic (at least 14 coronary angiographies and 24 right heart catheterizations with/without biopsy sampling). Neither of the angiographies showed signs of coronary artery disease of the native heart or vasculopathy of the allograft.\n",
      "\n",
      "Furthermore, the obtained biopsies delivered no evidence of rejection requiring therapy (≥2R) according to the revised classification of the ISHLT from 2004. One year following HHT, narrowing the pulmonary artery anastomosis was described. However, no further progression of the obstruction or deterioration of the right ventricular function in the following 30 years was observed, and the haemodynamic measures were stable.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(df[df[\"n_words\"].between(600, 800)].text.values[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The patient was a 92-year-old man who had long been treated for chronic kidney disease with renal anemia, atrial fibrillation with a slow ventricular response, and chronic heart failure of unknown cause. He was admitted to a local hospital because of progressive shortness of breath and systemic edema. He was treated with intravenous diuretics, but the response to treatment was unsatisfactory. Moreover, his renal function progressively deteriorated as a consequence of the administration of high-dose diuretics. At that point, he was transferred to our hospital for further treatment.\n",
      "\n",
      "On admission, his blood pressure was 98/48 mmHg, his heart rate was 44 beats/min, and his oxygen saturation was 96% (room air). Cardiac auscultation revealed bradycardia with an irregular rhythm, a prominent second heart sound with fixed splitting, and a Levine III/VI systolic regurgitant murmur in the fourth intercostal space. On inspection, he had severe leg edema extending from the foot to thigh level, prominent jugular venous distention, and abdominal distention, which was consistent with right heart failure. Chest radiography showed enlargement of the cardiac silhouette and bilateral pulmonary effusion. Electrocardiography demonstrated complete right bundle branch block and atrial fibrillation with a slow ventricular response. Transthoracic echocardiography revealed significant dilatation of the right atrium and ventricle, which resulted in dilatation of the tricuspid annulus and severe tricuspid regurgitation. Furthermore, distention of the inferior vena cava to 30 mm in diameter was observed without a visible respiratory change. Doppler echocardiography revealed an increased pressure gradient of 45 mmHg across the tricuspid valve, consistent with pulmonary hypertension. Unexpectedly, from the subxiphoid view, a 13×10 mm ostium secundum ASD with left-to-right shunt was detected, and the pulmonary-to-systemic-blood-flow ratio was 2.36. Transesophageal echocardiography confirmed a 13×13 mm stium secundum ASD next to the sinus of Valsalva with a dominant left-to-right, bidirectional shunt. A cardiac catheter examination showed a pulmonary artery pressure of 34/8 mmHg (mean pressure 16 mmHg), pulmonary vascular resistance of 84 dyn·s·cm5, and a significant step-up of oxygen saturation from the superior vena cava (75%) to the right ventricle (91%).\n",
      "\n",
      "Radiography and electrocardiography of the 92-year-old male patient with heart failure of unknown cause. A chest radiograph obtained on admission shows significant cardiomegaly and bilateral pleural effusion. An electrocardiogram obtained on admission shows atrial fibrillation with a slow ventricular response.\n",
      "\n",
      "Transthoracic echocardiography on admission of the 92-year-old male patient with heart failure of unknown cause. Both the right ventricle and atrium are significantly dilated with concomitant tricuspid annular dilatation. Severe tricuspid regurgitation is visible. The pressure gradient across the tricuspid value was 45 mmHg, indicating pulmonary arterial hypertension. Subxyphoid view: The ostium secundum atrial septal defect was clearly visible. SVC: superior vena cava, IVC: inferior vena cava, RA: right atrium, RV: right ventricle, LA: left atrium, LV: left ventricle, ASD: atrial septal defect\n",
      "\n",
      "Transesophageal echocardiography of the 92-year-old male patient with an ostium secundum atrial septal defect (ASD). A preoperative mid-esophageal sagittal view shows an ostium secundum ASD. The M-mode echocardiogram clearly shows a dominant left-to-right shunt through the ASD with a small right-to-left shunt during early systole. A preoperative mid-esophageal aortic valve short-axis view shows an ostium secundum ASD next to the sinus of Valsalva. Intraoperatively, the size of the ASD was measured using a sizing balloon and a Figulla Flex II® (21 mm) occluder was successfully deployed. ASD: atrial septal defect\n",
      "\n",
      "\n",
      "Subsequently, the patient's heart failure proved to be refractory to the best-practice treatment with cardiotonic drugs [intravenous dobutamine (3.5 μg/kg/min)], high-dose diuretics [furosemide (20 mg/day) and tolvaptan (15 mg/day)], and of warfarin (2 mg/day). Further complicating the situation, the patient's renal function progressively deteriorated during this treatment, which negatively affected the hemodynamic control. In this case, the intractable heart failure was attributable to the combined hemodynamic disturbances, including an ostium secundum ASD with a large shunt burden, secondary tricuspid regurgitation, and atrial fibrillation with a slow ventricular response. The ASD was considered to play a central role in the condition of the patient. After a thorough discussion within the heart team, transcatheter closure was scheduled despite the fact that the patient was a nonagenarian with multiple comorbidities. On the 32nd hospital day, this procedure was performed under general anesthesia. Using an 18-mm balloon, a pre-procedural occlusion test was performed under right-sided catheter monitoring. This revealed the absence of a hemodynamic exacerbation. Because the measured defect size was 15.5 mm in diameter, to completely enclose the sinus of Valsalva, a Figulla Flex IIⓇ occluder device (21 mm, Occlutech, Jena, Germany) was finally selected and successfully deployed without any complications (Fig. 3C). After device implantation, only clopidogrel (75 mg/day) was prescribed on top of warfarin to avoid the hemorrhagic complications.\n",
      "\n",
      "Immediately after ASD closure, the patient's hemodynamics became controllable without the need for inotropic medication or intravenous diuretics, and his renal function gradually improved. The patient was discharged on the 9th day after ASD closure.\n",
      "\n",
      "Surprisingly, the patient's heart returned to sinus rhythm, and not only the cardiomegaly but also the bilateral pleural effusion showed significant improvement at one month after ASD closure. Moreover, despite the long-term volume overload, the right heart showed significant reverse remodeling, and the cardiac output markedly improved from 2.8 L/min to 4.4 L/min. At 10 months after ASD closure, his heart failure symptoms showed a marked improvement to NYHA functional class I. At present, he is caring for his sick wife in their own home.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(df[df[\"n_words\"].between(900, 1100)].text.values[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "A 50-year-old male with a medical history of hypertension, gastro-oesophageal reflux disease, gout, hypothyroidism and anxiety presented to the emergency department with a 4-month history of progressive New York Heart Association (NYHA) class IV heart failure symptoms including dyspnoea, orthopnoea and paroxysmal nocturnal dyspnoea. He had been previously well, but recovered from a viral prodrome the previous month. He was a lifetime non-smoker, non-alcohol consumer and no other illicit drug use. His family history included an unspecified cardiac septal defect. On examination, the patient was afebrile, appearing comfortable in no distress on 3 L of nasal cannula oxygen, with normal blood oxygen saturations, a blood pressure of 119/79 mm Hg, heart rate of 104 bpm and normal respiratory rate. He had normal S1 and prominent S2 heart sounds with an S3 gallop and his jugular venous pressure (JVP) was elevated to the level of his earlobes, with course crackles in his chest. His abdomen was soft and nontender with no organomegaly and he had pitting oedema in his lower legs.\n",
      "\n",
      "He had multiple episodes of pronounced gait unsteadiness and at times would experience mechanical falls. These symptoms had been there throughout his adolescence and he endorsed he would require more upper limb strength to lift him off a chair and if on the floor he would need to get on his limbs first and push up with his arms. He also mentioned that as a child he would get muscle weakness and cramping during activity and had large calves. His neurological examination yielded a normal cranial nerve examination, reflexes were 2+ and symmetric with downgoing plantars bilaterally. His sensation was also grossly normal. He had atrophy of his quadriceps bilaterally, calf hypertrophy and normal strength in the upper extremities. He had mild weakness in his hip flexors (4/5) and hip abductors (4+/5), quadriceps (4+/5) and hamstrings (4/5) with preserved full distal strength in his lower extremities (graded in MRC muscle power scale). He had a waddling gait.\n",
      "\n",
      "\n",
      "Investigations\n",
      "\n",
      "ECG showed normal sinus rhythm, evidence of left atrial enlargement and left anterior fascicular block, with no signs of acute or chronic ischaemia or infarction. Transthoracic echocardiogram (TTE) showed severe LV dysfunction with moderate secondary mitral regurgitation (MR) with an estimated ejection fraction (EF) of 20% and right ventricular systolic pressure (RVSP) of 74 mm Hg. CT coronary angiogram and pulmonary embolism study (CT-CA) that showed no significant epicardial coronary artery disease and no evidence of pulmonary emboli. He had a negative haemochromatosis workup. His initial telemetry findings showed few runs of asymptomatic non-sustained ventricular tachycardia (NSVT).\n",
      "\n",
      "His 24-hour outpatient Holter was unremarkable. Cardiac MRI showed gross dilation of the LV with an EF of 17%. The LV was thin and hypertrabeculated in the anterior, lateral and inferior segments with delayed enhancement, suggestive of LVNC. His repeat TTE showed severe global reduced LV function with EF of 20%–25%, LV dilation and eccentric hypertrophy with grade II diastolic dysfunction. The RV was hypokinetic with RVSP of 40 mm Hg, restricted mitral leaflets and mild MR and tricuspid regurgitation. The atria were also mildly dilated. Given the findings of new onset heart failure and the delayed enhancement seen on cardiac MRI, a CA was performed, which demonstrated normal coronary arteries and left ventriculogram showing severe global hypokinesis and EF of 15%–20%. Contrast echocardiogram showed features consistent with LVNC.\n",
      "\n",
      "On review, the patient had recurrent syncopal episodes, prompting further risk stratification for sudden cardiac death (SCD), as well as candidacy for an implantable cardiac defibrillator (ICD). An 123I- Meta-iodobenzylguanidine (MIBG) scintigraphy scan showed decreased cardiac 123I-MIBG activity suggestive of moderate to severe cardiac sympathetic denervation, implying high risk for SCD.\n",
      "\n",
      "With regard to his muscular weakness, he had a normal CT brain and normal MRI brain and spine. He subsequently had an electromyogram (EMG) showing features consistent with nonspecific proximal lower extremity predominant myopathy, which led to a left quadriceps muscle biopsy. Histological examination revealed skeletal muscle with increased epimysial and perimysial fibroadipose tissue. An increased range of muscle fibre dimensions was evident, with many hypertrophic fibres measuring up to 150 µm in diameter, along with scattered single and very small collections of muscle fibres. Larger fibres were commonly rounded in appearance while normal and small-sized fibres were found to generally retain their usual polygonal contours. Occasional scattered degenerating or necrotic as well as regenerating fibres were identified, with several associated with collections of lymphocytes and macrophages. Blood vessels were unremarkable, and periodic-acid Schiff (PAS) and Oil Red O (ORO)-stained sections did not exhibit an apparent increase in glycogen or lipid, respectively. Myofibrillar ATPase-reacted sections demonstrated the normal checkerboard-like pattern of types 1 and 2 fibres, with all populations of fibres containing both types 1 and 2 fibres. An immunohistochemistry panel of merosin, beta-dystroglycan, alpha-sarcoglycan, beta-sarcoglycan, delta-sarcoglycan, dystrophin-1, and dystrophin-2 did not identify a definitive pathological abnormality. However, immunohistochemical analysis with dystrophin-3 antibodies demonstrated diminished to absent sarcolemmal positivity in most muscle fibres. Taken together, these findings were consistent with a nonspecific dystrophic/myopathic process with no inflammatory components, no rimmed vacuoles or inclusions noted.\n",
      "\n",
      "Genetic studies were considered and a gene panel for limb girdle muscular dystrophy turned out to be negative. He was found to have a hemizygous pathogenic variant in the DMD gene, which is designated as an in-frame deletion consistent with a diagnosis of BMD (c.5439_8237del, predicted to cause p.Glu2247_Gln2739del signifying deletions in exons 45–53 that results in truncated and dysfunctional dystrophin). He also was heterozygous for a variant of uncertain significance in the MYBPC3 gene that could potentially be responsible for his LVNC.\n",
      "\n",
      "\n",
      "Differential diagnosis\n",
      "\n",
      "In this gentlemen’s presentation of cardiomyopathy, an important distinction needed to be made between ischaemic and non-ischaemic aetiology. Ischaemia was essentially negated with a normal initial CT -CA and normal CA. A question of viral myocarditis as the causative trigger in the initial hospital presentation (given his viral prodrome) was considered, however, his LV systolic function did not improve over time. He subsequently had a cardiac MRI and contrast TTE which showed features consistent with LVNC.\n",
      "\n",
      "With respect to this patient’s weakness and ataxia, there could have been a multifactorial aetiology including a primary structural central nervous system lesion such as a stroke or multiple sclerosis, which was ruled out by a normal CT and MRI of his brain. He did have EMG evidence of lower limb myopathy and the quadriceps biopsy further showed that he had a nonspecific dystrophic process. Thus, he had a symmetric limb-girdle distribution myopathy. He had no contractures, militating a diagnosis of Emery-Dreifuss syndrome. Inclusion body myositis was ruled out as the biopsy showed no inflammatory features, no rimmed vacuoles and no inclusions. Danon disease was considered given the dyad of cardiomyopathy and skeletal myopathy, however, given the lack of any evidence suggesting cognitive dysfunction and no LAMP2 gene mutations, it made it less likely. Further genetic workup yielded a pathogenic variant in the DMD gene consistent with BMD.\n",
      "\n",
      "\n",
      "Treatment\n",
      "\n",
      "This patient was optimised medically and switched to sacubitril/valsartan with good response. He was deemed high risk for SCD and was booked for an elective primary prevention ICD. Unfortunately he experienced an out-of-hospital cardiac arrest from pulseless VT. He was successfully resuscitated and subsequently received a dual chamber ICD for secondary prevention. He was concomitantly placed on amiodarone as an antiarrhythmic for shock suppression therapy and subsequently switched to sotalol due to amiodarone intolerance. The patient went on to have recurrent syncopal VT episodes requiring multiple hospital admissions. His Interagency Registry for Mechanically Assisted Circulatory Support score was 2–3, which prompted an urgent referral for a LV assist device (LVAD) and he had a HeartMate 3 LVAD implanted.\n",
      "\n",
      "With regard to his BMD, the patient had no specific pharmacotherapy, however, he did attend regular follow-ups with neurology, physiatry, as well as speech pathology to monitor for any neurological and functional complications. This therapy formed an important aspect in preparing him for an eventual cardiac transplantation.\n",
      "\n",
      "His cardiac medications are as follows: sotalol, warfarin, sertraline, aspirin, metoprolol, furosemide, spironolactone and sacubitril/valsartan.\n",
      "\n",
      "\n",
      "Outcome and follow-up\n",
      "\n",
      "This patient follows up regularly with both the heart function clinics. He thinks his management of his activities of daily living are slowly improving. He will have occasional orthostatic light-headedness but denies any syncopal events. He states that he is limited more by leg weakness than any dyspnoea. He denies any ICD shocks or LVAD alarms.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(df[df[\"n_words\"].between(1500, 5000)].text.values[-1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAigAAAGjCAYAAAAGku4DAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjkuMywgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/GU6VOAAAACXBIWXMAAA9hAAAPYQGoP6dpAABBvklEQVR4nO3dd3hUVeL/8c8kJJOQSu+9I1IVgRACSIkUAUVdsEBwVdRVlOJv8WuBRR9UusgXkaWICu4CShORIDVSBQVdBIRQgwqhpZAyJPf3B9+ZJc6kTOrN8H49D4/m3nPOnMlJ+eTcc8+1GIZhCAAAwES8SroDAAAAf0ZAAQAApkNAAQAApkNAAQAApkNAAQAApkNAAQAApkNAAQAApkNAAQAAplOmpDuQH5mZmTp//ryCgoJksVhKujsAACAPDMNQYmKiqlevLi+vnOdISmVAOX/+vGrVqlXS3QAAAPlw9uxZ1axZM8cypTKgBAUFSbr5BoODg/Ncz2azaePGjerVq5d8fHyKqnsoQYzx7YFxvj0wzp4nISFBtWrVcvwez0mpDCj2yzrBwcFuB5SyZcsqODiYL3YPxRjfHhjn2wPj7LnysjyDRbIAAMB0CCgAAMB0CCgAAMB0CCgAAMB0CCgAAMB0CCgAAMB0SuVtxgBKL5vNpoyMjAK3UaZMGaWmpha4LZgX42x+3t7eRXYLeL4Dyr59+zRlyhTFxMTo4sWLCggI0J133qkRI0Zo+PDhTvc4Z2Rk6P3339fChQt1/PhxBQYGqlu3bpo4caKaNWtW4DcCwNwSEhIUHx+vtLS0ArdlGIaqVq2qs2fP8rgLD8Y4lw5Wq1UVK1Z0a1+yvMhXQFm5cqUeeeQRZWRkqG3btgoPD9fFixe1Y8cOxcTEaNOmTfrss88c5TMzM/XQQw/pyy+/VGhoqPr27av4+HitWLFCX331lbZs2aL27dsX2psCYC4JCQmKi4tTYGCgKlasKB8fnwL9wsnMzFRSUpICAwNzfZ4HSi/G2dwMw5DNZtO1a9cUFxcnSYUaUtwOKDdu3NBzzz2njIwMffbZZxo6dKjj3C+//KLOnTtr6dKl+utf/6pu3bpJkhYuXKgvv/xSjRo10o4dO1SlShVJN4PO4MGD9eijj+qXX35RmTJccQI8UXx8vAIDA1WzZs1C+Us4MzNT6enp8vPz4xeXB2Oczc/f319BQUE6d+6c4uPjCzWguD3iR44c0YULF9SkSZMs4USSmjVrpscee0zSzUtAdtOnT5ckvffee45wIkkPPvig7r//fh0/flyrV6/O1xsAYG42m01paWkKCQlhmh7wQBaLRSEhIUpLS5PNZiu0dt0OKFarNU/lKlSoIEk6efKkfvnlF/n7+6tv375O5QYPHixJWrt2rbtdAVAK2Bc38iwVwHPZv78LczGz2wGlfv36atCggY4ePaqlS5dmOffLL7/o008/Vbly5TRo0CBJ0sGDByVJLVq0cPkDqm3btpKkQ4cOud15AKUHsyeA5yqK72+3F314e3vr448/Vr9+/fToo49q2rRpatSokS5cuKAdO3aoefPmWrx4scqXLy9JOnPmjCSpZs2aLtuzHz99+nS2r5mWlpZl5X9CQoKkm1PH7kwn2csW5hQUzIUxNh+bzSbDMJSZmanMzMxCadMwDMd/C6tNmA/jXHpkZmY6Fs16e3tnW86dn835WpUaFhambdu2adCgQTpw4IAOHDggSfL19VXPnj1Vv359R9mkpCRJUtmyZV22FRAQIElKTEzM9vUmT56siRMnOh3fuHFjtu3mJDo62u06KF0YY/MoU6aMqlatqqSkJKWnpxdq2zn93IDnYJzNLz09XSkpKdq+fbtu3LiRbbnr16/nuc18BZRly5YpKipKHTp00LJly3THHXfo/Pnzmjp1qqZNm6YtW7Zo586deV6vkpvx48dr9OjRjo8TEhJUq1Yt9erVy60VwzabTdHR0erZsyfXw81ox/Tcy4SPzvE0Y2w+qampOnv2rAIDA+Xn51cobRqGocTERAUFBXHpyIMxzqVHamqq/P391aVLlxy/z+1XQPLC7YDy66+/atiwYapcubLWrVunwMBASVKjRo00b948nT9/XuvWrdPChQv17LPPOs5nl5qSk5MlSUFBQdm+ptVqdRl2fHx88vVLKL/1UMQseZjCzeO4McbmkZGRIYvFIi8vr0K7VdQ+3W9vtzT54Ycf1LZtW1WvXt2xd8StMjMzVb58eV27dk1PPfWUPvroI6cy27dvV0REhJo3b67//Oc/xdFth1OnTqlevXqKiIjQ1q1bi/S1SvM43268vLxksVhy/dnrzs9ltwPK559/LpvNpsjISEf4uNXDDz+sdevWafv27Xr22WdVu3ZtSdK5c+dctmc/XqdOHXe7AsBDzIg+5lZ5wzCUlpYmq9VarH9Zv9yzcYHbaNWqlYKDg3X+/HnFxsZmuSQuST/99JOuXbsmSYqJiXHZxo4dOyRJ4eHhBe4PYFZuR1J7oAgJCXF53n78ypUrkm5+M0rSzz//7HJxjH39SsuWLd3tCgCUOl5eXurUqZMk1wHEHj5atWqlI0eO6NKlS9mWIaDAk7kdUKpWrSpJ+v77712et2/QVrduXUlSvXr11KxZM6WkpOirr75yKr9ixQpJUv/+/d3tCgCUSvZg4SqgxMTEyMfHRy+99JIMw9B3332X5XxmZqZ27dqVpR3AE7kdUAYMGCDp5jXQuXPnZjm3e/duzZgxQ9J/N2CT5Fjg+sorr+jChQuO41988YXWrFmjhg0bOtoFAE9nDxb2mZBb7dixQ23btlXPnj1dljl48KASEhJUu3ZtxyX0S5cuady4cWrUqJH8/PxUvnx5RUZGauPGjS5f32KxqG7dukpPT9c//vEPNW3aVFarVQMHDnSUOXv2rB5//HFVqlRJZcuWVbt27fTpp59m+54Mw9Bnn32mzp07q0qVKvLz81OtWrXUo0cPzZkzx63PDyDlYw1K27ZtNXbsWE2dOlXPPfec5syZo+bNm+v8+fPatWuXMjMz9fTTT6tHjx6OOiNGjND69ev15ZdfqmnTprr33nsVHx+vbdu2yd/fX59++inP4QFw22jfvr2sVquOHj2q+Ph4VaxYUZIUGxur8+fPa8iQIapRo4bq1KnjNMvy58s7cXFx6tKli2JjY1W7dm0NHDhQFy9e1KZNm/TNN99o+vTpevnll536kJmZqYEDBzoW3LZs2TLLDuCdOnXS77//rvr166tHjx6Ki4vTE088oeeff97le3rllVc0depUWa1WdenSRRUrVtTvv/+uQ4cO6fjx49nWA7KTr1QwZcoUderUSR9++KH279+vo0ePKigoSBEREXrqqac0ZMiQLOW9vLy0fPlyzZo1SwsXLtS6desUEBCgBx98UBMnTlTz5s0L5c0AQGlgtVp19913KyYmRt99951jBtkeRjp37izp5p5TK1asUEpKivz9/bOUsQeUkSNHKjY2VkOHDtWiRYvk6+vrKNe7d2+NGzdO3bp1U+vWrbP04ezZs46QVKNGjSznnnvuOf3+++8aMWKE5s2b5/gDcu3atY5dwm+Vmpqq2bNnKygoSAcPHlS9evUc527cuOG4JAW4I9/3bQ0aNEjffPON4uPjZbPZdPnyZW3evNkpnNh5e3tr9OjR+vnnn5WSkqL4+HgtX76ccALgtuTqMo/9/8PCwhz/TU9P1549exxlbg0osbGxju0eZs+e7Qgn0s2QM3LkSGVkZGR7iWXy5MlO4SQ2NlYbNmxQcHCwpk+fnmV2u3///lku39slJCQoLS1NDRo0yBJOpJsb9bFWBvnBjeUAUAJcLZSNiYlR48aNValSJUn/DSr2MidOnNBvv/2mChUqqFmzZo7jkZGRjseL3Orxxx+X5Hqti8VicXlzwq1turpb09UfoZUrV1bNmjX1448/6u9//7tiY2NzeOdA3hBQAKAEdOrUSV5eXjpw4IBSUlJ08eJFHTlyxHF5R5LuvPNOBQcHO0KDPWh07txZFotF58+fl/Tfuyb/zH7c1YZwlStXdrkBpr3N7Pamyu61Pv74Y1WqVEnvvvuuGjRooLp162rYsGH6+uuvXZYHckNAAYASEBISopYtW8pms2n37t1O60+km+v3OnTooF27dikjI8Pt/U9y2sSusB47YNe9e3cdP35cn332mR5//HFlZmZqyZIl6tOnj8vLQkBuuHXmNuTurp1S4eygCSCr8PBw/fjjj4qJidHVq1clZQ0o0s3LPBs3btShQ4ecFshWr15dUvZPgz916pQkOa0zyUm1atVybDOnJ88HBwdr6NChGjp0qKSbW0889NBDWrlypdavX68+ffrkuR8AMygAUEJuXYeyY8cOValSRY0aNcpSxr4O5YsvvtCxY8cUEBCgtm3bSvpvmNmwYYMj4NzKvm+JO4tUb23T1YPdPv/88zy31aFDB8c6mJ9//jnP9QCJgAIAJcYeHHbu3KkffvjBEUZudc8998jb29txJ06HDh0cd9bUr19fffv2VWJiokaNGpXlcSK7du3S3Llz5e3t7dYeJA0aNFCvXr2UkJCgMWPGKCMjw3Fu/fr1Wr58uVOdM2fOaPHixU4PhU1NTdWWLVskSbVq1cpzHwCJgAIAJaZq1apq2LChkpKSdOPGDafLO5IUGBioVq1aOZ5v9ufZkHnz5qlevXpasmSJGjVqpCFDhqhHjx4KDw9XcnKy3nvvPac9UHIzd+5cValSRf/85z/VpEkTDRkyRBEREerXr5+eeeYZp/KXL19WVFSUKlWqpIiICD366KMaOHCgateurd27d+uuu+7SAw884FYfANagAChx7q5xyszMVEJCgoKDg+XlVbr/zgoPD9fx48clOa8/sQsLC3M8WPXPAaVGjRrat2+fJk+erFWrVumLL75Q2bJlde+992rMmDHq1auX232qX7++9uzZo1dffVXffPONVq1apaZNm2rRokWKiIhw2lelQYMGmjZtmr799lsdPnxYe/fuVUBAgOrVq6dXX31VTz/9tMs7hoCcWAzDMEq6E+5KSEhQSEiIrl27puDg4DzXs9lsjoVaPj4+RdhDczPtItktk3Mv0218jqcZY/NJTU3VyZMnVa9evUK7c8STAgqyxziXHnn9Pnfn9zcjDgAATIeAAgAATIeAAgAATIeAAgAATIeAAgAATIeAAgAATIeAAgAATIeAAgAATIedZFFwhbDBGgAAt2IGBQAAmA4BBQAAmA4BBQAAmA4BBQAAmA4BBQCKkcVicetf3bp13W7f3TqlzYgRIxQQEKALFy5kOf7nz52Xl5dCQkLUoUMHzZw5UzabrVBev27durJYLIXSltn88MMPslgseu+990q6K9zFA8AE8nIn2C0shiG/tDRZrFapOH9RFMLdaMOGDXM6FhMToxMnTqhVq1Zq3bp1lnMVK1Ys8Gt6kp9++kkff/yxxowZo8qVK7ssY/8cZ2Rk6NSpU9q5c6f27NmjdevWacOGDSpTxjN+9Z06dUr16tVTRESEtm7dWihttmnTRvfff78mT56sv/71rypfvnyhtJsfnjFKAFBKLF682OnY8OHDdeLECQ0cOFATJkwo9j6VJq+99pq8vb01duzYbMv8+XO8Z88ede3aVd9++60+//xzPfbYY0Xcy9Jt/PjxWrNmjd599129++67JdYPLvEAAEqFs2fPat26derdu3e2syeu3HPPPRo+fLgk6Ztvvimi3nmODh06qGHDhlq4cKHS09NLrB8EFAAwsUuXLmncuHFq1KiR/Pz8VL58eUVGRmrjxo1utfPzzz+rRo0a8vHx0WeffeY4fuPGDc2dO1cdO3ZUcHCw/P391bp1a82cOVM3btxwaufW9Rf//Oc/1bJlS/n7+6tq1ap65plndPXqVac6SUlJmjx5slq1aqWQkBAFBgaqQYMGeuihh9wKDAsXLlRmZqaGDBni1nuXpDvuuEOSnNatSNL169c1adIktWjRQv7+/goJCVGXLl30+eef59imYRiaNWuWmjdvLj8/P9WoUUMvvviiy8+BvfyyZcvUvXt3lStXTn5+fmrWrJkmTJig69evO5Xv2rWrLBaLTp06paVLl6pDhw4KCgpSaGioJkyYoHr16kmStm3blmXtjT2MSdKOHTv0t7/9TS1btlS5cuXk7++vpk2b6u9//3u2/ZSkIUOGKD4+Xl9++WWOn4OiREABAJOKi4tT+/btNXXqVKWnp2vgwIFq06aNNm3apN69e2vGjBl5amfXrl3q0qWLrly5otWrV+vRRx+VJKWkpKhXr1567rnndOzYMXXo0EE9e/bUb7/9ppdfflkPPvigMjMzXbb5yiuv6Pnnn1e1atV03333yTAMffTRR7r//vtlGIajXEZGhnr06KFXX31V58+fV9euXdW3b19VrVpV69ev17Jly/L8+Vi3bp2km7+43ZWYmChJTjMviYmJ6tKli9544w1duHBB/fr1U1hYmPbu3ashQ4Zo1KhR2bb5wgsvaNy4capZs6YGDBigjIwMzZ49WxEREUpISMhSNjMzU48++qiGDh2qffv2qXXr1urTp4+Sk5M1ceJEdevWTSkpKS5fZ/LkyXr88cfl6+urfv36qUWLFmrdurUefPBBSVKVKlU0bNgwx7/OnTs76o4bN04LFiyQv7+/7r33Xt17771KSEjQu+++q86dOyspKcnla9o/x1999VXOn9gixBoUADCpkSNHKjY2VkOHDtWiRYvk6+sr6eai2t69e2vcuHHq1q2b08LaW33zzTd68MEH5ePjo40bN2b55TV27Fht2bJFjzzyiObNm6eQkBBJN39p/+Uvf9GaNWv00UcfaeTIkU7tfvLJJzp06JCaNGkiSYqPj1fHjh21Y8cObdmyRd27d5ckbd++XXv27NHdd9+t7du3y8/Pz9FGQkKCfv311zx9LpKSkvTDDz+oevXqql69ep7q3GrDhg2SpMjIyCzHX331Ve3fv1/dunXT6tWrFRQUJEk6cuSIIiIi9P7776tnz57q16+fy8/Brl271K5dO0cfBwwYoM2bN+uNN97QzJkzHWWnTZumZcuWqWvXrlq2bJmqVq0qSUpPT9dzzz2nBQsWaOLEiXrnnXecXmfJkiXavHmzIiIishxv3bq1Vq5cqaZNm7pc2yRJb775pjp16uQYW0lKS0vTiy++qI8++kjTp0/XG2+84VTvrrvukpeXl7Zt2+ay3eLADAoAmFBsbKzWrVunwMBAzZ492xFOJKlz584aOXKkMjIyNGfOnGzb+Ne//qX+/fsrMDBQW7duzRJOLly4oPnz56tWrVpatGhRll9gQUFBWrBggXx9fTV37lyXbU+aNMkRTqSbdxvZg8z27dsdxy9evChJCgsLyxJOJCk4ONjxyz03hw8fVkZGRpbXzE1mZqZOnDihZ599Vtu3b9eAAQP0yCOPOM4nJydrwYIF8vLy0v/+7/86wokkNW3aVK+99pokadasWS7b/9vf/pal//axslgsWrBggVJTUyXdvIz23nvvKSAgQJ9//rkjnEiSr6+vZs+erapVq+qjjz5yOWP15JNPOoWTvLrvvvuyjK0kWa1WzZw5U2XKlNHq1atd1gsODla1atV05swZXblyJV+vXVAEFAAwoZiYGEk3/+J3davn448/LunmGgNXPvzwQw0dOlQ1a9ZUTEyMWrVqleX81q1bZbPZFBkZKX9/f6f6VatWVaNGjfTTTz+5vPTQq1cvp2ONGzeWJP3222+OY61bt5aXl5cWLVqk+fPn69KlS9m95RzZ146UK1cu17L2tRje3t5q2LChPvzwQz311FP68ssvs9xivH//fqWkpKht27Zq2rSpUzv2z/F3333nMjj85S9/cTrWvHlztWrVyjHjI0kHDhxQfHy8OnXqpCpVqjjV8ff3V7t27XTlyhWXM0r3339/ru85J3Fxcfrwww/10ksvacSIERo+fLieffZZ+fr65jiDZf+6s4fM4sYlHgAwofPnz0tStpuu2Y/HxcU5nTt37pyeffZZ+fn5acuWLapTp45TmVOnTkmS5s+fr/nz5+fYl8uXL6tGjRpZjtWsWdOpnH0GIi0tzXGscePGeu+99zR+/Hg9/fTTGjlypFq0aKF7771Xw4cPV8uWLXN8bbtr165leY2c2PdBSU1N1cGDB3XkyBHNnz9fnTp1yrKANLfPcWhoqEJCQnTt2jVduXJFFSpUyHLe1efV3t6PP/7oaN/+uY6Ojs51g7f4+HinWaLatWvnWCcn06dP19///vd8bVIXHBwsSTkupi1KBBQAKIVy+kVXuXJlNW/eXN9++63Gjh2rZcuWOW1OZp8RaN26tdPsyp9ZrVanY15eeZ+AHzNmjB5++GGtWrVK0dHR2rFjh2bMmKGZM2dqxowZOS5Etbt1fUxu/rweY8qUKY5Fvd26dcs2WLhSGDvG2j/XDRs2VFhYWI5l/xyCJDldGsur3bt3a8yYMQoJCdGsWbPUtWtXVa1a1TGe1atXzzLb9Wf2UBgaGpqv1y8oAgoAmJB9Iejp06ddnrf/Vf7nmQ3p5rqGtWvXqm/fvlqxYoW8vLy0dOlSeXt7O8rYZ0A6d+6s2bNnF3LvndWqVUsvvPCCXnjhBd24cUOff/65oqKi9Morr+iJJ57I9dKN/e6by5cvu/3a48aN06ZNm7Rx40ZNnDhRCxculJT75/jatWu6evWq/P39Xfbv9OnTuvPOO10ev7V9++c6p8WsRcF+i/Dbb7/ttINxSkqKfv/99xzr29eeVKpUqWg6mAvWoACACdkXtG7YsMHlFPunn34qSQoPD3dZ39/fX+vWrVNERIT+/e9/6/HHH1dGRobjfLdu3eTt7a1169YV2jNq8qpMmTJ67LHHdPfddys9PT1Pd/LccccdKlOmjI4ePZqv17TfHfPJJ584AkS7du3k7++v/fv3u+yD/XMcFhbmcsbo3//+t9OxI0eO6Mcff1RgYKDj7qq7775bISEh2rZtW74CVnbsC6dd7Vcj/TdguLoct3z58iy3g/9ZQkKCzp8/r9q1a+dp3U9RIKAAgAnVr19fffv2VWJiokaNGpUlROzatUtz586Vt7e3nn/++WzbKFu2rL766iuFh4dr2bJlGjZsmONyQ40aNTRixAidOnVKQ4YM0R9//OFU//jx41q5cmWB3seWLVu0adMmp0WmJ0+e1C+//CKLxeLyF+ifBQQEqE2bNvrtt99crrvJTZs2bTRw4EDHHTX2NkeMGKHMzEw9//zzSk5OdpQ/duyY3nrrLUnSiy++6LLN2bNnOxbCSjc3fHvhhRdkGIaioqIci4+tVqteeeUVJSYm6oEHHlBsbKxTW3Fxcfrkk0/cek8VK1aUj4+PTpw4kSV82tkXLS9YsCDL18/hw4f1//7f/8ux7X379skwjHzfPVQYuMQDACY1b948hYeHa8mSJdq2bZs6duyoixcvauvWrcrIyNC0adNy3ANFuvlLeP369YqMjNRnn30mb29vLVq0SF5eXpo1a5ZOnTqllStXasOGDWrdurVq166t5ORkHT58WMePH9eAAQMcG4Llx8GDB/Xyyy+rUqVKateunSpUqKCLFy9q27ZtSktL0wsvvJDnfU369u2rffv2aevWrY7N5twxYcIErV69WgsXLtTrr7+uqlWravLkydq9e7eio6NVv359RUREKDk5WZs3b1ZqaqpefPFF9e/f32V7jz32mO655x51795dISEh2r59u37//XfdcccdmjRpUpayf//733XkyBF98sknatasmdq0aaN69eopPT1dR48e1eHDh9WyZUvHnUN54evrq8jISK1du1atWrVS27Zt5evrq7CwMEVFRSkqKkrTpk3T2rVr1aRJE9199926fPmytm3bpoEDB2rv3r3ZXt6yP3ywb9++ee5PYWMGBQBMqkaNGtq3b5/GjBmjMmXK6IsvvtD+/ft177336ptvvtHo0aPz1E5gYKC+/vprderUSUuWLNGTTz6pzMxM+fv76+uvv9bHH3+se+65R7/88otWrFih77//XpUqVdLEiRMdsw351a9fP7322mtq3LixDh48qOXLl+s///mPOnfurJUrV2a7x4grI0aMkLe3t5YuXZqvvrRq1UqDBg1Samqqpk+fLunmXUHbtm3TxIkTVbFiRa1Zs0Y7duzQXXfdpaVLl+bYv/fff1+TJ0/W6dOntXr1alksFj3//PPasWOH094jXl5eWrJkiVavXq2ePXvq5MmTWrlypWJiYuTn56dx48Y51sa445///Kcef/xxXbp0SUuXLtWCBQscm6tVqFBB+/bt09ChQ5Wenq41a9YoLi5OkyZNynUH32XLlqlixYoaNGiQ230qLBYjp4tQJpWQkOC49ct+G1Re2Gw2rV+/Xn369JGPj08R9tDcZkQfc7vOyz0bZ39yy+TcG8jLY+oLoR3G2HxSU1N18uRJ1atXL993I/xZZmamEhISFBwc7NbdJChdXI3zoEGDtG7dOp09ezbLhmcoPLt27VKnTp30yiuv5Plpxnn9Pnfn9zeXeEwmp/CQY0i4XeQWYgwvSc4bLgHwDJMmTdKaNWs0depUTZ06taS745HeeecdhYaG5rpOpajxpwcAoNRo0aKFhg0bprlz57p8MjEK5ocfftCaNWs0fvx4lzsYFydmUAAApcrChQvztV4DuWvTpk2Otx8XJ2ZQAACA6TCD4qlyWKvR4czNh3Xtrv10npvLbm1MntfF5GUBLAAA/4cZFAAAYDoEFAAAYDoEFADFwiwL7wAUvqL4/iagAChS9ifoFvcD6QAUH/v3961PzC4oAgqAIuXj4yOr1apr164xiwJ4IMMwdO3aNVmt1kLdwZu7eAAUuYoVKyouLk7nzp1TSEiIfHx8ZLFY8t1eZmam0tPTlZqaylb3HoxxNjfDMGSz2XTt2jUlJSWpRo0ahdo+AQVAkbM/cyM+Pl5xcXEFbs8wDKWkpMjf379AQQfmxjiXDlarVTVq1HDr2Xh5QUABUCyCg4MVHBwsm82mjIyMArVls9m0fft2denShYdCejDG2fy8vb2LbGwIKACKlY+PT4F/oHl7e+vGjRvy8/PjF5cHY5xvb1zUAwAApkNAAQAApkNAAQAApkNAAQAApkNAAQAApkNAAQAApkNAAQAApkNAAQAApkNAAQAApkNAAQAApkNAAQAApkNAAQAApsPDAj3AjOhjTsc6nLmkjvUrlEBvAAAoOGZQAACA6RBQAACA6RBQAACA6bAGpYS4WjcCAABuYgYFAACYToECysWLFzV27Fg1adJE/v7+Kl++vNq2batx48a5LL927VpFREQoODhYwcHB6tq1q7766quCdAEAAHigfAeU/fv3q1mzZpo2bZp8fHw0YMAAdejQQZcvX9aMGTOcys+cOVP333+/du7cqbCwMHXv3l179+5Vv3799MEHHxToTQAAAM+SrzUoFy9eVGRkpFJSUrR69Wrdf//9Wc7v3bs3y8dHjx7V2LFjZbVatWXLFnXs2FGSdOzYMXXq1Ekvv/yyIiMj1bBhw3y+DQAA4EnyNYPy5ptvKj4+XlOmTHEKJ5LUvn37LB/PmjVLGRkZGjlypCOcSFLjxo31P//zP7px44ZmzZqVn67ApHbFXsr2HwAAuXE7oKSkpOjTTz9VQECAoqKi8lTHvs5k8ODBTufsx9auXetuVwAAgIdy+xLP999/r8TERHXu3Fn+/v76+uuvFR0drdTUVDVu3FgPP/ywqlev7ih/9epVnTlzRpLUpk0bp/Zq1aqlihUr6vTp00pISFBwcHAB3g4AAPAEbgeUw4cPS5IqV66sgQMHavXq1VnOv/rqq1qwYIGGDBkiSY5wUq5cOQUEBLhss2bNmoqPj9fp06d15513Op1PS0tTWlqa4+OEhARJks1mk81my3Pf7WXdqVNULEaG23Wy67ertjIt3rIZrifIMi3e+e6Dyz65eB37a7isk02/CoO9bTOMMYqOmb6XUXQYZ8/jzli6HVCuXLkiSVqzZo28vb01Z84cPfTQQ7p+/bo++OADTZ06VcOGDVOzZs3UunVrJSUlSZLKli2bbZv24JKYmOjy/OTJkzVx4kSn4xs3bsyx3exER0e7Xaew1ctHnfXrXW/u5qqt+AqdtN71p1P6v2cI1ksp+GZxN/vUNNvXcFknu34VIjOMMYoe43x7YJw9x/Xr1/Nc1u2AkpmZKUm6ceOG3n77bT333HOOc1OmTNHp06e1fPlyTZkyRZ999pm7zbs0fvx4jR492vFxQkKCatWqpV69erl1Schmsyk6Olo9e/aUj49PofQtv+ZsOe52nee7ub7LyVVbd59brPZ1y7ssv/fUZUnSvprD3e6Dyz7tmJ7ta7iSXb8Kg83wUnRSY1OMMYqOmb6XUXQYZ89jvwKSF24HlMDAQMf/u1okGxUVpeXLl2vbtm1ZyueUmpKTkyVJQUFBLs9brVZZrVan4z4+Pvn6os1vvcJk5HAJJDvZ9dlVW15GhnwsmS7Le/3fpZ389MFln1y8jlcOl4+y61dhMsMYo+gxzrcHxtlzuDOObi8GqFOnjqSbl2wqVarkdL5u3bqSpAsXLkiSateuLenmpSF7EPmzc+fOZWkbAADc3twOKPY7cVJSUrIsXLW7fPnm1L595iQ0NNQRUn744Qen8mfPnlV8fLzq1KnDHTwAAEBSPi7x1K5dW61atdLBgwe1bds29erVK8t5+6WdW28p7tu3r+bOnasVK1aoc+fOWcqvWLFCktS/f3+3O4+i1+HMRzkX2JLDalgAAPIpX/d7vvLKK5KksWPH6rfffnMc//HHHzVt2jRJ0siRIx3HR40aJW9vb3344YfavXu34/ivv/6qt99+W2XKlNGoUaPy9QYAAIDnydezeIYOHaqNGzfq448/VvPmzdWpUyelpKRo586dSktL01NPPaWHHnrIUb5JkyaaMmWKRo8erfDwcPXs2VO+vr7auHGjUlJS9P777/McHgAA4JCvgCJJixYtUlhYmObNm6etW7fKYrGobdu2euaZZzRs2DCn8i+//LIaNmyoKVOmaMeOHZKku+66S6+88or69euX/3cAAAA8Tr4DisVi0VNPPaWnnnoqz3X69+/PWpM8yHbdx63rPbqNL57OAABQAopuz3EAAIB8IqAAAADTIaAAAADTyfcaFJSwLZMd/9vhzKV8NZHrHicAAJQQZlAAAIDpEFAAAIDpEFAAAIDpEFAAAIDpEFAAAIDpEFAAAIDpEFAAAIDpEFAAAIDpsFFbKbIrNn8bshUlM/YJAFD6MYMCAABMh4ACAABMh4ACAABMh4ACAABMh0Wy8Ew7pkuWzOzPdxtffH0BALiNGRQAAGA6BBQAAGA6BBQAAGA6BBQAAGA6BBQAAGA6BBQAAGA6BBQAAGA6BBQAAGA6BBQAAGA6BBQAAGA6BBQAAGA6BBQAAGA6BBQAAGA6BBQAAGA6BBQAAGA6BBQAAGA6ZUq6Ayg6u2IvlXQXAADIF2ZQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6bBRG25PWybnXqbb+KLvBwDAJWZQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6RBQAACA6ZQp6Q54uhnRx0q6CwAAlDrMoAAAANMhoAAAANMhoAAAANMhoAAAANMhoAAAANMhoAAAANMhoAAAANMhoAAAANMhoAAAANMpcEC5dOmSKleuLIvFooYNG+ZYdvHixWrfvr0CAwNVvnx59enTRzt37ixoFwAAgIcpcEAZM2aM4uPjcy330ksvKSoqSj///LN69Oih9u3bKzo6Wl26dNGqVasK2g0AAOBBChRQvv32W3388cd66qmnciy3adMmzZo1SxUqVNDBgwe1atUqbdiwQdu3b5e3t7eioqJ09erVgnQFAAB4kHwHlJSUFD3zzDNq3ry5xo4dm2PZ6dOnS5Jee+01NWrUyHG8Y8eOGjlypK5evaoFCxbktyvwELtiL7n8BwC4/eQ7oEycOFGxsbH68MMP5ePjk225lJQUbd68WZI0ePBgp/P2Y2vXrs1vVwAAgIfJV0A5dOiQpk2bpqioKIWHh+dY9ujRo0pLS1OlSpVUs2ZNp/Nt27Z1tAkAACBJZdytkJmZqb/+9a8KDQ3Ve++9l2v5M2fOSJLLcCJJAQEBCg0N1ZUrV5SYmKigoCCnMmlpaUpLS3N8nJCQIEmy2Wyy2Wx57ru9rDt1CspiZLhdJ9PiXQQ9MQ+b4ToXZ/e+syufU1l36mTfWPF9ncA9JfG9jOLHOHsed8bS7YAye/Zs7du3T4sWLVKFChVyLZ+UlCRJKlu2bLZlAgICdPXq1WwDyuTJkzVx4kSn4xs3bsyx3exER0e7XSe/6uWjTnyFToXeDzNZn5jNiWy+nLItn4PopMbuV3J64fUFbwNFqji/l1FyGGfPcf369TyXdSugnDlzRq+99poiIiI0fPhwd/uVb+PHj9fo0aMdHyckJKhWrVrq1auXgoOD89yOzWZTdHS0evbsmeO6mcI0Z8txt+vcfW5x4XfERNrXLe/y+N5Tl90q74rN8FJ0UmP1DDwmH0tmvvrnED469zIoESXxvYzixzh7HvsVkLxwK6A8//zzSk9P14cffpjnOoGBgZJyTk3JycmS5HL2RJKsVqusVqvTcR8fn3x90ea3Xn4Y+bhc45WPy0KlSXbBIbv3nZ+g4WPJLHhA4Qei6RXn9zJKDuPsOdwZR7cCyrp16xQaGqqRI0dmOZ6amipJiouLU9euXSVJn3/+uapWraratWtLks6dO+eyzeTkZF29elXlypXLNqAAAIDbi9trUK5evapt27a5PJeamuo4Zw8tTZo0kdVq1cWLFxUXF6caNWpkqXPgwAFJUsuWLd3tCgAA8FBu3epgGIbLfydPnpQkNWjQwHGsbt26kiR/f391795dkrR8+XKnNlesWCFJ6t+/f0HeBwAA8CDF8jRj+wLXt956S7/++qvj+K5duzRv3jyFhobqySefLI6uAACAUqBYAkqPHj00atQoXbp0Sa1bt9bAgQPVp08fdenSRTdu3NCiRYsUGhpaHF0BAAClQLEEFEmaOXOmFi1apGbNmik6Olq7du1Sjx49tH37dg0cOLC4ugEAAEoBtxfJulK3bl0ZhpFrueHDhxfr/ilm1OHMRyXdBQAATK/YZlAAAADyioACAABMh4ACAABMh4ACAABMh4ACAABMh4ACAABMh4ACAABMh4ACAABMp1A2arvdzYg+VtJdAADAozCDAgAATIeAAgAATIeAAgAATIc1KCh2u2IvlXQXAAAmxwwKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHRbJAtnZMjn3Mt3GF30/AOA2xAwKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwHQIKAAAwnTIl3QGgVNsyOfcy3cYXfT8AwMMwgwIAAEyHgAIAAEyHgAIAAEyHNSiFqMOZj0q6CwAAeARmUAAAgOkQUAAAgOkQUAAAgOmwBgUoDdhvBcBthhkUAABgOgQUAABgOgQUAABgOgQUAABgOiySdcOM6GMl3QUAAG4LzKAAAADTIaAAAADTIaAAAADTIaAAAADTIaAAAADTIaAAAADTIaAAAADTIaAAAADTIaAAAADTIaAAAADTIaAAAADTIaAAAADT4WGBKLV2xV5yOpZp8ZYqlEBnCmLL5JLuAQCYDjMoAADAdAgoAADAdAgoAADAdFiDAo+099RleRkZTsc71i9tC1QA4PbEDAoAADAdtwPK9evXtWrVKj355JNq0qSJ/Pz8FBAQoFatWukf//iHkpKSsq27ePFitW/fXoGBgSpfvrz69OmjnTt3FugNAAAAz+N2QFm6dKkGDRqkhQsXytvbW/fff7/Cw8N18uRJvfnmm7r77rt14cIFp3ovvfSSoqKi9PPPP6tHjx5q3769oqOj1aVLF61ataow3gsAAPAQbgcUHx8fPf300zp8+LAOHz6sf//739qwYYOOHj2qNm3a6MiRI3rppZey1Nm0aZNmzZqlChUq6ODBg1q1apU2bNig7du3y9vbW1FRUbp69WohvSUAAFDauR1Qhg0bpnnz5qlZs2ZZjlerVk1z5syRJH3xxRdKT093nJs+fbok6bXXXlOjRo0cxzt27KiRI0fq6tWrWrBgQb7eAAAA8DyFuki2VatWkqS0tDRdunRzl8+UlBRt3rxZkjR48GCnOvZja9euLcyuAACAUqxQA0psbKykm5eBypcvL0k6evSo0tLSVKlSJdWsWdOpTtu2bSVJhw4dKsyuAACAUqxQ90GZNWuWJCkyMlJWq1WSdObMGUlyGU4kKSAgQKGhobpy5YoSExMVFBTkVCYtLU1paWmOjxMSEiRJNptNNpstz/2zl3Wnzq0sLvbVuFWmxTtf7SJnNsN1jnb1+bYfy24ssmurSOX29VZYfcrn13VpVNDvZZQOjLPncWcsLYZhGIXxouvXr1e/fv1UpkwZ7du3z3G5Z+nSpXr00UcVFhammJgYl3Vr1qypuLg4xcXFqXr16k7nJ0yYoIkTJzodX7p0qcqWLVsY3QcAAEXs+vXrGjp0qK5du6bg4OAcyxbKDMqRI0f02GOPyTAMTZkyxRFOCsv48eM1evRox8cJCQmqVauWevXqlesbvJXNZlN0dLR69uwpHx8ft/sxZ8vxHM/ffW6x220id+3rlnd5fO+py07HMi3eulz+HpW/vMflTrLuvkapEj469zIeoqDfyygdGGfPY78CkhcFDihxcXGKjIzUlStXNHr0aI0aNSrL+cDAQEk3U1N2kpOTJcnl5R1JslqtjktGt/Lx8cnXF21+6xm5XMJx5xci8s7HkunyeE6fby8jw63xyO41SpXb8Ad4fr+XUbowzp7DnXEs0MXvy5cvq1evXjp9+rSioqI0depUpzK1a9eWJJ07d85lG8nJybp69arKlSuXbUABAAC3l3wHlKSkJN133306fPiwHnjgAc2fP18Wi8WpXJMmTWS1WnXx4kXFxcU5nT9w4IAkqWXLlvntCgAA8DD5CihpaWkaMGCA9u7dq969e2vZsmXy9nZ9+cPf31/du3eXJC1fvtzp/IoVKyRJ/fv3z09XAACAB3I7oGRkZGjIkCHavHmzwsPD9cUXX8jX1zfHOvYFrm+99ZZ+/fVXx/Fdu3Zp3rx5Cg0N1ZNPPuluVwAAgIdye5HsBx98oC+//FKSVLFiRT333HMuy02dOlUVK1aUJPXo0UOjRo3SrFmz1Lp1a/Xs2VPp6emKjo6WYRhatGiRQkND8/8uAACAR3E7oFy5csXx//ag4sqECRMcAUWSZs6cqdatW+uDDz5QdHS0fH191aNHD73++uvq1KmTu90AAAAezO2AMmHCBE2YMCFfLzZ8+HANHz48X3Vx+9oVe6mkuwAAKGYlsO83AABAzggoAADAdAgoAADAdAgoAADAdAgoAADAdAgoAADAdAgoAADAdAgoAADAdNzeqO22tWWyOpxhwzAAAIoDMygAAMB0CCgAAMB0CCgAAMB0WIMCKOcHEnasX6EYewIAkJhBAQAAJkRAAQAApkNAAQAApkNAAQAApsMiWSAX2S2gZfEsABQdZlAAAIDpEFAAAIDpEFAAAIDpEFAAAIDpEFAAAIDpEFAAAIDpEFAAAIDpsA8K4Cm2TC6cdrqNL5x2AKAAmEEBAACmQ0ABAACmQ0ABAACmQ0ABAACmwyJZF2ZEH3M61uGM6wfGAR4nL4ttWUgLoIgxgwIAAEyHgAIAAEyHgAIAAEyHNSgAzM3VmhjDS1JTacd0yZLJmhjAAzGDAgAATIeAAgAATIeAAgAATIeAAgAATIdFsoCJ7Yp1vUFgx/oVirknAFC8mEEBAACmQ0ABAACmQ0ABAACmwxoUIJ/cXR+SXfmc6pRqPHQQQAEwgwIAAEyHgAIAAEyHgAIAAEyHgAIAAEyHgAIAAEyHgAIAAEyHgAIAAEyHgAIAAEyHjdoAlJy8bOYG4LbEDAoAADAdAgoAADAdAgoAADAd1qAApZC7DyosdKwdAVDEmEEBAACmQ0ABAACmQ0ABAACmQ0ABAACmwyJZoJBlt4C1tMnpfRTbYty8Ks5Fu93GF7yNvPS3MF4HKMWYQQEAAKZDQAEAAKZDQAEAAKbDGhTABIpj3YqnrI0BcHtgBgUAAJgOAQUAAJgOAQUAAJgOa1AAFJoSf4ihm/LV39z2MLmd9y8pzv1d2EvG4zGDAgAATKdYA0pKSoreeOMNNW7cWH5+fqpevbpGjBihuLi44uwGAAAwuWILKKmpqerevbsmTZqkpKQkDRgwQLVq1dKiRYvUpk0bxcbGFldXAACAyRVbQHnrrbe0e/dudezYUceOHdO//vUv7dmzR9OmTdPFixc1YsSI4uoKAAAwuWJZJJuenq4PPvhAkjRnzhwFBgY6zo0ePVoff/yxtm3bpv3796tdu3bF0SUABeDupm/5WYya02tkWrylCtLeU5flZWTk2FZ+Nqgr0GLfwnpwYSG0U6iLlotzwan9vRtekppKO6ZLlszie/3bQSlYZFwsMyjfffedrl27pgYNGqhNmzZO5wcPHixJWrt2bXF0BwAAmFyxBJSDBw9Kktq2bevyvP34oUOHiqM7AADA5IrlEs+ZM2ckSTVr1nR53n789OnTLs+npaUpLS3N8fG1a9ckSZcvX5bNZstzP2w2m65fv65Lly7Jx8cn23JpSdecjiWm3sjz66DkZFoMXb9+XYmpNxxT/7eTS0np2Z4z49dwfvvrapyza6sw33dO/TWj7N57vt7HpTxcKstLu260YzO8bv7MtqTLJz+XePLyWrerwhorNyUmJkqSDMPItWyxBJSkpCRJUtmyZV2eDwgIkPTfjv/Z5MmTNXHiRKfj9erVK6QeAgByNsFk7ZjttTzRhCJrOTExUSEhITmWKRU7yY4fP16jR492fJyZmanLly+rQoUKslgseW4nISFBtWrV0tmzZxUcHFwUXUUJY4xvD4zz7YFx9jyGYSgxMVHVq1fPtWyxBBT7XTvXr193eT45OVmSFBQU5PK81WqV1WrNciw0NDTf/QkODuaL3cMxxrcHxvn2wDh7ltxmTuyKZZFs7dq1JUnnzp1zed5+vE6dOsXRHQAAYHLFElBatWolSTpw4IDL8/bjLVu2LI7uAAAAkyuWgBIWFqaQkBCdOHFCP/74o9P5FStWSJL69+9fpP2wWq168803nS4XwXMwxrcHxvn2wDjf3ixGXu71KQSvvfaa3n77bXXq1EkbN2503Lkzffp0jRkzRhEREdq6dWtxdAUAAJhcsQWU1NRUde3aVXv27FG1atUUHh6u06dPa8+ePapUqZJ2796t+vXrF0dXAACAyRVbQJGklJQUTZ48WUuXLtXZs2dVvnx5RUZGatKkSdlu4gYAAG4/xRpQAAAA8qJYFsmWpJSUFL3xxhtq3Lix/Pz8VL16dY0YMUJxcXEl3bXb1v79+/XOO+/ogQceUM2aNWWxWPK04d7ixYvVvn17BQYGqnz58urTp4927tyZY53vvvtOffr0Ufny5RUYGKj27dtryZIlOdY5d+6coqKiVL16dfn5+alx48Z68803lZqa6tb7vJ1dv35dq1at0pNPPqkmTZrIz89PAQEBatWqlf7xj384dpd2hXEuXaZPn64HHnhAjRo1UkhIiKxWq+rUqaMnnnhCP/30U7b1GGfkyvBgKSkpRocOHQxJRrVq1YyHH37YaN++vSHJqFSpknHixImS7uJtacCAAYYkp385GTVqlCHJ8Pf3NwYMGGD07t3bKFOmjOHt7W18+eWXLuusWLHC8Pb2NiwWixEREWE8+OCDRmhoqCHJGDNmjMs6v/76q1GxYkVDktGiRQvj4YcfNurXr29IMsLCwozU1NSCvv3bwvz58x3j2qxZM+Ohhx4yevfubQQFBRmSjKZNmxp//PGHUz3GufSpUKGC4efnZ7Rv394YNGiQMWjQIKNx48aGJMPHx8dYu3atUx3GGXnh0QHlf/7nfwxJRseOHY3ExETH8WnTphmSjIiIiJLr3G3snXfeMV5//XVjzZo1xm+//WZYrdYcA0p0dLQhyahQoYJx7Ngxx/GdO3cavr6+RmhoqHHlypUsdS5dumQEBwcbkoyVK1c6jv/+++9Gw4YNDUnGli1bnF4rLCzMkGS8+OKLjmM2m80YNGiQIcl488038/2+byeLFy82nn76aePw4cNZjp8/f95o06aNIckYMmRIlnOMc+kUExNjpKSkOB2fM2eOIcmoUqWKYbPZHMcZZ+SVxwaUtLQ0IyQkxJBkHDhwwOl8y5YtDUnG999/XwK9w61yCyj33XefIcmYMWOG07kXX3zRkGRMnTo1y/F3333XkGQMGDDAqc4XX3xhSDL69euX5fiePXsMSUblypWd/rL6/fffDR8fH6NcuXJZftjCfTt37jQkGVar1UhLS3McZ5w9T4MGDQxJxsGDBx3HGGfklceuQfnuu+907do1NWjQQG3atHE6P3jwYEnS2rVri7trcENKSoo2b94s6b9jdqvsxvGrr77Ktk7fvn3l5+enTZs2ZbkOba/Tv39/p42hqlSpovDwcF25ckUxMTEFeEew7yydlpamS//3OHfG2TP5+PhIknx9fSUxznCPxwaUgwcPSpLatm3r8rz9+KFDh4qtT3Df0aNHlZaWpkqVKrm8FT27ccxp/H19fdWiRQulpqbq2LFjeaqT02vBPbGxsZJu/vIqX768JMbZE33yySc6evSoGjVqpEaNGklinOEejw0oZ86ckaRs91exHz99+nSx9Qnuy20cAwICFBoaqitXrigxMVHSzUe0X7t2Lcd6rsafr5niMWvWLElSZGSk4y9bxrn0mzJlioYPH66HHnpILVq00BNPPKFq1app2bJl8vb2lsQ4wz1lSroDRcV+G2PZsmVdnrdvtW//JoA55TaO0s2xvHr1qhITExUUFJTlFlZ3xp+vmaK3fv16LViwQD4+Ppo0aZLjOONc+n3zzTf69ttvHR/XqVNHS5YsUbt27RzHGGe4w2NnUACYy5EjR/TYY4/JMAxNmTLFsRYFnmHTpk0yDENXrlzR9u3b1ahRI0VEROjtt98u6a6hlPLYgBIYGCjp5oZRriQnJ0uSgoKCiq1PcF9u4yg5j6W9Tk71XI0/XzNFJy4uTpGRkbpy5YpGjx6tUaNGZTnPOHuO0NBQhYeHa/369WrXrp1ef/117du3TxLjDPd4bECpXbu2pJu7CLpiP16nTp1i6xPcl9s4Jicn6+rVqypXrpzjB01wcLBCQkJyrOdq/PmaKRqXL19Wr169dPr0aUVFRWnq1KlOZRhnz+Pj46NHHnlEhmE47sphnOEOjw0o9unjAwcOuDxvP96yZcti6xPc16RJE1mtVl28eNHl4wmyG8ecxt9ms+nnn392bHudlzo5vRayl5SUpPvuu0+HDx/WAw88oPnz57t8rAHj7JkqVqwoSbp48aIkxhnu8diAEhYWppCQEJ04cUI//vij0/kVK1ZIunmPPMzL399f3bt3lyQtX77c6Xx249i3b98s52+1bt06paamqkePHvLz83Oqs3btWqWlpWWp88cff2jHjh0qV66cwsLCCvCObh9paWkaMGCA9u7dq969e2e5m+PPGGfPtG3bNklSgwYNJDHOcFMJbxRXpOxb3Xfq1MlISkpyHGere3MpyFb3VqvVra2x//jjjzxtjT1q1CjHMZvNZjzwwANsje2GGzduOLYTDw8PN5KTk3OtwziXPjExMcbXX39tZGRkZDmenp5uvP/++4aXl5fh7+9vnDlzxnGOcUZeeXRASUlJMe65554sDwu0f8zDAkvOunXrjHvuucfxz2KxGJKyHFu3bl2WOvaHi5UtW9YYMGCAcd999+Xp4WJeXl6GxWIxunXrZgwePNjxcLHRo0e7rHPs2DGjQoUKhiTjzjvvNB555BHHw8U6derEw8XyaObMmY6HBQ4aNMgYNmyYy38XL17MUo9xLl0WLVpkSDIqVqxo9O7d2xg6dKjRq1cvo1q1aoYkw8/Pz/jXv/7lVI9xRl54dEAxDMO4fv268frrrxsNGjQwfH19japVqxrDhw83zp49W9Jdu23Zf6jl9G/RokUu67Vr184oW7asERoaakRGRhrfffddjq8VExNjREZGGqGhoUbZsmWNu+66y1i8eHGOdc6cOWMMHz7cqFq1quHr62s0bNjQeP31110+EA2uvfnmm7mOsSTj5MmTTnUZ59IjNjbWePXVV42wsDCjWrVqho+PjxEQEGDccccdxgsvvGD8+uuv2dZlnJEbi2EYRiFeMQIAACgwj10kCwAASi8CCgAAMB0CCgAAMB0CCgAAMB0CCgAAMB0CCgAAMB0CCgAAMB0CCgAAMB0CCgAAMB0CCgAAMB0CCgAAMB0CCgAAMB0CCgAAMJ3/D30Sx6lkcsuiAAAAAElFTkSuQmCC",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df[\"n_words\"].hist(bins=50, alpha=0.5, label=\"Words\");\n",
    "df[\"n_tokens\"].hist(bins=50, alpha=0.5, label=\"Tokens (Roberta)\");\n",
    "plt.legend();"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df.boxplot(column=[\"n_words\", \"n_tokens\"]);"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>n_char</th>\n",
       "      <th>n_words</th>\n",
       "      <th>n_sentences</th>\n",
       "      <th>n_tokens</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>1000.000000</td>\n",
       "      <td>1000.000000</td>\n",
       "      <td>1000.000000</td>\n",
       "      <td>1000.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>3731.179000</td>\n",
       "      <td>638.256000</td>\n",
       "      <td>28.116000</td>\n",
       "      <td>888.068000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>1991.746719</td>\n",
       "      <td>342.448611</td>\n",
       "      <td>15.070955</td>\n",
       "      <td>482.138234</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>445.000000</td>\n",
       "      <td>76.000000</td>\n",
       "      <td>4.000000</td>\n",
       "      <td>117.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>2272.500000</td>\n",
       "      <td>385.000000</td>\n",
       "      <td>17.000000</td>\n",
       "      <td>546.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>3467.500000</td>\n",
       "      <td>594.000000</td>\n",
       "      <td>26.000000</td>\n",
       "      <td>827.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>4663.250000</td>\n",
       "      <td>793.250000</td>\n",
       "      <td>35.000000</td>\n",
       "      <td>1104.250000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>14524.000000</td>\n",
       "      <td>2649.000000</td>\n",
       "      <td>132.000000</td>\n",
       "      <td>3777.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             n_char      n_words  n_sentences     n_tokens\n",
       "count   1000.000000  1000.000000  1000.000000  1000.000000\n",
       "mean    3731.179000   638.256000    28.116000   888.068000\n",
       "std     1991.746719   342.448611    15.070955   482.138234\n",
       "min      445.000000    76.000000     4.000000   117.000000\n",
       "25%     2272.500000   385.000000    17.000000   546.500000\n",
       "50%     3467.500000   594.000000    26.000000   827.500000\n",
       "75%     4663.250000   793.250000    35.000000  1104.250000\n",
       "max    14524.000000  2649.000000   132.000000  3777.000000"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "29663722.txt\n",
      "A 39‐year‐old man presented in 1998 with shortness of breath during exertion. Nine years earlier, in 1989, he was treated for myocarditis after an upper respiratory tract infection presumably due to a self‐limited virus infection. No test was performed then for any specific viruses. The echocardiogram (ECHO) showed a mildly reduced septal movement of the left ventricle. A year later, during follow‐up, a new ECHO showed an entirely ordinary function of the left ventricle, but the left ventricular wall was at the upper reference thickness limit. In the following 8 years, he did not have any heart problems. There was no family history of heart disease.\n",
      "\n",
      "In 1998, the index patient experienced heart symptoms including breathlessness and therefore electrocardiography (ECG) and ECHO were performed. He had a regular sinus rhythm. Auscultation revealed a systolic murmur, heard best at the left parasternal region. The blood pressure was normal. The ECHO showed a thick interventricular septum at about 26 mm, and the posterior wall of the left ventricle was more than 16 mm thick. There were signs of outflow obstruction with a maximal flow velocity of 2.8 m/s at rest. An exercise test, where he cycled up to 130 W (55% of reference), was stopped because of a hypotension episode. He was initially treated with beta‐blockers. As no positive effect had been observed, he had a pacemaker (PM) implanted in 1999 with short A‐V interval. He was feeling better after PM implantation, and objectively, he was in a better condition.\n",
      "\n",
      "\n",
      "He experienced several problems with PM pocket infections that resulted in surgical extraction of the whole PM system in 2010. His clinical condition remained stable until 2013. Then he was admitted because of severe retrosternal chest pain that was due to a heart attack. Primary coronary angiography showed that the third marginal branch of the circumflex artery was occluded. The left anterior descending artery showed only slight atherosclerosis. The coronary circulation was ‘right dominant’ as the posterior descending artery was supplied by the right coronary artery, without any essential narrowing. He was treated with a drug‐eluting stent with a good result. As regards risk factors, he did not have any history of coronary artery disease and had no known thrombophilia. He was not obese, but he was smoking, which he stopped doing after the heart attack. He had slightly elevated cholesterol levels: total cholesterol of 6.8 mmol/L and LDL of 4.6 mmol/L. The ECHO showed a vigorous hypertrophied left ventricle with a septum thickness of 27 mm and at least moderate systolic dysfunction with a generally restrained wall motion. The worst abnormal movement was seen apically. No outflow obstruction was seen. The left atrium was moderately dilated. The pressure in the lung circulation was about 50 mmHg. The heart rate monitoring revealed short episodes of non‐sustained ventricular tachycardia, and this, together with the hypertrophied septum, prompted an implantable cardioverter defibrillator implantation. A year later, he suffered from atrial fibrillation attacks. During these episodes, he was extremely limited in his physical condition with severe dyspnoea, fatigue, and lack of energy, precluding any activity. A spirometry was also performed, showing a normal FEV1/VC ratio of 81% and normal total lung capacity. He had an optimal medical heart failure therapy with full‐dose beta‐blockers, angiotensin‐converting enzyme inhibitor and aldosterone antagonist. He was not a candidate for cardiac resynchronization therapy as he did not have a width‐increased QRS complex. Ablation of his atrial fibrillation would not have had any profound effect because of the severe impairment of the ventricle systolic function.\n",
      "\n",
      "In 2015, ECHO showed a slightly dilated (about 80 mL/m2), asymmetrically hypertrophied left ventricle with severe impaired systolic and diastolic functions. VO2 max cycling in 2016 showed that he had a severely reduced maximum oxygen uptake of 1.2 L/min, equal to 14 mL/kg/min. A heart catheterization was performed. At rest, there was hypokinetic circulation with a cardiac output of 3.6 L/min and a systolic system pressure around 105 mmHg. End‐diastolic left ventricular pressure was moderately elevated to 24 mmHg with a corresponding rise in the pulmonary capillary wedge pressure, and secondary to this, there was a moderate pressure increase in the pulmonary circulation (pulmonary pressure: 56/27 mmHg). Pulmonary vascular resistance was slightly higher, 2.7 mmHg/L/min. The filling pressure of the left ventricle rose even when he lifted his feet to the bike pedals at rest. During the exercise test load, the end‐diastolic left ventricular pressure was severely elevated up to 38 mmHg, corresponding to a rise in pulmonary capillary wedge pressure and secondary elevated pressure in the pulmonary circulation with systolic levels of 70 mmHg. Magnetic resonance imaging of the heart was not performed, but the patient underwent a myocardial biopsy that showed moderate interstitial fibrosis, focal cell hypertrophy, and even atrophy, with no signs of storage/infiltrative disease. His severe clinical deterioration as well as the ominous results of the above examinations prompted a new heart to be transplanted, and he has recently undergone the operation well.\n",
      "\n",
      "\n",
      "Genetic method\n",
      "\n",
      "Next‐generation sequencing with a heart cardiomyopathy gene panel, including 84 genes, was performed. The index patient was found to be homozygous for the MYBPC3 variant NM_000256.3:c.2618C>A,p.(Pro873His). Multiplex ligation‐dependent probe amplification was used to confirm that the MYBPC3 c.2618 G>A substitution was in true homozygous state. With American College of Medical Genetics and Genomics criteria14 for predicting pathogenicity of genetic variants, MYBPC3 c.2618 C>A was predicted to be ‘likely pathogenic’ (Class 2) in the heterozygous state.\n",
      "\n",
      "\n",
      "Clinical and genetic follow‐up of relatives\n",
      "\n",
      "Cascade genetic screening using Sanger sequencing was offered to family members, primarily to first‐degree relatives. The patient's parents were not alive and could not be genetically tested. There was no known consanguinity. So far, 12 family members have been analysed for the MYBPC3 c.2618 C>A variant. One brother to our index patient also had the mutation in the homozygous form and seven first‐degree or second‐degree relatives were shown to be heterozygous carriers of the variant. All the relatives who have the variant in heterozygous form have a normal ECG, a normal ECHO, and no heart problems so far.\n",
      "\n",
      "Our patient (III: 2 in the pedigree) has three children, one daughter and two sons. The youngest son (IV: 3 in the pedigree) has not been properly evaluated yet. The eldest son (IV: 1 in the pedigree), who is 29 years old, has the variant in heterozygous form. He has a normal ECG, a normal ECHO, and no heart problems. Our patient's daughter (IV: 2 in the pedigree) is 25 years old. She also has the variant in heterozygous form. She does not have any cardiopulmonary symptoms either. ECHO in 2016 showed a normal‐sized left ventricle with normal systolic and diastolic functions.\n",
      "\n",
      "The patient's sister (III: 4 in the pedigree), who is 43 years old, has the variant in heterozygous form. She does not experience any heart problems. Her ECG shows sinus tachycardia, with 105 b.p.m. and slight ST‐T changes inferiorly. The ultrasonography of the heart has been completely normal without any signs of cardiomyopathy. She has normal wall thickness of the left ventricle with normal systolic and diastolic functions. A cardiac stress test showed normal work capacity; she cycled up to 143 W (88% of reference) and stopped because of general fatigue. She has three children, two sons who are 16 and 10 years old (IV: 8 and 9 in the pedigree) and an 18‐year‐old daughter (IV: 7 in the pedigree). All of them have been offered genetic testing, and they are still waiting for the results. None of them have experienced any heart symptoms.\n",
      "\n",
      "The patient's 54‐year‐old brother (III: 3 in the pedigree) who has the variant in homozygous form cycled 220 W (corresponding to 95% of reference) during an exercise test. No arrhythmia and no evidence of underlying coronary insufficiency were seen. He can sometimes experience a chest discomfort even at rest but no pain, dizziness, fainting, or shortness of breath. The ECHO showed a normal‐sized left ventricle, regionally increased wall thickness, moderately increased septum (16 mm), slightly increased over the posterior wall (13 mm) and a normal systolic function (ejection fraction of about 56%). The ECG showed sinus rhythm with increased R‐wave amplitude in the left‐sided ECG leads, as seen in ventricular hypertrophy. This man has three sons (10, 16, and 20 years old; IV: 4, 5, and 6 in the pedigree). All of them are heterozygous for the variant and have normal ECGs and ECHOs. A cousin to our index patient (III: 1 in the pedigree) who is 52 years old also carries the variant in heterozygous form. He also has a normal ECHO and ECG and does not have any cardiac symptoms.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "30226919.txt\n",
      "The patient is a 60-year-old female with Chagas heart disease and cachexia, admitted due to heart failure decompensation attributed to bronchopneumonia. She eventually had a cardiac arrest with pulseless electrical activity after lung biopsy.\n",
      "\n",
      "The patient was being followed up at InCor since the age of 48 years, diagnosed with Chagas disease. She initially complained of palpitations, which subsided after amiodarone was prescribed. In addition, she had systemic arterial hypertension.\n",
      "\n",
      "Her laboratory tests revealed: potassium, 5.2 mEq/L; sodium, 144 mEq/L; creatinine, 0.8 mg/L; hemoglobin, 16.2 g/dL; hematocrit, 48%; glycemia, 87 mg/dL; cholesterol, 200 mg/dL; triglycerides, 53 mg/dL; TSH, 1.16 microIU/mL; free T4, 1.1 ng/dL; ALT, 8 IU/L; AST, 10 IU/L.\n",
      "\n",
      "At the time, the ECG revealed diffuse ventricular repolarization changes.\n",
      "\n",
      "The echocardiogram (August 2004) showed the following: aorta, 28 mm; left atrium, 52 mm; septal thickness, 11 mm; posterior wall, 7 mm; left ventricle (diast/syst), 71/62 mm; left ventricular ejection fraction (LVEF), 26%, with posterior (basal), inferior (basal) and lateral (basal) akinesia, and small apical aneurysm; right ventricle, 28 mm (dilated and hypokinetic); severe mitral regurgitation; and right ventricular systolic pressure, 65 mm Hg.\n",
      "\n",
      "The chest X-ray (2012) showed cardiomegaly.\n",
      "\n",
      "The Holter ECG at that time showed frequent ventricular extrasystoles and nonsustained ventricular tachycardia.\n",
      "\n",
      "The patient remained asymptomatic until 2013 (57 years of age) using hydrochlorothiazide (25 mg), spironolactone (25 mg), carvedilol (12.5 mg), enalapril (20 mg) and amiodarone (100 mg) daily. In April 2013, she had a resuscitated cardiac arrest, preceded by malaise and sustained ventricular tachycardia, receiving an implantable cardioverter defibrillator (ICD) with cardiac pacemaker programing for bradycardia episodes (ICD-T - ICD with antibradycardia and antitachycardia pacing and shock), being prescribed 600 mg of amiodarone daily.\n",
      "\n",
      "Five days before that episode, she had upper digestive bleeding with hematemesis, when endoscopy revealed gastric ulcer with no active bleeding, and clean base (Forrest III), with a lower risk for rebleeding.\n",
      "\n",
      "The patient experienced appropriate shock in May 2014. She was receiving an amiodarone dose lower than prescribed, thus the dose was increased, but the patient did not tolerate it because of dyspepsia. A cardiac electrophysiology study was indicated, aimed at the possible ablation of the sustained ventricular tachycardia pathways.\n",
      "\n",
      "The chest X-ray revealed pulmonary congestion and more severe cardiomegaly.\n",
      "\n",
      "The echocardiogram (August 4, 2014) revealed: aorta, 27 mm; left atrium, 43 mm; ventricular septal thickness, 9 mm, posterior wall, 8 mm; left ventricular diameters, 68/57 mm; LVEF, 30%. The left ventricle showed eccentric hypertrophy and reduced systolic function due to an inferolateral wall aneurysm (mid and basal segments) and an apical aneurysm. The right ventricle was normal. There was moderate mitral valve regurgitation. The pulmonary artery pressure was 25 mm Hg.\n",
      "\n",
      "Her coronary tomography angiography (July 28, 2014) evidenced no coronary lesion. The cardiac electrophysiology study (July 31, 2014) identified poorly-tolerated sustained ventricular tachycardia triggered by extra-stimuli, which required electric cardioversion. The electroanatomic mapping revealed a scar associated with low and slow late potentials in the lateral (mid and basal segments), antero-lateral (mid and basal segments) and inferolateral (mid and basal segments) walls. Because of the proximity to the circumflex sub-branches, the radiofrequency pulses were not delivered through the epicardium, but through the endocardium. After the procedure, the new stimuli no longer triggered ventricular tachycardia similar to that initially observed. However, several poorly tolerated tachycardias of different morphologies were triggered, requiring cardioversion.\n",
      "\n",
      "On outpatient follow-up (November 2014), the patient complained of dyspnea on exertion and dizziness when changing from supine to orthostatic position.\n",
      "\n",
      "Her physical examination (November 11, 2014) revealed: weight, 70 kg; height, 1.7 m; arterial blood pressure, 102/80 mmHg; heart rate, 68 bpm. The pulmonary auscultation was normal. On cardiac auscultation, her heart rhythm was regular with no abnormal heart sound, and a systolic heart murmur was heard over the mitral area (++/4+). The abdominal examination was normal. There was no edema, and her pulses were palpable and symmetrical. Because of her complaints and arterial blood pressure levels, hydrochlorothiazide was suspended, and the other medications, maintained.\n",
      "\n",
      "Her laboratory tests (October 2014) showed: hemoglobin, 13.2 g/dL; hematocrit, 43%; leukocytes, 7220/mm3 (normal differential count); platelets, 200000/mm3; total cholesterol, 180 mg/dL; HDL-cholesterol, 73 mg/dL; LDL-cholesterol, 88 mg/dL; triglycerides, 95 mg/dL; glycemia, 94 mg/dL; creatinine, 0.96 mg/dL; sodium, 141 mEq/L; potassium, 4.8 mEq/L; AST, 79 IU/L; ALT, 111 IU/L; uric acid, 4.2 mg/dL; C-reactive protein, 6.78 mg/L; TSH, 2.85 µg/mL; free T4, 1.62 mg/dL.\n",
      "\n",
      "On outpatient follow-up visits (October 2015 and March 18, 2016), she denied dyspnea, chest pain, palpitations and syncope, but complained of dizziness. The ICD/pacemaker assessment was normal.\n",
      "\n",
      "Her chest X-ray (2015) revealed pulmonary congestion and cardiomegaly.\n",
      "\n",
      "On September 22, 2016, the patient was admitted due to decompensated heart failure and bronchopneumonia. She reported progressive worsening of dyspnea, which was then triggered on mild exertion. She denied chest pain and fever, but reported dry cough, lack of appetite and weight loss. Her physical examination revealed an emaciated patient (53 kg), on regular general condition, tachypneic, with heart rate of 72 bpm, arterial blood pressure of 95/60 mm Hg, and O2 saturation of 92%. Her auscultation revealed rales over the pulmonary bases, rhythmic heart sounds, and systolic heart murmur over the mitral area (++++/6+). Her abdomen was flaccid, with a tender liver, palpated 2 cm from the costal margin. There was lower limb edema (+++/4+).\n",
      "\n",
      "The patient was using amiodarone (200 mg), enalapril (5 mg), hydrochlorothiazide (25 mg), levothyroxine (25 µg), metoprolol (100 mg), simvastatin (20 mg), warfarin (5 mg).\n",
      "\n",
      "Her ECG (September 22) showed: sinus rhythm; heart rate, 63 bpm; indirect signs of right atrial overload (Peñaloza-Tranchesi); low-voltage QRS complexes on the frontal plane; probable electrically inactive lateral area; left anterior-superior hemiblock. After a few days, the new ECG revealed an operational pacemaker with atrial stimulus propagating to the ventricle (AAI).\n",
      "\n",
      "Her chest X-ray (September 22, 2016) evidenced the presence of an ICD/pacemaker with electrodes in the left atrium and ventricle, pulmonary congestion, opacity area suggestive of pneumonia in the right pulmonary lower field (air bronchogram), elevation of the left main bronchus (suggestive of enlarged left atrium), and global enlargement of the heart area, attributed mainly to the right ventricle.\n",
      "\n",
      "Her laboratory tests (September 22) revealed: hemoglobin, 8.2 g/dL; hematocrit, 26%; leukocytes, 17500/mm3 (neutrophils 79%, eosinophils 0%, lymphocytes 15% and monocytes 6%); platelets, 344000/mm3; urea, 33 mg/dL; creatinine, 0.71 mg/dL; AST, 148 IU/L; ALT, 136 IU/L; gamma GT, 36 IU/L; alkaline phosphatase, 75 mg/dL; total proteins, 6.9 g/dL; albumin, 3.1 g/dL; C-reactive protein, 124.39 mg/L; sodium, 140 mEq/L; potassium, 3.6 mEq/L. Arterial blood gas analysis: pH, 7.54; pCO2, 31.1 mm Hg; pO2, 62.3 mmHg; O2 saturation, 93%; bicarbonate, 26.2 mmol/L; base excess, 3.9 mmol/L.\n",
      "\n",
      "Because of the diagnostic suspicion of pneumonia, ceftriaxone and clarithromycin were initiated.\n",
      "\n",
      "The dyspnea and edema improved, arterial hypotension episodes occurred, and the dry cough and mild hyperthermia (37.6ºC) persisted.\n",
      "\n",
      "Assessment of the ICD/pacemaker revealed 14 episodes of ventricular tachycardia in July 2016: 12 abolished by burst (high-frequency stimuli) and 2 abolished with 31-J shocks.\n",
      "\n",
      "Her echocardiogram (September 26, 2016) showed: aorta, 26 mm; left atrium, 60 mm; basal and mid right ventricle, 43 mm and 33 mm, respectively; ventricular septal thickness, 10 mm; posterior wall, 7 mm; left ventricle (diast/syst), 73/60 mm; LVEF, 40%. The atria were severely enlarged, the left ventricle was dilated with dyskinesia of the lateral wall (basal segment), akinesia of the inferior wall (basal segment), and apical aneurysm. The right ventricular function was normal. The mitral and tricuspid valves showed severe regurgitation due to inadequate leaflet coaptation. Systolic pulmonary artery pressure was estimated at 47 mmHg. No pericardial change was observed.\n",
      "\n",
      "On the days following admission, her laboratory tests continued to show leukocytosis (around 19000), anemia, hypoalbuminemia (1.9 g/dL) and elevated C-reactive protein (above 150 mg/L).\n",
      "\n",
      "A new chest X-ray detected an opaque nodule in the right base.\n",
      "\n",
      "Chest tomography (September 28, 2016) evidenced: pacemaker with endocavitary electrodes in the right chambers; dilation of the pulmonary trunk (41 mm); permeable trachea and main bronchi of normal caliber; diffuse thickening of the bronchial walls; enlarged pulmonary hila; and hilar calcifications that could be lymph node sequelae. There was an irregular nodule measuring 2.3 x 2.5 x 1.9 cm in the transition between the medial and lateral segments of the middle lobe, in addition to diffuse ground-glass opacity with septal thickening, mainly in the bases, compatible with congestion. Furthermore, there was a peripheral hyperdense area, close to the pleural surface of the right superior lobe, suggestive of subacute parenchymal bleeding or accumulation of amiodarone. The pulmonary vascularization was increased, and there was small bilateral pleural effusion. In the liver, low-density nodules were identified, but their assessment was limited due to lack of contrast media imaging. In addition, there were sparse nodular calcifications in the liver parenchyma, whose density was diffusely increased (suggestive of amiodarone deposition). Dilation of the inferior vena cava and of the hepatic veins, as well as ectasia of the gallbladder, was observed. No lymph node enlargement was identified. The heart was diffusely enlarged, with predominance of the left atrium.\n",
      "\n",
      "Because the patient was emaciated, had moderate reduction of the LVEF and altered pulmonary imaging, the search for consumptive syndrome causes other than heart failure began. Sputum tests (three samples on different days) were negative for acid-fast bacillus. The bacteriologic examination of the sputum revealed the usual local flora: Gram-positive bacilli, Gram-positive cocci, Gram-negative bacilli, Gram-negative diplococci and Gram-negative coccobacilli.\n",
      "\n",
      "The patient was submitted to biopsy of the pulmonary nodule (October 12, 2016), which revealed a granulomatous chronic inflammatory process with extensive area of necrosis. The search for fungi was negative and that for acid-fast bacillus was ongoing.\n",
      "\n",
      "On the night of October 12, 2016, 12 hours after the biopsy, the patient woke up complaining of ill-defined malaise. Her initial examination revealed arterial blood pressure of 50/40 mmHg, O2 saturation of 99% with O2 catheter, tachycardia and tachypnea. The patient had a cardiac arrest with pulseless electrical activity. She was resuscitated but developed asystole and died.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "32595119.txt\n",
      "The patient is a 51-year-old white man with a medical history significant for severe coronary artery disease resulting in cardiogenic shock (at one point requiring a short-term left ventricular assist device), heart failure with reduced ejection fraction estimated at 20%–25%, hypertension and schizophrenia who presented with his brother to the emergency department with 5-day history of fatigue, ataxia, altered mental status and abnormal behaviour.\n",
      "\n",
      "His brother states that he has been getting steadily worse, with multiple near falls and unsteadiness in 2 days leading up to admission. He has never had any symptoms like this before, and has poor insight into his symptoms. His behaviour and mental status have also been inappropriate, as the brother states he has been unable to complete activities of daily living such as bathing or feeding himself. His affect has also been more flat than normal, with the patient’s brother reporting significantly longer time to respond to questions than his baseline. He also reported one episode of hyper elation and agitation that resolved after several hours. He has been alert and oriented to only person and place, but not time (normally he is fully oriented). The patient denies any shortness of breath, chest pain, nausea, headache, vomiting, diarrhoea or decreased oral intake. He and his brother deny any trauma. The patient denies any hallucinations, delusions, depressed mood or worsening negative symptoms of schizophrenia. His medication regimen is notable for spironolactone 25 mg daily, torsemide 200 mg two times per day and metolazone 2.5 mg daily for diuresis. This large dose of diuretics was due to a recent hospitalisation for congestive heart failure exacerbation with volume overload. It was during this hospitalisation that torsemide was increased, and spironolactone was added with metolazone. His other home medications included atorvastatin 80 mg daily, clopidogrel 75 mg daily, hydroxyzine 25 mg as needed for itching, mirtazapine 30 mg daily, olanzapine 10 mg daily, trazodone 50 mg as needed for sleep, metoclopramide 5 mg as needed for nausea and pantoprazole 40 mg two times per day for heartburn. While the patient does have a history of poor medication adherence and health literacy, his brother states that he has been taking his medications as prescribed leading up to the onset of these symptoms.\n",
      "\n",
      "The patient had a blood pressure of 91/73 mm Hg on admission, with his normal baseline systolic blood pressure being around 100 mm Hg. His pulse, temperature, oxygen saturations and respiratory rate were within normal limits. On physical examination, he was generally in no acute distress. He was alert and oriented, with no focal neurologic deficit, and a flat affect. He had very dry mucous membranes, decreased skin turgor and no oedema. His cardiac examination was notable for an irregular rhythm, no appreciated jugular venous distention with equal peripheral pulses. His pulmonary examination was overall clear to auscultation. Abdomen was non-distended, with normal bowel sounds.\n",
      "\n",
      "Basic metabolic panel on admission was notable for a serum sodium of 108 mmol/L, potassium of 1.5 mmol/L, chloride of 65 mmol/L, blood urea nitrogen (BUN) of 82 mg/dL and a creatinine of 2.32 mg/dL (baseline 1.2 mg/dL). His serum osmolality was 242 mOsm/Kg H2O. His urine sodium was 20 mmol/L, urine potassium 25.6 mmol/L, urine chloride 20 mmol/L and urine osmolality 204 mOsm/kg H2O. His brain natriuretic peptide (BNP) was 2113 pg/mL, which is around his baseline. His glucose on admission was 119 mg/dL. His most recent lipid panel from 8 months prior had a total cholesterol of 263 mg/dL, high-density lipoprotein (HDL) of 37 mg/dL, low-density lipoprotein (LDL) of 183 mg/dL and triglycerides of 217 mg/dL.\n",
      "\n",
      "Notable imaging includes a non-contrast CT head that was unrevealing for acute abnormalities, and his ECG was found to have no changes from the previous studies. In the setting of the patient’s presenting symptoms and severe hyponatremia, he was admitted to the internal medicine teaching service.\n",
      "\n",
      "\n",
      "Outcome and follow-up\n",
      "\n",
      "Given his significant electrolyte abnormalities, prerenal azotemia, extensive and recently advanced home diuretic regimen and hypovolemic physical examination, the patient was assessed to be in severe hypotonic hyponatremia due to hypovolemia from over-diuresis as the cause of his presenting symptoms. In concordance with cardiology consultation, he was treated with gradual sodium correction with isotonic fluids. Normal saline was introduced at 100 mL/hour, with sodium checks in every 4 hours to avoid correction greater than 8–10 mmol/L in 24 hours. His home diuretics were held while correcting sodium. We also held his other home medications, including his schizophrenia medication olanzapine due to the risk of syndrome of inappropriate antidiuretic hormone (SIADH), which may worsen his hyponatremia. In addition, with the patient’s hypokalemia requiring aggressive repletion, we were concerned with continuing his olanzapine and its inherent risk of QT-interval prolongation. His electrolytes improved on this therapy, with a peak in sodium to 119 mmol/L on the morning of hospital day 4. However, by that afternoon, his sodium actually decreased to 116 mmol/L. At this point, his potassium and chloride had corrected, and his creatinine returned close to baseline. His presenting symptoms of ataxia, altered mental status and fatigue had slightly improved. He was able to walk around the room with supervision and had no falls. He was awake throughout the day and did not report fatigue. However, given that he was a poor historian with a very flat affect secondary to his schizophrenia history, it was difficult to ascertain his insight into his symptoms. It was also difficult to tell if his negative symptoms had worsened while holding olanzapine, but his brother confirmed that he was around his baseline in this regard. While he was oriented to person, place and time, his lack of insight and inability to describe his concerns remained a challenge throughout the hospitalisation.\n",
      "\n",
      "Following his initial presentation and volume repletion, his physical examination, symptoms, labs and imaging supported an euvolemic aetiology of his hyponatremia. He remained clear on pulmonary auscultation and did not have any abdominal distention, jugular venous distention or lower extremity oedema. He also did not report any cough, orthopnea, or paroxysmal nocturnal dyspnoea. His BNP had decreased to 1837 pg/mL. A chest radiograph showed right basilar atelectasis with possible infiltrate, but was mostly stable compared with baseline. In conjunction with an euvolemic hyponatremia, an evaluation for SIADH was started. This was not only supported by his current examination status, but he was also being treated with olanzapine prior to admission, which has a risk for SIADH. His intravenous fluids were stopped and he was placed on a 1000 mL/day fluid restriction. However, his hyponatremia failed to significantly improve with a value of 117 mmol/L on the morning of hospital day 5, and 118 mmol/L on the morning of day 6. His urine electrolytes included a urine sodium of less than 20 mmol/L, urine potassium 26.9 mmol/L, urine chloride 23 mmol/L and urine osmolality 315 mOsm/kg H2O. His low urine sodium suggested that SIADH was not the aetiology of his hyponatremia. He remained clinically euvolemic on physical examination on hospital day 6, including normal pulmonary examination to auscultation, no jugular venous distention, no oedema, normal capillary refill and no abdominal distention. He also did not report cough, orthopnea or paroxysmal nocturnal dyspnoea, and continued to state that he had been resting comfortably every night.\n",
      "\n",
      "In the setting of likely mismanagement of this patient’s hyponatremia, the primary inpatient teaching service used point-of-care ultrasound on the morning of hospital day 6 to better assess the patient’s volume status. The patient was found to have a moderate-sized right pleural effusion and diffuse pulmonary parenchymal B-lines suggesting pulmonary oedema. His inferior vena cava appeared plethoric and its diameter measured 2.5 cm with no respiratory variation. His estimated Caval Index was 1, given this lack of respiratory change, which is significantly higher than the estimated 0.35 in euvolemic patients.2 In all, the ultrasound findings supported hypervolemia. As a result, a diuretic regimen was started with oral torsemide 60 mg two times per day and his volume response and sodium were monitored closely. His sodium improved to 126 mmol/L on hospital day 7, and then he was successfully discharged home with a sodium of 132 mmol/L on hospital day 8. He was stable at time of discharge, with discharge summary stating to monitor volume status closely in upcoming appointments. He was also counselled on medication adherence, frequent weight monitoring and fluid restriction. Home health services were called prior to his discharge to discuss assisting his mother and brother with his care.\n",
      "\n",
      "While the internal medicine teaching service and the cardiology service recommended discharge to skilled nursing facility to help manage his medications and chronic debility, he wanted to be discharged home to his mother and brother. He followed up with his cardiologist 2 weeks after discharge, and was scheduled with his primary care physician but never arrived at that appointment. At the time of his cardiology follow-up, his diuretic regimen was torsemide 100 mg two times per day (down from 200 mg two times per day), spironolactone 25 mg daily (same as prior to hospitalisation) and metolazone 2.5 mg daily (same as prior to hospitalisation). In setting of his heart failure with reduced ejection fraction, he was started on 25 mg daily of metoprolol succinate. He had also resumed his home medications that were held during the hospitalisation, most notably olanzapine 10 mg daily and mirtazapine 30 mg daily for his schizophrenia. He had no complaints of fatigue, altered mental status, ataxia or abnormal behaviour. His sodium at this visit was 130 mmol/L, somewhat stable since discharge. Medication non-adherence remained an issue at follow-up, with patient having little understanding of his medical history or current medications. Home healthcare services assisted with medication adherence.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "35456383.txt\n",
      "A 28 year-old male was referred to the clinic in February 2019 with complaints of episodes of greyout in the eyes, accompanied by a decrease of the heart rate to 40 BPM, and reduced tolerance for physical exertion. The patient underwent clinical examination including collection of venous blood samples for DNA-diagnostics, blood tests (full blood count, biochemical panel and international normalized ratio, INR), electrocardiography (ECG), 24-h ECG monitoring, echocardiography (ECHO), chest computed tomography (CT), liver magnetic resonance imaging (MRI), and liver biopsy (hematoxylin and eosin staining, Van Gieson staining, Perles staining).\n",
      "\n",
      "Whole exome sequencing (WES) for the proband’s DNA was performed using a SureSelect All Exons V7 library preparation kit (Agilent Technologies, Santa Clara, California, USA) followed by next-generation sequencing on an Illumina platform (NextSeq 550, Illumina, San Diego, CA, USA). Reads were aligned to the human genome build GRCh37/UCSC hg19 and the variant calling with an automatic module EMSEMPLE_VEP with the following analyze of the sequence variants using a custom-developed bioinformatics pipeline. Confirmation of genetic findings in proband was performed by capillary Sanger resequencing on an ABI 3730XL DNA Analyzer according to the manufacturer’s instructions (Thermo Fisher Scientific, Waltham, MA, USA). The direct capillary Sanger resequencing with alternative oligoprimers was performed for the coding exons and flanking 100 bp of intronic areas of the HFE gene to avoid an occasional loss of the second rare variant on NGS testing.\n",
      "\n",
      "Pathogenicity assessment of all variants confirmed by Sanger re-sequencing was performed according to ACMG (2015) criteria (on behalf of the ACMG Laboratory Quality Assurance Committee) [5].\n",
      "\n",
      "The study was performed in concordance with the Declaration of Helsinki in its current form and approved by the Sechenov University Local Ethics Committee (protocol № 11–15 from 16 February 2019), Moscow, Russia. Voluntary informed consent was obtained from the patient.\n",
      "\n",
      "Significant events in the patient’s family history were found in the mother’s male lineage: a fatal stroke at 50 years of age in an uncle; the death of the grandfather at 53 years of age. No other family members were affected by RCM. The patient did not smoke, drink alcohol, or follow any special diet. He has worked out regularly at the gym (moderate exercise). From 23 years of age (2014), complete right bundle brunch block (RBBB) on the ECG and frequent premature supraventricular beats (PSBs) appeared. Since 2017, there have been episodes of transient II degree, type 2 AV block, accompanied by presyncope. From this period, the patient started taking paroxetine 20 mg/day due to depressive disorder. In November 2018 there was an episode of CHF decompensation with ascites, hydrothorax, hydropericardium, which required hospitalization in the emergency department. A bit later, a transient III degree AV block was registered. The ECHO revealed moderate hypertrophy of the left ventricle (LV, septum, and posterior wall 1.4 cm), left atrium (LA) dilatation up to 112 mL and diastolic dysfunction with a restrictive filling pattern. Ejection fraction (EF) of LV was preserved (66%). To rule out the glycogen storage disease, the activity of lysosomal enzymes was assessed: all indexes were normal. As well, a cardiac MRI was performed: LV EF 53%, interventricular septum 1.2 cm, LA 200 mL, diffuse accumulation of contrast with thickened endocardium (3–4 mm) of both left and right ventricles, site of intramyocardial late gadolinium enhancement (LGE) in LV were observed.\n",
      "\n",
      "On examination in our clinic, the patient had a regular pulse (110 BPM), BP was 140/80 mm Hg. A single hyperpigmentated site (3 cm) was on the forearm skin. Physical examination revealed enlargement of the liver (+2 cm from the costal margin). No signs of pulmonary congestion or peripheral edema were found.\n",
      "\n",
      "Blood tests including full blood count, biochemical panel (including creatine kinase) and INR were normal except for an increase in serum iron level (40.9 μmol/L, normal range 9–31), transferrin saturation percentage (85.2%) and slightly elevated liver function tests (AST 39 U/L, ALT 63 U/L). The ECG showed bifascicular block. The ECHO confirmed the presence of restrictive cardiomyopathy with hyperechogenic and layered LV myocardium, which could be the sign of storage disease. Chest CT was normal, without any signs of mediastinum lymphadenopathy. Liver MRI confirmed hepatomegaly.\n",
      "\n",
      "Early onset of symptoms, their gradual and steady progression, combined with features of clinical course made the diagnosis of primary RCM the most probable. The whole exome sequencing was performed. A mutation in the sarcomeric gene desmin (DES) in the heterozygous state was found. Missense variant chr2:g.220290456C>T (ENST00000373960.3:c.1360C>T, ENSP00000363071.3:p.Arg454Trp) in the DES gene affects the tail region of desmin protein in a direct neighborhood of CRYAB-interacting domain (aminoacids 438–453) [6]. This variant was shown to disturb severely filament-formation competence and filament-filament interactions, and to increase interaction with CRYAB protein (PS3 strong criterion) [7], not found in gnomAD genomes (PM2_Supporting); its pathogenic computational verdict was based on 12 pathogenic predictions vs. no benign predictions (PP3_Supporting criterion), and ClinVar classifies this variant as Pathogenic with two stars (multiple consistent, 10 submissions) (PP5_Supporting). Summarizing this evidence, we classify this variant as Likely Pathogenic (Class IV). DNA samples from parents were unavailable and the origin of the mutation (de novo vs. inherited) was not tested.\n",
      "\n",
      "At the same time, the prominent RCM phenotype required ruling out its secondary forms. Amyloidosis was highly unlikely, due to the age of the patient and early onset of symptoms. Cardiac sarcoidosis was more likely among the secondary forms (a typical pattern of LGE in MRI, RBBB combined with severe AV block), but chest CT demonstrated no signs of sarcoidosis. There is an accumulation of contrast with thickened endocardium by MRI but the absence of eosinophilia in the blood and intraventricular thrombosis made Loeffler endocarditis unlikely. Blood tests showed a marked increase in serum iron level and transferrin saturation and a moderate increase of liver function tests, together with liver enlargement and site of skin hyperpigmentation it made hemochromatosis plausible. In the HFE1 gene, a recessive mutation, typically associated with hemochromatosis was found, but in heterozygous state: missense variant chr6:g.26093141G>A (ENST00000357618.5:c.845G>A, ENSP00000417404.1:p. Cys282Tyr). This variant is a well-known common mutation (prevalence is 0.03825 in gnomAD genomes) [8]. It affects the Alfa-3 region of Hereditary hemochromatosis protein (aminoacids 206–297) and posttranslational modification of the protein disturbing disulfide bond between 225Cys and Cys282 aminoacids [9] (Criterium PS3_Strong and PM1_Strong); pathogenic computational verdict based on 7sevenpathogenic predictions vs. 3 benign predictions (PP3_Supporting); it was classified as pathogenic in more than 10 articles and many ClinVar submitters (PP5_Strong). Taking all the evidence, we classify this variant as Pathogenic (Class V). As it is in a heterozygous state, it does not fully confirm but also does not deny the presence of hemochromatosis.\n",
      "\n",
      "The patient had absolute indications for implantation of a pacemaker. However, because of unpredictable progression of CHF and as a consequence of highly possible ventricular rhythm abnormalities, a cardioverter defibrillator (ICD) was implanted. CHF treatment was initiated (bisoprolol up to 5 mg/day with subsequent withdrawal, torasemid 5 mg/day and spironolactone 25 mg/day). A diet with a strict restriction of iron was recommended.\n",
      "\n",
      "The patient was admitted again in December 2019 to correct the treatment. He was doing well except for episodes of irregular heartbeat. The physical examination revealed hepatomegaly (+3 from the costal margin), the consistency of the liver was firm, palpation was painless. The ECHO did not show any significant dynamics. Holter monitoring revealed 7700 PSBs. Lappaconitine hydrobromide (class IC) 75 mg/day was administered. The number of PSBs reduced to 1500/day. Blood tests showed an increase in hemoglobin to 17.5 g/dL, erythrocytes 5.8 × 106/L, hematocrit 51%, a moderate increase in total and direct bilirubin, normalization of serum iron level and transferrin saturation percentage. The last, however, did not allow us to rule out hemochromatosis. In addition, a significantly enlarged and firm liver in the absence of other signs of right-sided heart failure could be considered to be a sign of hemochromatosis.\n",
      "\n",
      "A liver biopsy was obtained to verify the diagnosis of hemochromatosis, assess its possible contribution to the RCM progression and determine indications for treatment. The biopsy revealed three groups of morphological changes: (1) The nuclei of several hepatocytes were large with optically empty vacuoles. Fragments of the cytoplasm of some hepatocytes resembled ground glass (hyperplasia of the granular endoplasmic reticulum). Moderate focal hydropic and balloon dystrophy of hepatocytes of zones 2 and 3 of the acinus and moderate diffuse fine fatty dystrophy of hepatocytes (up to 40%) without zonal predominance (++) were observed. In the cytoplasm of hepatocytes of acinus zones 2 and 3, there were moderate amounts of small and large greenish-brown Pearl’s-negative granules: bilirubin. Diffuse steatosis (++), bilirubinostasis and cholangiopathy, and signs of hepatocytes hyperfunction are consistent with drug exposure to the organ; (2) dilation of centrilobular sinusoids, central vein sclerosis and capillarization of adjacent sinusoids may be the consequence of prolonged CHF; (3) mild hemosiderin accumulation is a sign of hemosiderosis (+).\n",
      "\n",
      "Two years later, the patient remains relatively stable. He is now on the waiting list for heart transplantation in the case of deterioration or heart failure.\n",
      "\n",
      "\n",
      "\n",
      "33863765.txt\n",
      "A 77-year-old man presented to the emergency department with worsening shortness of breath, weakness and fatigue on a background of severe AS awaiting elective SAVR. His background history was also notable for stage 1 prostate cancer which was under surveillance, osteoporosis, pernicious anaemia and lumbar spinal stenosis. He noticed worsening shortness of breath 7 weeks prior to admission and a declining exercise tolerance. He was under surveillance for AS for the past 12 years but became symptomatic 11 months prior to this presentation. His dyspnoea had worsened from New York Heart Association (NYHA) II at baseline to NYHA IV dyspnoea. He was feeling generally weak and had taken minimal oral intake in the days prior to admission. He attended his general practitioner 4 days prior to admission and was prescribed coamoxiclav with no improvement in symptoms for a presumed lower respiratory tract infection. He had no significant family history, drank 7 units of alcohol per week and was a non-smoker. He lived at home with his partner and was independently mobile and independent in his activities of daily living. He was due to undergo elective SAVR the same week of admission and was planning to liaise with the admissions department the following day to see if a bed was available.\n",
      "\n",
      "He was sinus tachycardic on presentation at a rate of 105, however, his other vital signs were within normal limits. He had fine bibasal end-inspiratory crackles, an elevated jugular venous pressure (JVP), bipedal oedema to his shins and a loud ejection systolic murmur over the aortic area. Bedside echocardiographic findings were in keeping with severe low flow/low gradient AS.\n",
      "\n",
      "An initial diagnosis of decompensated congestive cardiac failure secondary to severe AS and AI with hypervolaemic hyponatraemia was made. The patient underwent diuresis with a 40 mg bolus of intravenous furosemide with subsequent regular two times per day intravenous dosing and underwent strict fluid balance monitoring and had serial troponins and biochemistry done 4 hourly overnight.\n",
      "\n",
      "That evening, the patient developed haemodynamically significant atrial fibrillation with a rapid ventricular rate of 140 bpm and a blood pressure (BP) of 90/60 mm Hg requiring transfer to the coronary care unit for intravenous amiodarone infusion. He was successfully chemically cardioverted back to normal sinus rhythm and had normalisation of his BP.\n",
      "\n",
      "The following day he began to have worsening dyspnoea and orthopnea despite three doses of intravenous furosemide 40 mg and his sodium remained static at 116. He also remained clinically overloaded on examination and was commenced on a furosemide and dobutamine infusion. He was seen by the cardiothoracic team who felt he was unsuitable for SAVR in light of pulmonary oedema and hyponatraemia and recommended medical therapy with a view to re assess suitability for SAVR once stabilised. He subsequently became hypotensive and his clinical status deteriorated despite optimal medical management with furosemide infusion titrated up to 240 mg/24 hours and dobutamine to 7.5 μg/kg/hour. Further up titration in dobutamine was not tolerated due to the development of haemodynamically significant atrial fibrillation. The patient developed KDIGO III acute kidney injury (AKI) becoming oliguric 3 days into admission with an uptrend in urea and creatinine noted. Metolazone was added to facilitate diuresis and a moderate improvement in sodium was noted to 124.\n",
      "\n",
      "Day 4 into admission, the patient deteriorated further and began to desaturate on room air. He looked increasingly tired and pale and was finding it difficult to speak. An emergency non-contrast-gated cardiac CT was arranged in light of the patients renal function to facilitate the possibility of eTAVI the following morning which revealed a type 1 L–-R bicuspid valve. An elective TAVI that was due to occur the following day had been cancelled, opening up an emergency slot. A discussion was held with the patient and his family explaining the he was no longer suitable for SAVR but TAVI in this context also carried significant risks. After deliberation the patient gave his consent to proceed with eTAVI 5 days into admission.\n",
      "\n",
      "\n",
      "Investigations\n",
      "\n",
      "The patient’s pre admission echo showed peak and mean gradients of 76/50 mm Hg, respectively, severe aortic valve calcification, an aortic valve area (AVA) of 0.63 cm2 and a left ventricular ejection fraction (LVEF) of 50%. Furthermore, he had a normal coronary angiogram performed 3 months prior.\n",
      "\n",
      "Laboratory investigations revealed the following: troponin 181 ng/L, N-terminal (NT)-pro-brain natriueretic peptide (BNP) 26 323 ng/L, sodium 116 mmol/L, serum osmolarity 248 mOsmol/Kg, urinary osmolarity 845 mOsmol/kg, urinary sodium <20 mmol/L, urea 8.6 mmol/L, haemoglobin 106 g/L, mean corpuscular volume (MCV) 93.3fl, mean corpuscular haemoglobin (MCH) 32.5 pg and C reactive protein (CRP) 12.56 mg/L. The remaining biochemistry, including thyroid function tests and cortisol, was within normal limits\n",
      "\n",
      "A repeat echocardiogram was performed which revealed globally reduced left ventricular systolic function with an approximate LVEF of 20%, severely calcified and immobile aortic valve leaflets suggestive of a functionally bicuspid valve with severe concurrent aortic incompetence (pressure half time of 180 ms). A peak and mean gradient of 31 mmHg and 20 mmHg, respectively, and an AVA of 0.7 cm2 was noted. There was moderate to severe tricuspid regurgitation and less than 50% inferior vena cava collapse.\n",
      "\n",
      "An emergency CT coronary angiogram and thoracic aorta was performed on day 4 to delineate aortic anatomy and to facilitate valve sizing. No contrast was administered due to the patient’s worsening renal failure. Preoperative measurement taken from the patient’s non-contrast cardiac CT showing an annulus perimeter of 76.7 mm. Non-contrast cardiac CT also demonstrates heavy calcification of the leaflets into the left ventricular tract with a suggestion of a type I L–R bicuspid valve (Sievers classification). Although image quality is enhanced with contrast, accurate ECG gating and appropriate heart control during the scan can produce adequate imaging for TAVI planning in patient with concurrent renal disease.\n",
      "\n",
      "\n",
      "Diagnosis\n",
      "\n",
      "Severe bicuspid AS with cardiogenic shock and cardiorenal syndrome.\n",
      "\n",
      "\n",
      "Treatment\n",
      "\n",
      "An eTAVI was carried out under general anaesthetic to facilitate transeosophageal echocardiogram (TOE) guidance due to severe left ventricular dysfunction and severe agitation. Right radial access was gained with a 7-French glidesheath and 0.018 cm wire was placed in the right superficial femoral artery using a long multipurpose catheter. Right femoral access was gained using a micropuncture kit and two proglides were prepared. A 14 French sheath was inserted into the right common femoral artery. Six thousand units of intravenous heparin was administered. Activated clotting time was 320 s. The valve was crossed with a straight wire and a safari wire was placed in the left ventricle. The aortic valve was predilated with a 22 mm Numed balloon (NuMed, New York, USA) and a 34 mm Core Valve Evolut Pro (Medtronic, Minneapolis, Minnesota, USA) was then deployed. The 1–2+ paravalvular leak was noted on TOE after valve deployment. The right femoral artery was closed with two proglides and a TR band was placed over the right radial artery. No contrast media was administered during the procedure and post dilatation was avoided due to severely a calcified bicuspid native aortic valve. No new left bundle branch block, atrioventricular block or PR prolongation were noted following the procedure. The patient was transferred to the cardiac care unit for monitoring after the procedure.\n",
      "\n",
      "\n",
      "Outcome and follow-up\n",
      "\n",
      "No postprocedural complications were noted and the patients BP normalised with dobutamine support post eTAVI. His post-eTAVI echo revealed an improvement in his LVEF from 20% to 30% with mild paravalvular leak. No significant procedural-related complications were encountered during the course of the admission and inotropic support was weaned on day 2 postprocedure.\n",
      "\n",
      "Trends in the patient’s BP, urine output (UO), creatinine and sodium over the course of the admission. He was commenced on a furosemide infusion at day 1, dobutamine at day 2 and eTAVI was performed on day 5. He underwent haemodialysis on days 7, 8 and 11. Dobutamine and furosemide infusions were weaned on day 7. Graph A illustrates systolic and diastolic BP measurements taken during admission. Normalisation of systolic BP is seen acutely post-TAVI. Graph B illustrates UO recorded over a 24-hour period. UO was down trending since admission due to cardiorenal syndrome. Further worsening in UO was noted post-TAVI due to acute tubular necrosis (ATN). The patient subsequently became polyuric 4 days post-TAVI due to resolution of the prerenal insult and ATN. Graph C illustrates creatinine trends during the admission. Creatinine levels begin to downtrend 6 days post-TAVI with concurrent haemodialysis days 7, 8 and 11 of admission. Graph D illustrates sodium levels which normalised after cardiac output improvement post-TAVI and subsequent diuresis.\n",
      "\n",
      "He was discharged to his local regional hospital after a 21 day admission and underwent inpatient rehabilitation. Currently, the patient is back to his baseline function and remains at home living independently 6 months postprocedure. His discharge echo revealed an EF of 40% with a mild paravalvular leak.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "33544806.txt\n",
      "Clinical history\n",
      "\n",
      "Four years before the admission described in this paper, a 13-year-old male patient, known to have idiopathic biventricular dilated cardiomyopathy, was registered in our Emergency Institute for Cardiovascular Diseases and Transplantation. He was included on the waiting list for heart transplantation. After two years, his condition worsened and presented the clinical picture of cardiogenic shock. At that time, he was urgently hospitalized, intubated and ventilated, with extracorporeal membrane oxygenation (ECMO) back-up. As the creatinine level was slightly elevated, he also needed renal support. A cf-LVAD was implanted at another clinic.\n",
      "\n",
      "In the early postoperative phase, the pump’s power consumption increased. This was an indicator of possible pump thrombosis. Unfractionated heparin and systemic thrombolysis with tissue plasminogen activator (tPA) was carried out. As the pump function did not improve, it was replaced with another pump six days after LVAD implantation. After another two weeks, a transient stroke and mild pancreatitis were diagnosed, without significant complications. In the early and late postoperative days, several bleeding episodes occurred, one with cardiac tamponade, which required reintervention.\n",
      "\n",
      "During hospitalization, the patient presented with a fever (38°C) and elevated serum levels of C-reactive protein (CRP >200 mg/dL; normal range <5 mg/dL). As a sputum culture was positive for Klebsiella pneumoniae and coliform bacilli, Meropenem and Vancomycin were administrated with good results.\n",
      "\n",
      "After obtaining normal LVAD function, progressively increasing systemic blood pressure required the long-term administration of Enalapril 20 mg bis in die (BID – twice a day) and Bisoprolol 5 mg quaque die (QD – once a day). As renal function improved after the LVAD implant, there was no need for diuretics at discharge.\n",
      "\n",
      "No other significant or uncontrolled events occurred in the first year. At 12 months after the LVAD implant, the patient suffered two episodes of brain hemorrhage, for which he was hospitalized and operated on twice in the Clinic of Neurosurgery, without sequelae. In the following six months, he had another three small hemorrhagic strokes causing hemianopsia, without motor deficit. He also showed repeated episodes of kidney decompensation, with serum creatinine levels up to 2.7 mg% (normal ranges 0.6–1.2 mg%). This was kept under control with diuretics.\n",
      "\n",
      "The patient neglected to have properly monitored coagulation parameters in the ambulatory and did not regularly control the blood pressure values.\n",
      "\n",
      "Present admission\n",
      "\n",
      "Clinical findings\n",
      "\n",
      "At 18 months after LVAD implant, the 17-year-old normosthenic male was hospitalized with the suspicion of acute appendicitis. We noted altered general status, intense abdominal pain, headache, dyspnea, and fatigue after limited physical effort. On admission, the patient was conscious, partially cooperative and without fever. Cardio-respiratory function was checked: pump sound was detected with cardiac auscultation, there was no palpable peripheral pulse, mild peripheral edema, no pulmonary crackles. The medium systolic blood pressure was 100 mmHg. On palpation of the abdomen, there was no muscular defense, but the liver was enlarged.\n",
      "\n",
      "The patient was undergoing therapy with anti-hypertensive medication, which included an angiotensin-converting enzyme (ACE) inhibitor (Enalapril 20 mg BID) and alpha–beta blocker (Carvedilol 12.5 mg BID). Long-term treatment with an antiaggregant (Aspirin 100 mg QD), an anticoagulant [Acenocoumarol QD for international normalized ratio (INR) 2–3], a diuretic (Furosemide 40 mg QD) and a proton pump inhibitor (Omeprazole 20 mg BID), was also declared.\n",
      "\n",
      "Laboratory examinations\n",
      "\n",
      "On admission, the hematological and serum biochemical analyses showed a compensated renal function (creatinine – 1.13 mg/dL, creatinine clearance – 98 mL/min, urea – 36.8 mg%), with mild elevated uric acid (9.81 mg%, with normal ranges of 3.5–7.2 mg/dL). Liver enzymes were within normal ranges, with serum glutamic–oxaloacetic transaminase (GOT) of 9 IU/L (normal ranges 5–34 IU/L) and glutamate–pyruvate transaminase (GPT) of 6 IU/L (normal value <55 IU/L), same as the value of total bilirubin (0.47 mg/dL).\n",
      "\n",
      "A slightly high level of serum procalcitonin (1 ng/mL, with normal range <0.5 ng/mL), and a normal value of lactate dehydrogenase (LDH), respectively 110 mg/dL, were also reported. An acute infection was dismissed by normal serum level of CRP (5 mg/dL) and total leukocytes, which were 6000/μL (normal values 3600–10 000/μL) [6].\n",
      "\n",
      "Coagulation parameters showed a poorly controlled risk of hemorrhage, with an INR value of 5.4, under anti-coagulant treatment (reference for INR: 2–3). This was associated with normal platelets (275 000/μL; normal range 150 000–450 000/μL) and low hemoglobin values (8.6 g/dL; normal ranges 11–17 g/dL).\n",
      "\n",
      "During hospitalization, the laboratory examinations indicated the progressive development of multiple organ failure syndrome (MOFS). Two weeks after admission, renal failure was proved by the following parameters: high creatinine (9.02 mg%); low creatinine clearance (10 mL/min; normal reference ranges 107–139 mL/min); uremia (235 mg%); hypoproteinemia (plasma proteins: 5 g/dL; normal values 6.4–8.3 g/dL); low plasma albumin (2.2 g/dL; normal values 3.5–5.2 g/dL); high uric acid (17.66 mg%). Liver enzymes were kept within normal ranges (GOT – 23 IU/L, GPT – 17 IU/L), with progressively increasing total bilirubin (2.02 mg/dL) and LDH (222 mg/dL) and normal values of leukocytes (9120/μL). Hemoglobin decreased to 6.8 g/L.\n",
      "\n",
      "The urine test detected hematuria, proteinuria and leukocyturia, without detection of nitrites, bilirubin, or urobilinogen and without modification of the urine density (1.025; normal values 1.005–1.030).\n",
      "\n",
      "Imagistic investigations\n",
      "\n",
      "On admission, chest X-rays showed no modifications of the lungs, a dilated heart and the LVAD in the apex of the LV. An electrocardiogram revealed left fascicular hemiblock and right bundle branch block, with a heart rate of 80 beats/min (bpm). The echocardiography showed dilatation of all ventricular and atrial cavities, with decreased ejection fraction (EF) of the LV at 10% (normal value >60%). Moderate hypokinetic right ventricle, mitral and tricuspid regurgitation was diagnosed, with properly working inflow cannula at the apex of the LV.\n",
      "\n",
      "Abdominal ultrasound examination detected hepatosplenomegaly and enlarged kidneys, with increased echogenicity of the renal cortex. A pseudonodular lesion was described at the lower splenic pole, without enlargement of the appendix. In the first days, the computed tomography (CT) examination of the cranial cavity did not show acute parenchymatous lesions but confirmed the patient’s history of repeated strokes. Through the 38/33 mm (centro-central/latero-lateral) right parietal craniotomy orifice, minimal extracranial herniation of the brain tissue was obvious. Hypodense lesion located at the level of the left lentiform nucleus and at the body of the left caudate nucleus, was suggestive of a healed ischemic stroke, with associated porencephalia.\n",
      "\n",
      "During the three months of hospitalization, CT scans performed during the seizures revealed new hemorrhagic outbreaks. In the last stages, chest X-ray showed diffuse veiling of both lung areas, which were treated as a bronchopneumonia.\n",
      "\n",
      "Diagnosis, therapy, and evolution\n",
      "\n",
      "Based on clinical and paraclinical examinations, the case was interpreted on admission as decompensated right heart failure with poor control of anticoagulation parameters in a patient with an LVAD implant.\n",
      "\n",
      "To prevent stroke and pump thrombosis in patients with LVAD implants, the systolic blood pressure should be maintained at a mean value of 70–80 mmHg. To achieve this, it was necessary to add the calcium blocker Amlodipine (10 mg QD) to the ACE inhibitor and alpha–beta blocker. The INR values were controlled with anticoagulants. Persistent headache with episodes of seizures and increased intracranial pressure were treated with osmotic diuretics (Mannitol) and neuroprotectors.\n",
      "\n",
      "Although an initial improvement was obtained, it was followed by the gradual deterioration of the general condition of the patient, with increased intensity of the headache. Hepato-renal failure occurred at two weeks after admission, followed by episodes of hemoptysis and worsening of peripheral edema. Blood pressure progressively collapsed, with gradual reduction of diuresis, up to 500 mL/day, and positive inotropic treatment with Dobutamine was needed.\n",
      "\n",
      "The LVAD controller indicated low flow alarms. The repeated echocardiography revealed significant dilatation of the ventricular and atrial cavities, with worsening of the right heart failure. Antibiotics, hepatoprotectives, gastroprotectives and analgesics, at progressively increasing doses, completed diuretic treatment on continuous infusion.\n",
      "\n",
      "At the final stage, MOFS occurred. Continuous veno-venous hemofiltration (CVVH) was initiated but, after 48 hours, the fatal cerebral hemorrhage was diagnosed. Death occurred three months after the final admission, 21 months after the LVAD implant.\n",
      "\n",
      "Autopsy findings\n",
      "\n",
      "The trephination orifices in the skull, which were performed over six months before the final admission, were identified in the occipital and temporal areas, with mild brain herniation. In the edematous brain parenchyma, reactive gliosis was confirmed under the microscope, as corresponding to these orifices. In the fronto-parietal area, multiple foci of parenchymatous hemorrhages were observed, the largest hematoma being 65×45 mm, which exerted mass effect over the median line. Multiple diapedesis hemorrhages were also seen (Figure ​(Figure1,1, D and E).\n",
      "\n",
      "Regarding the heart, the LVAD from the apex of the LV did not associate signs of thrombosis or dehiscence. Iatrogenic pericardial adherences were identified. The heart weight was 882 g, with dilatation of the cavities, causing secondary mitral and tricuspid insufficiency. No coronarosclerosis or thrombosis of the coronary arteries was observed. Histological findings consisted of marked fibrosis of the myocardium, along with a focus of septic abscess located at the level of the anterior wall of the LV.\n",
      "\n",
      "Examination of the lungs and respiratory tract revealed bilateral dystelectasia, which was clearly visible on the background of a brown parenchyma. Under the microscope, disseminated hemorrhages, with siderophages inside the alveolar spaces, which were colored in blue with Perls Prussian Blue staining, were admixed with neutrophils. Acute respiratory distress syndrome (ARDS) was proved by the presence of focal hyaline membranes upon alveolar septa, as indicators of shock lung.\n",
      "\n",
      "Centrilobular liver necrosis suggested the diagnosis of shock liver. The 380 g spleen showed, on the cut section, a 40×20×10 mm triangular, yellowish area, which was confirmed under the microscope as a superinfected splenic infarction.\n",
      "\n",
      "The enlarged kidneys (left – 380 g; right – 355 g) showed, on cut section, changes compatible with a diagnosis of shock kidney, i.e., medullary hyperemia and a pale, ischemic renal cortex. Microscopic analysis confirmed the diagnosis of shock kidney. Routine Hematoxylin–Eosin (HE) staining also revealed extensive glomerular changes, which consisted of an enlarged mesangial area, with focal glomerular sclerosis, highlighted in green with Masson’s trichrome staining. Crescentic proliferation of parietal cells of Bowman’s capsule was observed, without neutrophils. Interstitial nephritis was also documented.\n",
      "\n",
      "In paraffin-embedded kidney parenchyma tissue, IHC stainings were also performed. We used the cell–cell adhesion marker cluster of differentiation (CD) 44 (Dako©, Denmark, 1:50 dilution, sodium citrate pH 6 retrieval), Wilms’ tumor 1 (WT1) protein antibody (Dako©, Denmark, ready-to-use, high pH retrieval) and the stem cells-related markers CD133 (Millipore©, Denmark, 1:50 dilution, high pH retrieval) and octamer-binding transcription factor-3/4 (Oct-3/4) (Leica©, UK, 1:50 dilution, high pH retrieval). In the affected glomeruli, CD44 proved to mark the proliferated parietal cells, while WT1 positivity was clearly seen in the remnant podocytes and the mesangial cells. No positivity for CD133 or Oct-3/4 was highlighted.\n",
      "\n",
      "Based on the above-mentioned autopsy findings, renal failure was explained by a mesangioproliferative glomerulonephritis with extracapillary crescents and segmental glomerulosclerosis. Repeated hemorrhagic episodes, associated with terminal hemorrhagic pneumonia, also contributed to progressive degradation of the general status.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "33263366.txt\n",
      "We present a 55-year-old woman with a history of ST-segment elevation myocardial infarction 2 years before the operation that was treated by percutaneous coronary intervention with implantation of a drug-eluting stent into the left anterior descending artery. Further medical history included hypertension, dyslipidemia, nicotine abuse (20-pack-years), and implantation of a defibrillator. \n",
      "\n",
      "Despite successful implantation of a drug-eluting stent, she developed an anteroapical left ventricular aneurysm. Under optimal medical treatment according to the guidelines, her New York Heart Association functional class was 3, with a left ventricular ejection fraction of approximately 30% right before the operation. Her EuroSCORE II was 1.86% and her NT-proBNP plasma levels were 820 pg/ml. \n",
      "\n",
      "We performed the LIVETM procedure: 4 anchors were implanted via a left lateral thoracotomy to exclude the left ventricular scar. The surgical procedure was carried out as planned.\n",
      "\n",
      "A computed tomography angiographic scan demonstrates the morphology of the scar. Magnetic resonance imaging, which would have shown the distribution of scar tissue even more clearly, was not possible due to her status after placement of an implantable cardioverter defibrillator.\n",
      "\n",
      "A 14-Fr introducer sheath is brought into the right internal jugular vein and advanced into the right atrium. A standard Swan-Ganz catheter is then used to place a wire that will guide a snare into the pulmonary artery. Next, the lateral wall of the aneurysm is tapped with a needle that is advanced into the right ventricle. Over the needle a wire is inserted, and a 6-Fr sheath is brought into the right ventricle. The guidewire is then advanced through the 6-Fr sheath, into the snare and recovered through the 14-Fr sheath. Over this wire, the first anchor is placed to the right ventricular side of the interventricular septum. Then an epicardial anchor is placed as a counterpart over the tether of the right ventricular (RV) anchor that has been retrieved through the thoracotomy. The anchors are then approximated.\n",
      "\n",
      "We place standard 6-Fr sheaths via the femoral artery and vein. We perform left ventricular angiography to visualize the extent of the aneurysm to determine the position of the thoracotomy.\n",
      "\n",
      "We open the chest in the left 5th interspace. Compared to the thoracotomy for transapical transcatheter aortic valve replacement, this access is more dorsal, more cranial, and somewhat longer. We place stay sutures and insert a soft tissue retractor. The double lumen tube keeps the lung deflated and out of the way. The pericardial window is created anterior to the phrenic nerve. A 4/0 Prolene suture armed with Teflon felt on a snare is placed in the center of the aneurysm to facilitate manipulation of the heart while keeping the incision small. By moving the snare, we identify the landmarks and bring them into the incision. These landmarks include the left anterior descending artery, the lateral border of the scar, and the apex of the LV.\n",
      "\n",
      "At the same time that we perform the thoracotomy, we bring the 14-Fr introducer sheath into the right internal jugular vein. Next, we perform RV angiography with a standard pigtail catheter and mark the RV apex, the landing zone for the first anchor. Then, we use a standard Swan-Ganz catheter to place a wire that will guide a snare into the common pulmonary artery.\n",
      "\n",
      "The entry kit consists of an 18G straight needle connected to a Tuohy-Borst valve. A pressure line is attached to the assembly to enable continuous measurement of blood pressure at the tip of the needle. A standard 0.32 wire is loaded into the valve, and a syringe with diluted contrast medium is attached to confirm proper positioning of the needle once the RV has been entered.\n",
      "\n",
      "The white line represents the pressure at the tip of the entry needle. It starts with atmospheric pressure, becomes congruent with the arterial pressure once the LV is entered, and dampens briefly as the ventricular septum is reached; it finally displays a typical RV pressure curve. At this point, the wire is advanced into the RV cavity, and a small amount of dye is injected to rule out misplacement of the needle and the wire in the pericardium. \n",
      "\n",
      "It is extremely important to choose the point of septal puncture properly because it becomes the final position of the first anchor. We need to feel a strong resistance as we push the needle through the septum, because this resistance confirms that the needle is passing through the scar tissue (only this scar tissue will provide adequate support for the anchors). If the position of the needle is confirmed to be satisfactory, the entry kit is withdrawn and only the wire is left in place. We introduce a 6-Fr sheath into the RV over the wire. The end of the sheath is radiopaque for easier visualization under fluoroscopy and to allow for precise manipulation of the tip close to the septum. \n",
      "\n",
      "Once the sheath is in place, an Ampatz right modified (AR MOD) catheter is brought into the RV with its tip close to the septum and the opening pointing toward the RV outflow tract. Later, this catheter allows for a 0.18 guidewire to travel toward the pulmonary valve while staying close to the septum, thereby avoiding entanglement with the tricuspid valve or the papillary muscles. \n",
      "\n",
      "The wire is then caught by the snare. As soon as the wire is caught, it is drawn into the 14-Fr sheath and used to pull the tip of the 6-Fr sheath into the 14-Fr sheath. During this step, the anesthesiologist observes the tricuspid valve closely via transesophageal echocardiography to detect any change in valve function, which would indicate entanglement of the wire or the sheath in the tricuspid valve apparatus. \n",
      "\n",
      "Once the 2 sheaths are joined together, the heart is protected from damage caused by any moving wire. The AR MOD catheter is advanced into the 6 Fr sheath until it exits the 14 Fr sheath in the neck. Now we prepare the first anchor. The tip of the anchor can accommodate the 0.18 wire exiting the AR MOD catheter. The angulation of the anchor relative to the tip of the delivery device can be controlled by the handle of the delivery device. The anchor’s tether is now introduced over the wire into the tip of the AR MOD catheter. The combination of the tether, the wire, and the AR MOD catheter is then advanced toward the radiopaque tip of the 6-Fr sheath. Once the tether of the anchor exits the 6 Fr sheath through the lateral thoracotomy, the anchor can be pulled against the tip of the 6-Fr sheath. Then the whole assembly can be brought close to the septum. At this point, the anchor is still fully controllable and could still be completely removed. \n",
      "\n",
      "Once the position is deemed satisfactory, the 6-Fr sheath is removed, and the delivery tool is disconnected from the anchor, which is held in place by a continuous gentle pull only on the tether. Now the epicardial anchor is mounted on the tether. The 2 anchors are approximated using a force gauge under fluoroscopic control. The system is set to a force of approximately 2 newtons; any greater force could cause the anchor to cut through the scar tissue over time. With that move, the implantation of the first pair of anchors is completed. A second pair of anchors is placed using the same procedure. \n",
      "\n",
      "The most apical section of the aneurysm is not yet excluded. To achieve that goal, we use a modified anchor. Instead of an opening for a wire, the tip of the tether of this anchor carries a curved needle that can be brought directly from behind through the scar. The second anchor is installed and then approximated in the same fashion as the other anchors. A second pair of anchors is placed in the same way to exclude the apex completely.\n",
      "\n",
      "Chest tubes are placed and the 14-Fr sheath is removed. The chest is then closed in layers. \n",
      "\n",
      "\n",
      "Outcome\n",
      "\n",
      "The patient´s postoperative course was uneventful. After we removed the chest tubes, we started anticoagulation with warfarin that continued for 6 months. Transthoracic echocardiography prior to discharge showed a left ventricular ejection fraction of approximately 40%. The postoperative course was uneventful; the patient was discharged home on the 7th postoperative day. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "31378248.txt\n",
      "A 50-year-old man presented to his primary care provider with a 2-week history of progressively worsening dyspnea on exertion and chest discomfort while in the flat position. He described his dyspnea as a feeling of “breathing through a straw.” Additional symptoms included a weight gain of 5 kg in the prior 3 weeks, increased abdominal girth, and paroxysmal nocturnal dyspnea. He also noticed a decline in exercise tolerance from a prior ability to ascend 9 flights of stairs to tolerating only a few steps. He denied fevers, chills, night sweats, palpitations, lightheadedness, or dizziness. He had no recent upper respiratory illness symptoms, such as nasal congestion, sore throat, cough, or sinus pain. His medical history was notable for a small, congenital ventricular septal defect (VSD), obesity (body mass index, 35 kg/m2) and seasonal allergies. His only medication included fexofenadine. He never used tobacco products and reported an average alcohol intake of 2 to 3 beverages per week. In terms of family history, he has a brother with a history of atrial fibrillation; otherwise, there was no family medical history of heart failure or premature coronary artery disease. On physical examination, he was tachycardic with a heart rate of 148 beats per minute with an irregularly irregular rhythm, bibasilar crackles, abdominal distention, jugular venous distension, hepatojugular reflux, and 1+, symmetric, bilateral lower extremity pitting edema.\n",
      "\n",
      "The clinical findings are not suggestive of chronic obstructive pulmonary disease. There is no history of smoking and no wheezing on physical examination. His symptoms are consistent with a classic presentation of CHF. Patients with volume overload secondary to CHF often demonstrate dyspnea on exertion, weight gain, orthopnea, and paroxysmal nocturnal dyspnea. He also has physical examination findings of bibasilar crackles, pitting edema, and abdominal distension. The progressive nature of dyspnea is less consistent with pulmonary embolus or an acute coronary syndrome. Although constrictive pericarditis can manifest with jugular venous distension and chest discomfort in the flat position, he does not have pleuritic chest pain, fever, or a friction rub on physical examination.\n",
      "\n",
      "His laboratory studies were the following: hemoglobin, 16.0 g/dL; sodium, 143 mmol/L; creatinine, 1.2 mg/dL; low density lipoprotein, 77 U/L; high density lipoprotein, 54 mg/dL, triglycerides, 88 mg/dL; total cholesterol, 137 mg/dL; thyroid stimulating hormone (TSH), 2.0 mlU/L. An electrocardiogram (ECG) showed atrial fibrillation with rapid ventricular response (RVR) at rate of 148 beats per minute (bpm) without ST-T segment changes suggestive of ischemia. Chest radiography demonstrated new mild cardiomegaly.\n",
      "\n",
      "Right heart catheterization would provide additional hemodynamic information including cardiac output, filling pressures, and central venous pressure; however, it is not routinely indicated in new diagnosis of heart failure. A TTE is a first-line diagnostic test in new cases of heart failure to assess for left ventricular ejection fraction (LVEF) and structural changes, such as wall motion abnormalities or ventricular dilatation or hypertrophy. Cardiac magnetic resonance imaging can be used to evaluate assess wall motion abnormalities, function, and myocardial tissue perfusion, injury, infiltration, fibrosis, and viability, but is not an appropriate initial test. Endomyocardial biopsies are reserved for patients with progressively worsening heart failure despite appropriate medical therapy, for whom amyloidosis, hemochromatosis, or giant-cell myocarditis is suspected. Coronary angiogram can be considered in new diagnoses of heart failure to determine whether there is an ischemic etiology or reversible ischemia, especially in patients with risk factors. However, angiography would not be the first diagnostic test.\n",
      "\n",
      "His TTE showed an LVEF of 25% with severe generalized left ventricular hypokinesis, moderate right ventricular enlargement with moderate reduction in right ventricular systolic function, right ventricular systolic pressure of 56 mm Hg, severe left atrial enlargement, and mitral and tricuspid annulus dilatation with secondary functional severe mitral and tricuspid regurgitation. There was no change in his congenital VSD. At the time of the study, he was notably tachycardic (132 bpm). An ECG 1 year ago showed an LVEF of 60%, no regional wall motion abnormalities, normal right ventricular size and systolic function, small membranous VSD with restrictive left-to-right shunt, mild tricuspid regurgitation, mild mitral regurgitation, trivial aortic stenosis, and trivial aortic regurgitation.\n",
      "\n",
      "His clinical symptomatology of CHF and LVEF less than 50% classifies the diagnosis of heart failure with reduced ejection fraction (HFrEF).\n",
      "\n",
      "Along with a TTE, initial diagnostic evaluation for acute CHF presentations should include a 12-lead ECG to evaluate for acute myocardial infarction, tachyarrhythmia, conduction abnormalities, or left ventricular hypertrophy. A chest radiography should be obtained to evaluate for an acute cardiopulmonary process such as pneumonia, pulmonary edema, or pneumothorax. Other initial laboratory studies should include a complete blood cell count (CBC) with differential, electrolyte levels, creatinine, N-terminal-pro b-type natriuretic peptide, troponin level, urinalysis, lipid panel and TSH. Coronary artery disease causes approximately two thirds of CHF, and an acute coronary syndrome should be suggested as a cause of new-onset heart failure if there are elevated troponin levels, new ECG abnormalities, an acute onset of symptoms, or concurrent signs and symptoms of systemic hypoperfusion.1 Hyponatremia, if present, is a poor prognostic factor.2\n",
      "\n",
      "The patient also had an ECG Holter monitor revealing of atrial fibrillation with heart rates varying from 93–179 bpm (average, 126 bpm) with RVR occurring 99.9% of the time captured. He reported dyspnea while in atrial fibrillation with RVR. He was given furosemide and metoprolol tartrate by his primary care physician with plans to titrate to heart rates slower than 110 bpm.\n",
      "\n",
      "Three beta blockers with beta-1 activity have been shown to decrease mortality in heart failure: carvedilol, bisoprolol, and metoprolol succinate. A switch to atenolol would not be appropriate. There is some debate as to whether carvedilol is superior to metoprolol in mortality reduction, as shown by the COMET trial in 2003.3 In this study, carvedilol had better reduction in mortality rate compared with metoprolol tartrate. Carvedilol has alpha blockade properties that is speculated to be beneficial by facilitating vasodilation, glucose uptake, and insulin sensitivity. Of note, because the COMET trial used the tartrate formulation instead of the extended-release succinate form, a definite superiority between metoprolol succinate and carvedilol cannot be determined. Beta blocker dose response relationship to reduction in mortality has been shown; patients should be uptitrated on beta blockers as tolerated in HFrEF and until rate control is achieved in atrial fibrillation. Furosemide is a more appropriate diuretic than hydrochlorothiazide. Dosing should be based on volume status; however, there is no dose-dependent relationship to mortality outcomes. ICD placement consideration is indicated for primary prophylaxis against sudden cardiac death in patients with New York Heart Association Class II or III HFrEF with LVEF less than 35% after 3 months of optimal medical management. However, patients should be on optimal medical treatment and treated for reversible underlying etiologies before ICD implantation consideration. Similarly, mitral valve replacement is not indicated at this time, as his severe mitral regurgitation is functional and could improve with treatment of reversible causes. The 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society recommends long-term anticoagulation based on thromboembolic risk as determined by the CHA2DS2-VASC Score. This patient began taking long-term apixaban considering his moderate risk stratification (CHA2DS2-VASC score of 1 for heart failure, or 0.6% stroke per year risk), low LVEF with ventricular dilatation, and low bleeding risk. He transitioned to carvedilol for beta blockade, started taking lisinopril, and continued with furosemide as directed by his cardiologist.\n",
      "\n",
      "His HFrEF was thought to be most likely due to tachycardia-induced cardiomyopathy. Initial clues were new reduced LVEF with generalized hypokinesis in the setting of a new diagnosis of atrial fibrillation with predominant RVR on ECG Holter monitoring.\n",
      "\n",
      "On a return visit to his primary care physician, the patient had persistently elevated heart rates to the 130-bpm range despite being uptitrated on carvedilol therapy. His in-clinic blood pressure was 104/81 mm Hg.\n",
      "\n",
      "Tachycardia-induced cardiomyopathy results from prolonged elevated heart rate, which is often reversible upon control of the arrhythmia or heart rate. The goal of initial therapy is to achieve rate control. Increasing beta blockade would be an option for achieving rate control in this patient. However, rate control may be difficult to achieve with beta blockade in patients with rapid ventricular rates and new reduction of ejection fraction (EF)das in this case. Therefore, early electrical cardioversion is warranted to reduce the risk of further progression of HFrEF. Pacemaker placement is not indicated. ICD referral may be warranted at a later time, if left ventricular systolic function does not recover after appropriate medical therapy. Aspirin and clopidogrel are not indicated in heart failure or atrial fibrillation.\n",
      "\n",
      "Because of this patient’s markedly depressed EF, a TEE-guided direct cardioversion was pursued urgently; it was successful after the third synchronous shock of 100, 120, and 150 J. The TEE also showed severe left atrial enlargement, along with previously seen severe mitral regurgitation and severe tricuspid regurgitation. An ECG after cardioversion showed sinus rhythm with a heart rate of 94 bpm with premature atrial complexes.\n",
      "\n",
      "Although direct electric cardioversion is an effective way to revert to sinus rhythm, there is a high rate of atrial fibrillation recurrence, with as few as 23% of patients remaining in sinus rhythm after 1 year. Risk factors for reverting back to arrhythmia included duration of arrhythmia, atrial fibrillation (vs atrial flutter), and age. The patient was started on amiodarone after his cardioversion because of his severe left atrial enlargement and concern for early relapse.\n",
      "\n",
      "Amiodarone can cause adverse effects of long-term use, including pulmonary toxicity, thyroid dysfunction, hepatotoxicity. The risks and benefits of continuing the drug should be discussed with the patient. Baseline tests include chest radiography, pulmonary function tests, thyroid function tests, and transaminases. Hematologic, renal, and cardiac toxicities are uncommon; thus, CBC/peripheral smear/lactic acid dehydrogenase, sodium/potassium/creatinine, ECG Holter and ambulatory blood pressure monitoring, and cardiac catheterization are not routine studies before starting amiodarone.\n",
      "\n",
      "Repeated TTE 2 months later showed a significantly improved EF of 52%, with mildemoderate left ventricular enlargement, mild generalized hypokinesis, and borderline right ventricular enlargement with borderline decreased systolic function and estimated right ventricular systolic pressure of 32 mm Hg. The degree of mitral regurgitation had improved to mildemoderate severity and tricuspid regurgitation was trivial. The patient had a weight loss of 15 kg while taking furosemide and overall symptomatic improvement with increased exercise capacity.\n",
      "\n",
      "Four months later, a repeated TTE revealed a decline in EF to 35%−40 %, with substantial beat-to-beat variability, return of atrial fibrillation with RVR, moderate left ventricular hypokinesis, borderline decrease in right ventricular systolic function, and mild to moderate mitral regurgitation and tricuspid regurgitation. His heart rate was 111 bpm. He underwent repeat direct current cardioversion. Follow-up TTE 2 months after repeated direct current cardioversion showed improvement of his EF again to 61% without regional wall motion abnormalities and a mildly enlarged left ventricle. Long-term therapy with amiodarone was discussed with this patient, but not pursued because of potential adverse effects.\n",
      "\n",
      "Given recurrent episodes of atrial fibrillation, and subsequent reduced EF with each of these episodes, the decision was made to pursue a rhythm control strategy, and the patient underwent atrial fibrillation ablative therapy. He remained asymptomatic 6 months later, with no recurrent episodes, and maintained his left ventricular systolic function (EF = 61%).\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "34413281.txt\n",
      "A 37-year-old man from Pakistan with a history of hypertension presented to the Emergency Department with loss of consciousness following a 20-day history of palpitations, upper abdominal pain, and recurrent vomiting. Systemic review was notable for dizziness on standing, hoarseness of voice, and 7 kg of unintentional weight loss over the preceding month. There was no history of chest pain, sweating, abdominal pain, bleeding, or seizures. One year prior, the patient had been investigated under the care of Cardiology for chest pain and palpitations. His ECG had revealed a Wolff-Parkinson-White pattern, and thyroid function studies and ultrasound were consistent with hyperthyroidism secondary to thyroiditis. At the time, he was treated initially with propranolol and then carbimazole when his thyroid function failed to improve. He received regular outpatient follow-up and had reported improvement of his symptoms.\n",
      "\n",
      "On presentation he appeared diaphoretic and ill and was noted to have postural hypotension. Physical examination revealed a tender hepatomegaly of 4 cm under the costal margin and right lower-limb swelling in the thigh. Initial laboratory investigations showed leukocytosis, mild normocytic anemia, thrombocytosis, and elevated troponins. A coagulation profile demonstrated a prolonged prothrombin time (PT) of 29 s (normal range: 9.4–12.5 s), an international normalized ratio (INR) of 2.9, and an activated partial thromboplastin time (aPTT) of 43 s (normal range: 25.1–36.5 s). He was initially suspected to have sepsis and was treated with intravenous hydration and antibiotics, with good response. An ECG showed non-specific T wave inversions in leads V2–V5 without any ischemic ST-T segment changes, with Wolff-Parkinson-White pattern, similar to the ECG done 1 year before. A Doppler ultrasound of the right lower limb was negative for deep venous thrombosis. A transthoracic echocardiogram revealed severe, concentric biventricular hypertrophy with an ejection fraction of 56%, left ventricular septum end-diastole was 1.5 cm, and strain analysis showed severe reduction in global longitudinal strain (GLS) of 8.8% with apical sparing.\n",
      "\n",
      "Hypovolemia was corrected and cultures were subsequently negative, but the patient’s coagulation parameters failed to improve. A mixing study led to correction of the PT and aPTT, suggesting a clotting factor deficiency, and a follow-up assay of clotting factors revealed severe factor X deficiency with a level of 7.3% (normal range: 70–120%). Mild deficiencies were also present in factor VII (54%) and factor IX (62%).\n",
      "\n",
      "The patient was investigated for malignancy as a cause for acquired factor deficiency. An iodinated contrast enhanced computerized tomography (CT) scan of the neck, thorax, abdomen, and pelvis revealed thyroid enlargement, bilateral pleural effusion, and widespread lymphadenopathy in the cervical, hilar, mediastinal, and upper abdominal regions. A positron emission tomography (PET) scan revealed mesenteric and retroperitoneal lymph nodes with mild to moderate uptake, and the other previously visualized lymph nodes did not show any significant activity. In the absence of any obvious malignancy, the patient was investigated for infiltrative disease. ECG-gated, gadolinium-enhanced cardiac magnetic resonance imaging (MRI) revealed diffuse subendocardial and mid-anteroseptal heterogenous enhancement. There was circumferential myocardial hypertrophy and mild pericardial effusion. These findings were in keeping with infiltrative cardiac disease. MRI of the liver showed no signs of infiltrative liver disease, and liver enzymes were normal.\n",
      "\n",
      "Serum protein electrophoresis (SPE) showed polyclonal increase in gamma globulins, and immunofixation revealed free lambda light-chain. Serum lambda free light-chain (LaFLC) was high at 978.3 mg per liter, serum kappa free light-chain (KaFLC) was 36.2 mg/L, with kappa-to-lambda ratio of 0.04, and urine was positive for Bence Jones protein (0.1 g/L). The patient underwent fat pad biopsy plus bone marrow aspiration and biopsy to confirm the diagnosis of suspected light-chain amyloidosis. He required high doses of prothrombin concentrate to correct his coagulopathy before these procedures.\n",
      "\n",
      "At the time of the bone marrow collection, a complete blood count (CBC) showed mild normochromic normocytic anemia (hemoglobin 12.6 g/dL, normal range: 13–17), leukocytosis (12.0×103/μL, normal range: 4–10), and thrombocytosis (526×103/μL, normal range: 150–400), with rare circulating plasma cells noted on screening of the peripheral smear.\n",
      "\n",
      "Bone marrow (BM) aspirate was hypercellular with active trilineage hematopoiesis and showed increased plasma cells with uneven distribution, scattered and in clusters, with an average of approximately 20%.\n",
      "\n",
      "The plasma cells were morphologically abnormal, with many showing clearing of a large part of the cytoplasm, with deep condensed peripheral staining. Many cells appeared granulated with immunoglobulin inclusions (Russell bodies) and a few contained binucleated or pleomorphic nuclei.\n",
      "\n",
      "Immunophenotyping by flow cytometry on the bone marrow aspirate revealed 3% of monotypic plasma cells expressing CD38, CD138 with cytoplasmic lambda light-chain restriction, and aberrant CD56 and CD117 expression. The plasma cells were negative for CD19, CD20, and CD45. Flow cytometry showed <1% residual polytypic plasma cells, positive for CD19 and negative for CD56 and CD117, with a kappa-to-lambda ratio of 1.2. Four percent of B cells expressed CD19 and CD20, with a Kappa/Lambda ratio of 1.38, with no immunophenotypic evidence of a monotypic B cell population.\n",
      "\n",
      "Bone marrow biopsy was cellular to mildly hypercellular when adjusted to the patient’s age, with an average cellularity of 40–50%. There was trilineage hematopoiesis and interstitial infiltration with scattered clusters of lambda restricted plasma cells as highlighted by immunohistochemistry aberrantly expressing CD56 & CD117. The infiltration was roughly estimated at 20–30% of the core cellularity. The section showed a deposition of a pink, amorphous, waxy-looking deposit, in the thickened blood vessels wall, mainly within the adipose tissue, with some focal interstitial deposits. The deposited material-stained pink to red by Congo red on standard light microscopy and produced a characteristic apple green birefringence under polarized light, consistent with amyloid deposition. The deposits stained positive for periodic acid-Schiff (PAS) and amyloid P. The compiled findings confirmed bone marrow involvement by plasma cell neoplasm resulting in AL amyloidosis. Fat pad biopsy was not diagnostic.\n",
      "\n",
      "The patient spent the whole duration of his work-up as an in-patient. The Cardiology and Hematology teams were involved early during the hospital stay. His right leg swelling, which was initially associated with pain, resolved spontaneously within 5 days of admission. But later, he complained of shortness of breath that was worse when lying flat, which was investigated with a transthoracic echo, described above. As his coagulation parameters failed to improve, the patient’s home carbimazole therapy was stopped due to suspicion of carbimazole-induced coagulopathy. On day 20 of admission, after a pan CT and PET were unrevealing, the patient underwent abdominal fat pad biopsy and bone marrow biopsy in separate sittings, and both required prothrombin concentrate to achieve proper coagulation. A multidisciplinary team meeting was held, and the decision was made to resume his carbimazole due to persistent tachycardia, which was suspected to be due to hyperthyroidism.\n",
      "\n",
      "Later, a bone marrow biopsy confirmed a diagnosis of plasma cell dyscrasia resulting in AL amyloidosis, and he was transferred to the local specialized cancer hospital for initiation of chemotherapy.\n",
      "\n",
      "In summary, the patient was managed as a case of systemic AL amyloidosis secondary to plasma cell neoplasm manifesting with infiltrative heart disease, severe factor X deficiency, and possible thyroid involvement. The hepatomegaly was considered to be more due to cardiac hepatopathy than to amyloidosis. A thyroid or liver biopsy were not done due to high risk of bleeding.\n",
      "\n",
      "On day 27 the patient developed tachypnea that was attributed to heart failure. This was managed with diuretics and continuation of his previous thyroid medications. He was started on bortezomib, cyclophosphamide, and dexamethasone chemotherapy. He continued to have tachycardia, with ECG showing sinus rhythm with non-specific T wave changes, so he was started on metoprolol, with a plan for ablation at a later date. A repeat transthoracic echocardiogram demonstrated a severe drop in ejection fraction over 4 weeks, with an ejection fraction of 25% and severe diastolic dysfunction.\n",
      "\n",
      "The patient continued to experience persistent tachycardia and shortness of breath in spite of treatment. He was maintained on beta-blocker and diuretic therapy with cardiac monitoring as he was considered to be high risk for arrhythmia. On day 32 of admission, the patient developed cardiac arrest with a rhythm of pulseless electrical activity. After 2 cycles of resuscitation the rhythm degraded to asystole. Unfortunately, despite 40 min of cardiopulmonary resuscitation, the patient could not be revived. Given the worsening tachycardia and WPW pattern on ECGs, the patient’s cause of death was assumed to be arrhythmia secondary to conduction abnormalities as a result of infiltrative cardiac disease.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "32111708.txt\n",
      "A 66-year-old multiparous, postmenopausal woman presented in the emergency department with severe breathlessness at rest. She was apparently alright 6 months back. Since then she had been suffering from progressively increasing difficulty in breathing. Initially she felt breathless on moderate to severe exertion, but later it was more marked even pursuing normal daily activities. She also complained of cough, with expectoration of mucoid sputum, but without haemoptysis, wheeze or chest pain. Occasionally, she experienced nocturnal breathlessness at late hours of night, for which she had to get up from sleep and walk to take deep breath. There was history of breathlessness on lying flat too. She also complained of gradually progressive swelling of both legs for the same duration.\n",
      "\n",
      "The patient also complained of having difficulty in rising from sitting position and climbing up the stairs as well as combing her hair, and reaching for objects above her shoulder level for last 4 months which exacerbated in last 1 week. There was no history of dysphagia, oral ulcers or joint pains.\n",
      "\n",
      "There was no history of hypertension, diabetes, thyroid-related or cardiopulmonary disorders. Family history was unremarkable. There was no history of intake of any drugs or addiction. She received none of the adult vaccinations including the one against human papillomavirus. Regarding menstrual history, she was postmenopausal for last 18 years with no history of postmenopausal bleeding, but there was history of non-periodical, thin, watery non-offensive, occasionally blood-tinged painless vaginal discharge for last 8 months without postcoital bleeding. Regarding obstetric history, she was multiparous (parity 3, gravida 3), married at 14 years, non-promiscuous, with first and last childbirth at the age of 17 and 26 years, respectively. She belonged to a poor socioeconomic status.\n",
      "\n",
      "On examination she was severely short of breath, with propped up decubitus. She had mild pallor, cyanosis and oedema (pitting, bipedal, pretibial, sacral, periorbital). Neck veins were engorged. Her pulse was 110 bpm, regular; blood pressure 90/40 mm Hg, respiratory rate 30 per minute. All the heart sounds were soft, decreased in intensity, with audible S3 gallops. Chest auscultation revealed bibasilar extensive rales extending more than 10 cm above the diaphragm at the posterior scapular lines. There was soft, tender hepatomegaly with positive hepatojugular reflux. Dermatological examinations revealed the presence of heliotrope rash around eyelids characterised by periorbital, confluent and erythema; poikilodermatous changes consisting of erythema, altered pigmentation and telangiectasias were seen over the photo-exposed skin, that is extensor surfaces of the upper arm; the upper chest, in a ‘V-neck’ configuration; the upper back (shawl sign) and the lateral thighs (holster sign). On examination of hands, hyperkeratotic lesions were predominantly seen involving the centre of palms (mechanics hands) along with the presence of Gottron’s papules on proximal interphalangeal joints. Detailed neurological examination could not be done at that time as to manage the cardiac emergency was more important at that time.\n",
      "\n",
      "A bedside ECG, echocardiography, N-terminal pro-brain-derived natriuretic peptide (NT-proBNP) and Troponin-I tests were ordered. ECG revealed sinus tachycardia with non-specific ST-T changes. Echocardiography showed global hypokinesia with normal chamber dimensions, E-point septal separation (EPSS) of 16 mm with severely reduced left ventricular ejection fraction (LVEF) of 25%, grade 3 left ventricular diastolic dysfunction (LVDD) and tricuspid annular plane systolic excursion (TAPSE) of 16 mm. NT-proBNP level was very high (4500 pg/mL, n<115), and Troponin-T kit test and Troponin-I were strongly positive (cTnI 9.8 ng/mL, n<0.04). She was provisionally diagnosed as acute decompensated HF, then shifted to a cardiac critical care unit and got stabilised with standard management of HF.\n",
      "\n",
      "After initial cardiac stabilisation, detailed neuromuscular examination was taken up on the third day. Muscle power was reduced to 1/5 (using modified medical research council scale) in both upper and lower limb proximal muscle groups with tenderness and neck muscles were severely weak. Clinical findings almost settled the diagnosis of DM.\n",
      "\n",
      "Per vaginal speculum examination was done and Pap smear was taken. Per rectal examination was unremarkable.\n",
      "\n",
      "\n",
      "Investigations\n",
      "\n",
      "On the first day of admission, reports of complete blood count with differentials, iron studies, blood sugar, renal, liver, thyroid function tests, lipid profile, viral serology were normal except mild normocytic normochromic anaemia of chronic disease (10.8 g/dL, n>12.5; haematocrit 33%, n = 37–47; total iron-binding capacity 220 µg/dL, n = 250–450; serum iron 50 µg/dL, n = 40–180; ferritin 800 ng/mL, n = 10–291) and disproportionately increased level of aspartate amino transferase (370 U/L, n = 10–35) and C-reactive protein (CRP) (90 mg/dL, n<6). ECG showed sinus tachycardia with non-specific ST-T changes. Echocardiography revealed global hypokinesia with normal chamber dimensions, EPSS of 16 mm with severely reduced LVEF of 25%, grade 3 LVDD and TAPSE of 16 mm. NT pro-BNP was 4500 pg/mL (n<115), and Troponin-T kit test was strongly positive. She had normal coronaries on angiography. Thus, she was diagnosed as a case of biventricular HF with reduced ejection fraction (HFrEF) due to non-ischaemic cardiomyopathy.\n",
      "\n",
      "To confirm the diagnosis of DM and to search for any underlying malignancy, various directed investigation modalities were adopted thereafter. Serum creatinine phosphokinase (CPK) (7840 IU/L n<145), lactate dehydrogenase (560 U/L, n<10) and aldolase (78 U/L, n<6.0) levels were very high. Antinuclear antibody (ANA) (hep2) was strongly positive (36.40 U/mL, n≤10) and ANA profile exhibited strongly positive (3+) anti-Mi-2 antibodies. Antitranscription intermediary factor (TIF)-gamma antibody test was positive. MRI of clinically involved muscle groups displayed hyperintense signal in T2 throughout the affected muscles. Axial short-T1 inversion recovery (STIR) images showed diffuse hyperintensity suggestive of perimuscular oedema in all the thigh muscles particularly in hamstrings with involvement of subcutaneous tissue septa and skin thickening which were highly characteristics of DM. Muscle biopsy showed features of skeletal muscle with perifascicular atrophy, mild perivascular chronic non-specific inflammatory cell infiltrate and mature adipose tissue infiltration consistent with DM.\n",
      "\n",
      "\n",
      "Contrast-enhanced CT (CECT) scans of thorax, abdomen and pelvis failed to detect any abnormality. Mammography, breast ultrasound, transvaginal sonography and long loop colonoscopy were normal. Cancer markers such as cancer antigen (CA)-125, CA 19-9, carcinoembryonic antigen were negative. Only the Pap smear of cervix showed high-grade squamous intraepithelial lesion. Four weeks after diagnosis, she was transferred to department of gynaecology for total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH-BSO). The tissue biopsy obtained from hysterectomy showed well-differentiated SCC with faintly positive E-cadherin (suggesting good prognosis) and weakly positive vimentin (indicative of stunning differentiation) of TNM stage T1a1 N0 M0.\n",
      "\n",
      "\n",
      "Differential diagnosis\n",
      "\n",
      "\n",
      "Initially on admission, she had a working diagnosis of biventricular failure and course of evolution of symptoms and signs clearly suggested so. Echocardiographic findings and high level of NT-proBNP further attested the diagnosis of HFrEF. High levels of cardiac biomarkers, non-specific ST-T changes with central chest discomfort and signs of HF made us to rule out coexisting coronary artery disease (CAD) by coronary angiography. Ruling out CAD as a cause of HF also opened the avenue for myocarditis as a differential diagnosis. Serial echocardiography showed improvement in contractility of the myocardium and thereby increase in stroke volume, ejection fraction and amelioration of failure symptoms. We could not do a cardiac MRI and endomyocardial biopsy because of our poor resource set-up. Still, clinical course of the ailment, hectic rise in levels of cardiac enzymes in absence of myocardial infarction, outcome and most importantly coexistence of an autoimmune disease supported the diagnosis of myocarditis.8\n",
      "\n",
      "In a backdrop of subacute onset progressive bilateral symmetrical proximal muscle weakness with classic dermatological signs, the diagnosis was quite evident. High CPK levels, positive autoantibodies, classical muscle MRI and Electromyography (EMG) findings muscles followed by muscle biopsy sealed the diagnosis of definite DM.\n",
      "\n",
      "Careful medical history and physical examination of the patients (including gynaecological examination), taking into account the patient’s age and other risk factors, were carried out. Since this patient was at high risk (elderly at the time of onset and the presence of severe disease of the skin), symptoms of severe myopathy, significantly elevated markers of inflammation and positive for anti-TIF-1 gamma antibody, more advanced screening was considered. CECT of the chest, abdomen and pelvis, mammography, ultrasound of breasts, abdomen and pelvis, tumour markers, Pap smear and biopsy from cervix were opted for. This revealed the diagnosis of carcinoma of cervix.\n",
      "\n",
      "\n",
      "Treatment\n",
      "\n",
      "Management of HF: Initially the crisis was managed by moist oxygen, intravenous loop diuretics (intravenous furosemide 40 mg stat, followed by intravenous torsemide 20 mg every 6 hours), inotrops (dobutamine 10 μg/kg/min continuous intravenous infusion) and cardiac remodelling inhibitors (eplerenone 25 mg/day and ramipril 1.25 mg/day). Dobutamine infusion was gradually tapered off as LVEF and blood pressure improved over the course. After 3 days, carvedilol 6.25 mg/day was added. Ramipril was changed to valsartan/sacubitril (100 mg/day) thereafter.\n",
      "Management of DM: After stamping the diagnosis of DM on seventh day postadmission, she was put on intravenous methylprednisolone (1 g/day in 100 mL normal saline over 1 hour for 5 days) followed by oral prednisolone (50 mg/day). Along with that oral methotrexate (15 mg once per week) and azathioprine (100 mg/day) were added to her regimen. Daily physiotherapy was initiated.\n",
      "Measures taken for cervical cancer: One month after stabilisation of DM and HF, elective TAH-BSO was performed.\n",
      "\n",
      "\n",
      "Outcome and follow-up\n",
      "\n",
      "Cardiological outcome: Patient became haemodynamically stable within 3 days postadmission and by a week she was symptom free along with favourably down-going levels of cardiac biomarkers. None of antifailure medications needed to be continued except low-dose valsartan/sacubitril 100 mg/day during discharge. During discharge (nearly after 3 months of stay in hospital), she was free from clinical signs and symptoms of HF (New York Heart Association grade 1). Echocardiography showed only grade 1 LVDD (LVEF 65%). At discharge NT-proBNP was 180 pg/mL. After 1 month of follow-up postdischarge, echocardiography was completely normal.\n",
      "Rheumatological and neurological outcome: She did not initially respond well to therapy with steroids, methotrexate and azathioprine; at least for the first one and a half months, muscle weakness did not abate at all, though pain ameliorated. Skin manifestations were abolished by the end of third week after commencement of immune-suppressive therapy. At sixth week, she started showing some improvement of her proximal muscle power and this was more pronounced in upper extremities. Up to 12th week, the improvement speed was maintaining a plateau. Within 13th week, she started showing fast improvement in her hamstrings power. She started her activities of daily living without much help from others. She was discharged with prednisolone 20 mg/day, azathioprine 100 mg/day, calcium +vitamin D3 once per day, methotrexate 10 mg/week. Inflammatory markers and muscle strength got normalised in 4 months.\n",
      "Gynaec-oncological outcome: Urge urinary incontinence developed postoperatively, which was managed conservatively with Kegel’s exercises. Periodic follow-up did not show any residual tumour activity.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "38050248.txt\n",
      "Patient information\n",
      "The case involves a 42-year-old female patient, Ms. Emily Turner, of Caucasian ethnicity. Ms. Turner works as an elementary school teacher, leading an active lifestyle. The patient’s age, gender, and occupation are crucial demographic factors contributing to a comprehensive understanding of her medical history.\n",
      "\n",
      "Main symptoms\n",
      "Upon presentation, Ms. Turner chief complaints included palpitations, unexplained weight loss, and increased anxiety. These symptoms were accompanied by heightened sensitivity to heat and intermittent episodes of fatigue. The constellation of these symptoms prompted her to seek medical attention, leading to a detailed clinical evaluation.\n",
      "\n",
      "Medical, family, and psychosocial history\n",
      "Ms. Turner medical history revealed no significant chronic illnesses; however, there was a family history of autoimmune disorders, notably Hashimoto thyroiditis and rheumatoid arthritis. This genetic predisposition provided valuable context for her current presentation. Psychosocially, Ms. Turner described increased stress due to her profession’s demands and family responsibilities.\n",
      "\n",
      "Relevant past interventions and outcomes\n",
      "In the past, Ms. Turner had sought medical consultation for weight loss management, which yielded limited success. She had been prescribed dietary modifications and exercise routines, which helped stabilize her weight temporarily. However, the persistence of her symptoms prompted further investigation.\n",
      "\n",
      "Genetic information\n",
      "Genetic testing was performed to assess for predisposition to autoimmune disorders, given the family history. Results indicated specific genetic markers associated with susceptibility to thyroid dysfunction and autoimmune conditions, reinforcing the potential relevance of hereditary factors.\n",
      "\n",
      "These pseudonymously outlined patient-specific details form the foundation for understanding the unique context in which Ms. Turner thyrotoxic cardiomyopathy developed. They underscore the significance of considering demographic, medical, familial, and psychosocial factors when analyzing the complexities of her case.\n",
      "\n",
      "\n",
      "Clinical findings\n",
      "During the physical examination of Ms. Emily Turner, several pertinent findings emerged, shedding light on the cardiovascular sequelae of her hyperthyroidism and thyrotoxic cardiomyopathy.\n",
      "\n",
      "Cardiovascular examination\n",
      "\n",
      "Elevated heart rate. A palpable and sustained tachycardia was noted, with a resting heart rate exceeding 100 beats per minute. This high heart rate was consistent with the hyperthyroid state, reflecting the direct impact of excess thyroid hormones on cardiac contractility and heart rate regulation.\n",
      "\n",
      "Irregular rhythms. Auscultation revealed intermittent irregular heartbeats, suggesting arrhythmias such as atrial fibrillation or atrial flutter. The presence of these arrhythmias further emphasized the cardiac repercussions of thyrotoxicosis.\n",
      "\n",
      "Murmurs and gallops. A systolic murmur was audible over the mitral area, possibly indicative of increased flow across the mitral valve due to hyperdynamic circulation. A third heart sound (S3 gallop) was auscultated, suggesting impaired left ventricular function.\n",
      "\n",
      "Peripheral edema. Mild peripheral edema was detected, hinting at potential fluid retention secondary to impaired cardiac function. This finding supported the possibility of heart failure due to thyrotoxic cardiomyopathy.\n",
      "\n",
      "Endocrine and general examination\n",
      "\n",
      "Thyroid enlargement. Physical examination of the thyroid gland revealed diffuse enlargement, consistent with a goiter, corroborating the diagnosis of hyperthyroidism.\n",
      "\n",
      "Fine tremor. A fine tremor was observed in the patient’s outstretched hands, a classic neurological manifestation of hyperthyroidism that underscores the systemic impact of thyroid hormone excess.\n",
      "\n",
      "Psychosocial evaluation\n",
      "\n",
      "Anxiety and restlessness. The patient exhibited signs of restlessness and anxiety, which could be attributed to the direct influence of excess thyroid hormones on the central nervous system.\n",
      "These clinical findings collectively portrayed a complex interplay between thyroid dysfunction and cardiovascular alterations. The physical examination underscored the remarkable influence of hyperthyroidism on cardiac function, evident through the elevated heart rate, arrhythmias, murmurs, and signs of heart failure. These findings informed the subsequent diagnostic and therapeutic interventions to manage Ms. Turner thyrotoxic cardiomyopathy.\n",
      "\n",
      "Timeline depicting the crucial milestones related to the diagnosis and interventions for Ms. Emily Turner thyrotoxic cardiomyopathy\n",
      "\n",
      "Month 1:\n",
      "Ms. Turner presents with palpitations, weight loss, and anxiety. Physical examination reveals elevated heart rate, irregular rhythms, and mild peripheral edema.\n",
      "Initial thyroid function tests show significantly elevated levels of free thyroxine (T4) and suppressed thyroid-stimulating hormone (TSH), confirming hyperthyroidism.\n",
      "Cardiovascular imaging (echocardiogram) reveals impaired left ventricular function and signs of heart failure.\n",
      "\n",
      "Month 2:\n",
      "Ms. Turner genetic testing results indicate specific genetic markers associated with thyroid dysfunction and autoimmune disorders.\n",
      "Consultation with an endocrinologist confirms the diagnosis of thyrotoxic cardiomyopathy, a rare manifestation of hyperthyroidism affecting cardiac function.\n",
      "\n",
      "Month 3:\n",
      "Initiation of antithyroid medications (methimazole) to manage excess thyroid hormone production.\n",
      "Commencement of beta-blocker therapy to control heart rate and manage arrhythmias.\n",
      "\n",
      "Month 4:\n",
      "Follow-up thyroid function tests show a gradual decline in free T4 levels and normalization of TSH, indicating a positive response to antithyroid medications.\n",
      "Ms. Turner heart rate stabilizes within a normal range, and the irregular heartbeats become less frequent.\n",
      "\n",
      "Month 6:\n",
      "A repeat echocardiogram reveals improved left ventricular function and reduced signs of heart failure.\n",
      "Ms. Turner weight stabilizes, and her anxiety symptoms diminish.\n",
      "\n",
      "Month 9:\n",
      "Thyroid hormone levels continue to trend towards normal range, and antithyroid medication dosage is adjusted accordingly.\n",
      "The echocardiogram shows further improvement in left ventricular function, and arrhythmias are infrequent.\n",
      "\n",
      "Month 12:\n",
      "Ms. Turner thyroid function tests return to within the normal range, indicating successful management of hyperthyroidism.\n",
      "An echocardiogram confirms significant improvement in cardiac function, and peripheral edema resolves completely.\n",
      "\n",
      "\n",
      "\n",
      "Diagnostic assessments\n",
      "\n",
      "Diagnostic methods\n",
      "The diagnostic assessment for Ms. Emily Turner thyrotoxic cardiomyopathy involved a multidimensional approach encompassing various methods:\n",
      "\n",
      "\n",
      "Physical examination\n",
      "The physical examination revealed elevated heart rate, irregular heart rhythms, peripheral edema, and thyroid enlargement. These findings provided crucial clues to the underlying cardiovascular and endocrine abnormalities.\n",
      "\n",
      "\n",
      "Laboratory testing\n",
      "Thyroid function tests played a pivotal role in confirming the diagnosis of hyperthyroidism. Elevated free thyroxine (T4) levels and suppressed thyroid-stimulating hormone (TSH) levels were consistent with this disorder. Genetic testing was also performed to assess hereditary predisposition to thyroid dysfunction and autoimmune conditions.\n",
      "\n",
      "\n",
      "Cardiovascular imaging\n",
      "Echocardiography was employed to visualize the heart structure and function. The echocardiogram revealed impaired left ventricular function and signs of heart failure, thereby indicating the presence of thyrotoxic cardiomyopathy.\n",
      "\n",
      "\n",
      "Diagnostic challenges\n",
      "Several challenges were encountered during the diagnostic process:\n",
      "\n",
      "\n",
      "Financial constraints\n",
      "Financial limitations have impeded access to specific diagnostic tests and medications, potentially affecting the timeliness and comprehensiveness of the assessment.\n",
      "\n",
      "\n",
      "Language and cultural factors\n",
      "Effective communication and understanding of Ms. Turner symptoms and medical history could have been influenced by language barriers and cultural nuances.\n",
      "\n",
      "\n",
      "Diagnostic reasoning\n",
      "In Ms. Turner case, the primary diagnosis of thyrotoxic cardiomyopathy was reached through careful diagnostic reasoning:\n",
      "\n",
      "\n",
      "Clinical presentation\n",
      "The combination of palpitations, weight loss, anxiety, and elevated heart rate initially indicated hyperthyroidism.\n",
      "\n",
      "\n",
      "Thyroid function tests\n",
      "Elevated free T4 and suppressed TSH levels were consistent with hyperthyroidism. However, the cardiac manifestations indicated the presence of thyrotoxic cardiomyopathy as the underlying complication.\n",
      "\n",
      "\n",
      "Echocardiography\n",
      "The echocardiogram confirmed impaired cardiac function, linking the hyperthyroidism to cardiomyopathy.\n",
      "\n",
      "\n",
      "Prognostic characteristics\n",
      "In thyrotoxic cardiomyopathy, prognostic assessment revolves around cardiac function and the response to treatment. As Ms. Turner cardiac function improved throughout treatment, evidenced by echocardiographic findings, her prognosis became more favorable. Typically used in oncology, staging does not directly apply to thyrotoxic cardiomyopathy; cardiac function parameters serve as prognostic indicators, guiding treatment response evaluation and long-term outcome predictions.\n",
      "\n",
      "\n",
      "Therapeutic Interventions\n",
      "The management of Ms. Emily Turner thyrotoxic cardiomyopathy involved a comprehensive and multifaceted approach:\n",
      "\n",
      "\n",
      "Pharmacologic interventions:\n",
      "Antithyroid Medications: Mys. Turner was prescribed methimazole, an antithyroid medication, to inhibit excessive thyroid hormone production—this pharmacologic intervention aimed to normalize thyroid hormone levels and mitigate their impact on cardiovascular function.\n",
      "Beta-Blockers: To control her elevated heart rate and manage arrhythmias, Ms. Turner was administered beta-blockers. These medications reduce heart rate, decrease cardiac workload, and enhance cardiac stability.\n",
      "\n",
      "Self-care strategies\n",
      "Lifestyle Modifications: Ms. Turner was advised to adopt stress-reduction techniques, prioritize adequate sleep, and maintain a balanced diet to support her overall health and recovery.\n",
      "\n",
      "Administration of intervention\n",
      "Antithyroid Medications (Methimazole): Initiated at 10 mg daily, Ms. Turner dosage was adjusted based on regular thyroid function tests. Dosage titration aimed to achieve normal thyroid hormone levels while minimizing the risk of hypothyroidism.\n",
      "Beta-Blockers: Ms. Turner was prescribed propranolol at 40 mg twice daily. The dosage was tailored to her heart rate and individual response to achieve heart rate control and symptom relief.\n",
      "\n",
      "Changes in intervention\n",
      "\n",
      "Dosage adjustment of antithyroid medications. As Ms. Turner thyroid hormone levels normalized, her methimazole dosage was gradually reduced. This adjustment aimed to prevent overtreatment while maintaining thyroid function within the normal range.\n",
      "\n",
      "Modification of beta-blocker dosage. As Ms. Turner heart rate stabilized within a healthy range and arrhythmias diminished, the propranolol dosage was tapered down. This reflected her improved cardiac function and reduced need for heart rate control.\n",
      "\n",
      "Rationale for changes\n",
      "\n",
      "Dosage adjustment of antithyroid medications. Reducing the methimazole dosage prevented the risk of inducing hypothyroidism, a common side effect of excessive treatment. This step ensured that Ms. Turner thyroid function was restored to a balanced state.\n",
      "\n",
      "Modification of beta-blocker dosage. As her cardiac function improved and her heart rate stabilized, lowering the propranolol dosage reflected the positive response to treatment. The gradual reduction of medication aimed to maintain her heart rate within a physiological range without unnecessary drug exposure.\n",
      "\n",
      "Follow-up and outcomes. Ms. Emily Turner follow-up encompassed regular assessments to monitor her progress:\n",
      "\n",
      "Clinician-assessed outcomes\n",
      "Cardiac Function Improvement: Subsequent echocardiograms revealed progressive improvement in left ventricular function and resolution of heart failure signs.\n",
      "Heart Rate Control: Ms. Turner heart rate stabilized within the normal range, with arrhythmias becoming infrequent.\n",
      "Normalization of Thyroid Function: Thyroid function tests consistently showed free T4 and TSH levels within the normal range, indicating successful management of hyperthyroidism.\n",
      "\n",
      "Patient-assessed outcomes\n",
      "Symptom Relief: Ms. Turner reported reduced palpitations, anxiety, and fatigue, contributing to an enhanced quality of life.\n",
      "\n",
      "Significant follow-up test result\n",
      "\n",
      "Thyroid function tests. Regular thyroid function tests confirmed the sustained normalization of thyroid hormone levels, confirming the effectiveness of antithyroid medications.\n",
      "\n",
      "Echocardiograms. Serial echocardiograms demonstrated the progressive improvement of left ventricular function, validating the efficacy of the treatment approach.\n",
      "\n",
      "Intervention adherence and tolerability. Intervention adherence and tolerability were assessed through:\n",
      "Patient Self-Reports: Ms. Turner provided feedback on her adherence to medication regimens and any observed side effects.\n",
      "Clinical Consultations: Regular clinical check-ins allowed clinicians to inquire about any difficulties or concerns related to medication adherence and tolerability.\n",
      "\n",
      "Adverse and unanticipated events\n",
      "\n",
      "Adverse events. Ms. Turner reported mild gastrointestinal symptoms, such as nausea and upset stomach, attributed to the antithyroid medication. These symptoms were managed through dose adjustments and supportive measures.\n",
      "\n",
      "Unanticipated event. Ms. Turner experienced brief palpitations and shortness of breath during the follow-up. This unanticipated event prompted additional cardiac assessments, which revealed no significant changes. The event was attributed to a temporary increase in stress and resolved spontaneously.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "36279710.txt\n",
      "A 60 s woman was found unconscious on the bed by her husband. He immediately called an ambulance, and the paramedics arrived at the scene 6 min after the call and took her to the emergency hospital. However, she had cardiopulmonary arrest upon arrival at the hospital and died after failed cardiopulmonary resuscitation. The patient was diagnosed with rheumatoid arthritis (RA) 25 years before her death and was on regular physician follow-up. At 15 years before her death, she complained of stomach discomfort and was diagnosed with a gastric ulcer due to amyloidosis. However, since no medical records were retained, it is unknown if she was diagnosed with RA-associated gastric AA amyloidosis upon pathological analysis of biopsied samples. At 14 years before her death, she was diagnosed with renal failure due to amyloidosis and underwent dialysis. Thereafter, she had multiple bone fractures (e.g., thoracic and lumbar vertebrae), possibly due to osteoporosis caused by chronic renal failure and dialysis-related hypotension. She also often experienced fall injuries during this time.\n",
      "\n",
      "Several years before death, she underwent coronary artery stenting due to angina pectoris of unknown etiology and had been receiving steroid therapy for interstitial pneumonitis due to RA and secondary pulmonary hypertension. However, she stopped taking disease-modifying anti-rheumatic drugs (DMARDs) for RA during this time, probably to avoid adverse effects of anti-rheumatoid drugs for pneumonitis (e.g., methotrexate-associated pneumonitis). At 1 day before her death, she fell and had injuries in her head and right elbow and went to the emergency doctor. However, she was discharged home by the doctor because she had no fracture in her head and right elbow, and her general condition was good. On the morning of her death, she complained of drowsiness and loss of appetite and did not have breakfast. At 1 h before her death, her husband came to take care of her but found her unconscious on the bed.\n",
      "\n",
      "She had been taking steroids for RA, aspirin and statins for coronary artery disease, prostacyclin agonists for pulmonary hypertension, and several dialysis treatment drugs (e.g., adrenergic receptor agonists for dialysis-related hypotension). Her husband reported that she did not drink alcohol and had no history of smoking. She had no family history of sudden unexpected death. The emergency physician indicated that postmortem computed tomography (CT) did not show bone fractures or intracranial hemorrhage in the patient (data not shown). A total blood count test of postmortem blood obtained by the emergency physician showed mildly elevated white blood cells, moderately reduced red blood cells, and mildly reduced platelet counts.\n",
      "\n",
      "Serum biochemical analysis of the blood showed severely reduced levels of albumin and glucose, and severely increased levels of creatinine and C-reactive protein, suggestive of renal failure and systemic inflammation. Moreover, the levels of troponin-T, creatinine kinase, creatinine kinase-myoglobin binding, and N-terminal pro-brain natriuretic peptide, markers of cardiac injury and heart failure, were also significantly increased.\n",
      "\n",
      "\n",
      "Her primary physician reported that she had nausea and vomiting after dialysis the day before her death, but these are well-known symptoms of chronic kidney disease and hemodynamic changes due to dialysis; therefore, the doctor did not perform cardiac functional analysis. In addition, no other noticeable signs were identified on physical examination or vital signs. The doctor did not believe that dialysis directly contributed to her death. The precise etiologies of cardiac injuries, RA, pulmonary diseases, medications, and fall injuries were unknown, as were their contributions to her death. Therefore, a complete forensic autopsy was performed 2 days after death.\n",
      "\n",
      "Autopsy findings\n",
      "Postmortem CT revealed a severely enlarged heart and thyroid gland with low-density parenchymal areas, a high-density area in the right coronary artery (consistent with stenting), pulmonary effusion, and severely atrophic kidneys. CT-based skeletal muscle index at the third lumber level, a marker of sarcopenia, was severely reduced to 13.2 cm2/m2 (clinical cutoff level: 29.6). Consistent with the CT interpretations of the emergency doctor, no fractures or signs of severe hemorrhage (e.g., intracranial hemorrhage) were identified.\n",
      "\n",
      "The deceased was 156 cm tall and weighed 39.2 kg, with a body mass index of 16.1 kg/m2 (severe emaciation). External examination showed multiple bruises (at most 20 × 6 cm in the right elbow) and abrasions (at most 4 × 1 cm) on the head, chest, right elbow, and right leg, probably worsened by aspirin treatment (data not shown). The neck was severely enlarged in the front region, suggesting thyroid gland disease. The right foot showed mild bunion (big toes), claw toes (second and fifth toes), callus (second toe), and hammer toes (second and third toes), all of which were compatible with RA. Consistent with the clinical history, mild whitish changes in skin coloration and moderately reduced lividity were found, suggesting moderate anemia.\n",
      "\n",
      "Internal examination revealed severe cardiac hypertrophy and severe epicardial fat deposits, with a weight of 447 (314.4 ± 60.5 g), even in the severe emaciation state. Although intermediate-to-severe atherosclerotic changes were found in the coronary arteries with right coronary artery stenting, no signs of thrombus, aneurysms, or ruptures were observed. The horizontal heart section showed moderate cardiac hypertrophy and scattered yellowish discoloration in the right ventricle and the posterior wall of the left ventricle, suggestive of amyloidosis. The thyroid gland was severely enlarged with a heterogeneous yellowish color change, suggesting fat deposition with parenchymal destruction. In the lungs, slight emphysematous changes were identified in the apex regions; however, no typical signs of interstitial pneumonitis, such as honeycombing, were observed. Pericardial effusion (20 ml), pulmonary effusion (left: 72 ml; right: 120 ml), and abdominal ascites (small amount) were identified, possibly due to heart failure (effusion due to increased pressure of capillaries owing to ineffective pumping of blood) or severe emaciation (effusion by reduced osmotic pressure to vessels from tissues owing to hypoalbuminemia). A small amount of salicylic acid, a metabolite of aspirin, was detected in the serum; however, no toxins or alcohols were identified in the serum or urine by gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry. Tests for hepatitis B and C were negative. A screening test for cardiac injuries using heart-type fatty acid-binding protein was positive.\n",
      "\n",
      "Histological examination of the heart and thyroid revealed amorphous deposits with parenchymal cell destruction, suggestive of systemic amyloidosis. The deposits were positive for amyloid A as noted upon Congo red staining and birefringence microscopy, which confirmed amyloidosis. The positivity of the Congo red-stained area was abolished after permanganic acid treatment (data not shown), suggesting AA amyloidosis rather than amyloid light chain (AL) amyloidosis. Immunohistochemical staining of the deposits for amyloid A (anti-amyloid A antibody, x100, M0759, Agilent Technologies, Santa Clara, CA, USA) was positive, whereas that for β2-microglobulin (anti-beta-2-microglobulin antibody, x400, A0072, Agilent Technologies, Santa Clara, CA, USA), a marker for Aβ2 amyloidosis (dialysis-related amyloidosis), were negative, confirming AA amyloidosis (most probably due to RA). Notably, peripheral regions that stained positive with Congo red and unstained cytoplasm of cardiomyocytes were highly birefringent when viewed under polarized light. Furthermore, the total area of apple-green colored deposits shown via birefringence microscopy were larger than the deposits stained positive with Congo red when viewed without polarized light (data not shown). The apple-green colored deposits seen under polarized light were not only present in the ventricular wall, but were also found in the cardiac conduction system such as sinoatrial node, a sinoatrial artery, and a right coronary artery. In the thyroid, clusters of mature adipocytes replacing the thyroid tissue, which is a characteristic histological feature of amyloid goiter, were observed. Interestingly, small deposits stained positive with Congo red were found primarily around the mature adipocytes, whereas large deposits were found around destructed parenchymal cells. In contrast to the differences observed in the staining patterns in the heart, apple-green colored deposits in the thyroid gland were smaller than the deposits stained positive with Congo red, as viewed without polarized light. In addition, dense areas in the thyroid stained positive with Congo red showed little to no correlated apple-green birefringence. Other organs, such as the kidneys, lungs, and pancreas, also showed AA deposition with parenchymal cell destruction, suggestive of a highly active state of systemic AA amyloidosis.\n",
      "\n",
      "Serum biochemical analysis using the cardiac blood obtained on autopsy showed active RA as evidence by increased anti-cyclic citrullinated peptide antibody level, but negative for rheumatoid factor; active systemic AA amyloidosis as evidenced by increased serum amyloid A peptide (SAA) level; and destructive hyperthyroidism as evidenced by increased levels of thyroglobulin, free triiodothyronine (T3), and free thyroxine (T4) with a normal thyroid-stimulating hormone (TSH) level. However, no suggestive signs of autoimmune thyroiditis, such as Hashimoto’s disease and Basedow disease (negative for anti-thyroglobulin and anti-thyroid peroxidase antibodies) were observed. In the lung, no signs of interstitial pneumonitis (e.g., interstitial inflammatory infiltrations with/without granulomas and signs of diffuse alveolar damage) were found.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "33692775.txt\n",
      "A today 25-year old woman with a complex 3-year history of cardiomyopathy following viral myocarditis underwent successful orthotopic heart transplantation at our institution.\n",
      "\n",
      "Six months prior to transplantation, she was listed in a prioritized status (Eurotransplant “HU” high urgent) but heart failure symptoms worsened with refractory signs of cardiogenic shock despite increased inotropic support. INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profile was at level 2. Left ventricular assist device (LVAD, HeartWare, HeartWare Inc.) was implanted in April 2017, i.e. 6 months before transplantation. During the initial postoperative period, the patient developed treatment-refractory right heart failure. Weaning of inotropic agents was again unsuccessful and led to massive dizziness, arrhythmia, and impaired flow of the LVAD. The patient was again placed in the highest priority status (Eurotransplant “HU” high urgent) for a heart transplant while staying hospitalized in the ICU. Inotropic support before transplantation was maintained with Dobutamine (3.2 µg/kg/min) and Milrinone (0.5 µg/kg/min). LVAD flow remained around 3.8–4.1 l/min.\n",
      "\n",
      "At the time of admission for transplantation, the patient had well-controlled pulmonary pressure (18/13 mm Hg) and low PVR (95 Dynes.s.cm-5). ABO status was compatible (B-/B-), cytomegalovirus mismatched (CMV −/+). The initial HLA antibody results of this mother were reported as being positive for Class I (Luminex Screen solid-phase arrays) specified for HLA B13, B41, B44, B45, B47, B49, B50, B60, B62, B71, B72, B76, and in a weaker expression for HLA B51, B54, B55, B56, B59, B63, B78. No preformed antibodies were cytotoxic. No C1q binding ability could be detected before transplant. The prospective donor-specific crossmatch was negative.\n",
      "\n",
      "The donor was a 51-year old woman with a history of moderate alcohol consumption and chronic pancreatitis who was transferred to the emergency department of another hospital after the intentional ingestion of Methanol. Despite vasopressor support with noradrenaline, continuous hemodialysis, and therapy directed towards the preservation of neuronal function the donor’s condition had evolved to brain death four days after admission. Echocardiography revealed normal heart function and diameters. Cardiac catheterization ruled out coronary artery disease, and the ECG was unremarkable.\n",
      "\n",
      "The heart transplantation was uneventful with an allograft ischemic time of 287 minutes. The LVAD was explanted. Pathological findings of the native heart confirmed interstitial fibrosis and mild hypertrophy consistent with the etiology of dilated postmyocarditic heart disease. The patient received induction therapy with cumulative 2 mg/kg body weight (120 mg) of anti-thymocyte globulin (ATG) and triple‐maintenance immunosuppression therapy with Cyclosporine (switched to Tacrolimus on POD 9), Mycophenolate Mofetil, and Prednisone. The retrospective HLA crossmatch was negative; the retrospective amount of HLA mismatch was HLA-A/B/C/DR/DQ: 0/2/-/2/2. The initial postoperative course was uncomplicated, and the patient was extubated 48 hours after surgery.\n",
      "\n",
      "On postoperative day (POD) 5, a decrease in myocardial function was noticed on transthoracic echocardiographic (TTE) follow up (FU). Pulsed-wave tissue Doppler imaging (PW-TDI) revealed a reduction of the radial and longitudinal systolic peak velocities (Sm) from 10/9 cm/s to 6/8 cm/s as signs for potential rejection (8). At this time point, the patient was already off inotropic support. The ECG remained unchanged (9). Right ventricular (RV) biopsy was performed. Histology revealed no cellular rejection (Level 0R of the International Society for Heart and Lung Transplantation criteria, IHSLT), but acute pathologic antibody-mediated rejection (pAMR grade 1 (I+), i.e. positive immunohistochemical staining with normal biopsy history.\n",
      "\n",
      "We administered 60 mg of ATG, two infusions with low‐dose intravenous immunoglobulin (1mg/kg body weight each), combined with steroid pulse therapy. No plasmapheresis was performed. At this time point, the expression of the donor-specific HLA Class 1 IgG against B44 had increased and C1q binding ability could be detected for non-donor specific B45 with a possible crossmatch. Six hours after RV biopsy, the patient presented signs of hemorrhagic shock. Computer tomography revealed acute retroperitoneal bleeding as a complication of the femoral puncture and the patient had to undergo emergent surgical decompression. Transfusion of 2 units of ABO-compatible packed red blood cells was necessary. The postoperative course was satisfying, with an echocardiogram showing ongoing improvement in cardiac function (PW-TDI Sm 10/9 cm/s). Ongoing tests on donor-specific HLA-IgG-antibodies revealed increased activity against B44, and increased complement binding activity of these antibodies was detected for the first time on POD 11. The patient was transferred to the transplantation unit of our institution on POD 12. Four cycles of plasmapheresis were performed. Two more doses of 60 mg ATG were administered when a slight decrease in myocardial function was again observed on POD 13. Despite a first remission in the histological stains on POD 21 (pAMR grade 0 in second RV biopsy), the patient presented persistent atrial arrhythmias (atrial flutter with varying A-V conduction) as well as non-sustained ventricular tachycardia (nsVT).\n",
      "\n",
      "A first CMR was performed on a Philips Ingenia 3.0 Tesla Scanner one month after transplantation. The exam revealed concentric left ventricular (LV) hypertrophy with moderately impaired biventricular function in line with prior TTE findings. Multiple cystic structures were found in the septal, mediolateral, and anterior parts of the LV with a crescent-shaped course ranging from the cavum through the myocardium to the epicardium. Late Gadolinium Enhancement (LGE) demonstrated high signal intensity of the described cystic lesions indicating fibrotic replacement. There was no evidence of regional myocardial edema in the T2-weighted images outside the above areas. Myocardial relaxation times were slightly increased (T1 native 1,389 ms; normal range 1,098–1,354 ms at 3 Tesla. T2 52 ms; normal range 35–51 ms at 3 Tesla).\n",
      "\n",
      "RV biopsy four weeks after transplant revealed ongoing AMR (pAMR grade 2) with T-cell infiltrates and cell destruction including the vessels. Three more cycles of plasmapheresis, three doses of ATG, and steroid pulse therapy were administered. Five days later, a single dose of Rituximab was given to the patient.\n",
      "\n",
      "In the 6-week FU, CMR LV-function had increased to about 50–55%. The cystic structures in the LV remained unchanged. Corresponding T2 images were strongly hyperintense and the LGE pattern was suspicious for mitochondrial cardiomyopathy. Electron microscopy of the biopsy specimens was performed. Ultrastructural findings revealed the presence of intracellular fat droplets, a high amount of fibrous tissue, and degenerative products. The morphology of mitochondria was found to be normal. The high amount of fatty-fibrous tissue in the right ventricle raised the suspicion of Arrhythmogenic right ventricular cardiomyopathy (ARVC) or another specific underlying cardiac disease of the donor.\n",
      "\n",
      "A genetic study of donor DNA was initiated. Next-generation sequencing with Illumina TruSight™ Cardio Sequencing Kit (Illumina, San Diego, CA, USA) including 174 potential genes for Cardiomyopathies was performed.\n",
      "\n",
      "Sequencing revealed two genetic variants in the coding gene for Titin with uncertain impact on the pathogenesis of ARVC, i.e. classification 3 in the American College of Medical Genetics and Genomics (ACMG) guidelines. No other specific findings, i.e. no genetic variants explaining either the persistent rejection or the cystic changes could be detected.\n",
      "\n",
      "FU TTE found levels of Sm to remain on a relatively low level despite the treatment efforts (10/8 cm/s for radial and longitudinal values respectively). Expression of the donor-specific HLA Class 1 antibodies against B44 was still detectable at week seven after transplant. Steroid pulse therapy, three more cycles of plasmapheresis (without additional ATG) plus increased dosages of mycophenolate mofetil (4g/d) were administered. Under this regimen, the patient finally attained and maintained remission. RV biopsy at week eight after transplant showed no signs of cellular or antibody-mediated rejection (ISHLT level 0R, pAMR grade 0). Despite the high frequency of intravenous steroids and the required changes in the immunosuppressive regimen, the transplant course was uneventful regarding infection. The patient’s tacrolimus levels were maintained at around 12–14 ng/ml.\n",
      "\n",
      "Before discharge CMR before discharge showed normal T1 values as compared to the previous examinations as a possible sign of remission. No change in the intramyocardial cysts was found. A wearable cardioverter defibrillator (LifeVest, ZOLL, Pittsburgh, PA, USA) was put on to prevent cardiac arrest due to heart rhythm disturbances. The patient was discharged ten weeks after transplantation to a cardiovascular rehabilitation center. TTE, lab, and clinical state remained stable, and the patient was in a very satisfying condition when seen in the outpatient department for regular clinical, biochemical, and echocardiographic FU. RV biopsy FU exams showed no pathology for cellular or humoral rejection. At the time of writing this report, 32 months after transplant have elapsed and the patient is in a stable clinical state. CMR 32 months FU shows cardiac function to remain stable. However, measures of extracellular volume remain slightly elevated (ECV 33%, cutoff 30%) indicating diffuse fibrosis of the myocardium.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "38552076.txt\n",
      "2. Patient information\n",
      "Mrs. O.K.O., a 34-year-old female of Nigerian descent, is a typist residing in Awka. She is a Pentecostal Christian and has completed education up to the Senior Secondary Certificate Examination. Mrs. O.K.O. is para 3, with 1 living child and a history of 2 previous pregnancies complicated by preeclampsia.\n",
      "\n",
      "2.1. Chief complaints\n",
      "Mrs. O.K.O. presented with progressive shortness of breath on exertion over the past 3 months, bilateral leg swelling for the last 10 weeks, and orthopnea for the past month. These symptoms severely impacted her daily activities, including breastfeeding and ambulating short distances.\n",
      "\n",
      "2.2. Medical history\n",
      "Diagnosed with hypertension 3 years ago during pregnancy, Mrs. O.K.O. occasionally takes Amlodipine 10 mg daily with good adherence. She had a history of preeclampsia in her 2 previous pregnancies. The last delivery was 4 months before the presentation. Mrs. O.K.O. is not known to have diabetes or any known drug allergies.\n",
      "\n",
      "2.3. Family history\n",
      "Mrs. O.K.O. is the third of 7 siblings in a monogamous family. Her father and elder sister died from an illness of unknown cause. There is no known family history of diabetes, hypertension, sickle cell disease, asthma, or epilepsy.\n",
      "\n",
      "2.4. Psychosocial history\n",
      "Married to 1 husband, Mrs. O.K.O., and her spouse have 1 living child (daughter). She lives a sedentary lifestyle with a lack of physical activity. There is no history of tobacco or alcohol use. Mrs. O.K.O. has stopped breastfeeding due to worsening symptoms.\n",
      "\n",
      "2.5. Relevant past interventions\n",
      "Managed for preeclampsia in her 2 previous pregnancies, Mrs. O.K.O. experienced severe hypertension leading to an intrauterine fetal demise at 34 weeks and fetal distress at 36 weeks, necessitating an emergency cesarean section. Unfortunately, the neonate died approximately 6 hours postdelivery.\n",
      "\n",
      "2.6. Current presentation\n",
      "Mrs. O.K.O.’s symptoms include progressive shortness of breath, bilateral leg swelling, orthopnea, and paroxysmal nocturnal dyspnea. She also reports a dry cough evolving into thick, frothy, whitish sputum. Associated symptoms include early satiety, easy fatigability, and nocturia. Despite herbal medication use, her symptoms worsened, leading to her seeking expert care.\n",
      "\n",
      "Note: The information provided is de-identified to protect patient privacy.\n",
      "\n",
      "Timeline: Depicting essential milestones related to our diagnoses and interventions\n",
      "\n",
      "Timeline of Mrs. O.K.O’s case\tEvent/intervention\tOutcome/response\n",
      "Before presentation\t- Previous pregnancies with preeclampsia\t- Intrauterine fetal demise at 34 weeks\n",
      "- Previous cesarean section\t- Neonatal distress at 36 weeks\n",
      "3 months before presentation\t- Onset of progressive dyspnea on exertion\t- Mild impact on sleep and daily activities\n",
      "2 weeks before presentation\t- Initiation of lower extremity swelling, especially feet\t- Difficulty wearing shoes, pain in feet\n",
      "- Paroxysmal nocturnal dyspnea\t- Waking up short of breath after 3 hours of sleep\n",
      "1 month before presentation\t- Development of orthopnea\t- Sleeping on a chair due to worsening symptoms\n",
      "At presentation\t- Expert care sought after herbal medication use\t- Decompensated heart failure diagnosed\n",
      "Admission (day 3)\t- Initiation of diuretics, spironolactone, and antihypertensives\t- Reduction in symptoms and improved exercise tolerance\n",
      "Day 5\t- Introduction of sacubitril/valsartan and digoxin\t- Subsiding cough, reduced leg swelling\n",
      "Day 7 (discharge)\t- Comprehensive medication regimen\t- Marked improvement in symptoms; patient requesting discharge\n",
      "\n",
      "\n",
      "\n",
      "3. Diagnostic assessment\n",
      "\n",
      "3.1. Methods\n",
      "\n",
      "1. Physical examination:\n",
      "Cardiovascular status assessment includes heart sounds, jugular venous pressure, and peripheral pulses.\n",
      "Respiratory examination for signs of heart failure such as crackles and reduced air entry.\n",
      "Abdominal examination for hepatomegaly and ascites.\n",
      "\n",
      "2. Laboratory testing:\n",
      "Complete blood count reveals anemia (packed cell volume [PCV]: 27%).\n",
      "Serum electrolytes, urea, and creatinine are within normal limits, except for mild elevation in creatinine (1.1 mg/dL).\n",
      "Urinalysis showing proteinuria.\n",
      "\n",
      "3. Imaging:\n",
      "Chest X-ray demonstrating upper lobe diversion, cardiomegaly, and bilateral pleural effusion.\n",
      "Electrocardiogram revealed sinus tachycardia, left axis deviation, low voltage Q wave, R wave, S wave, and left atrial enlargement.\n",
      "Echocardiography indicated a mildly dilated left atrium, reduced left ventricular ejection fraction (35%), and global wall hypokinesia.\n",
      "\n",
      "3.2. Diagnostic challenges\n",
      "Financial constraints may limit access to specific diagnostic modalities.\n",
      "Language barriers could hinder effective communication during history-taking and examination.\n",
      "Cultural factors may influence patients’ willingness to disclose information or adhere to recommended diagnostic procedures.\n",
      "\n",
      "3.3. Diagnostic reasoning\n",
      "Mrs. O.K.O.’s history of hypertension, preeclampsia, and previous pregnancies complicated by heart failure symptoms strongly suggest PPCM.\n",
      "The presence of bilateral leg swelling, orthopnea, and paroxysmal nocturnal dyspnea align with heart failure symptoms.\n",
      "Anemia contributes to the decompensation of heart failure, evident from the PCV of 27%.\n",
      "\n",
      "3.4. Other diagnoses considered\n",
      "Dilated cardiomyopathy secondary to other etiologies.\n",
      "Endomyocardial fibrosis.\n",
      "Hypertensive heart disease.\n",
      "\n",
      "3.5. Prognostic characteristics\n",
      "Staging in heart failure (New York Heart Association [NYHA] classification) was used for prognostic assessment.\n",
      "Initial NYHA class III indicated a severe limitation of physical activity.\n",
      "Progression to NYHA class II after treatment signifies improving symptoms and functional capacity.\n",
      "Note: The diagnostic assessment involved a comprehensive approach considering clinical, laboratory, and imaging findings, along with addressing potential challenges.\n",
      "\n",
      "\n",
      "4. Therapeutic intervention\n",
      "4.1. Types of intervention\n",
      "\n",
      "\n",
      "1. Pharmacologic:\n",
      "Diuretics: Intravenous furosemide 40 mg twice daily initiated, later changed to oral torsemide 40 mg daily.\n",
      "Angiotensin receptor-neprilysin inhibitor (ARNI): Sacubitril/valsartan 50 mg twice daily.\n",
      "Digitalis glycoside: Digoxin 0.25 mg daily.\n",
      "Antihypertensive: Telmisartan 80 mg daily (withheld later).\n",
      "\n",
      "\n",
      "2. Preventive:\n",
      "Anticoagulation: Dabigatran 110 mg daily.\n",
      "Antiplatelet: Clopidogrel 75 mg daily.\n",
      "Statin: Rosuvastatin 20 mg nightly.\n",
      "\n",
      "\n",
      "3. Self-care:\n",
      "Dietary modification: Restriction of daily salt intake to 2 g/d.\n",
      "Daily weighing: Monitoring for fluid retention.\n",
      "\n",
      "4.2. Administration of intervention\n",
      "Intravenous furosemide 40 mg twice daily initially for diuresis, later transitioned to oral torsemide 40 mg daily.\n",
      "Sacubitril/valsartan 50 mg twice daily was initiated for ARNI therapy.\n",
      "Digoxin 0.25 mg daily is added to enhance myocardial contractility.\n",
      "Dabigatran 110 mg daily was started for anticoagulation.\n",
      "Clopidogrel 75 mg daily for antiplatelet effect.\n",
      "Rosuvastatin 20 mg nightly for lipid management.\n",
      "\n",
      "4.3. Changes in intervention\n",
      "Telmisartan withheld:\n",
      "Rationale: ARNI therapy was initiated for its beneficial effects on heart failure. Telmisartan, an angiotensin receptor blocker, was withheld to prevent redundancy in angiotensin II receptor blockade.\n",
      "Torsemide adjustment:\n",
      "Rationale: The transition from furosemide to torsemide was made for better bioavailability and efficacy in managing fluid retention.\n",
      "Dosage adjustment (day 5):\n",
      "Reduction in IV torsemide to 40 mg daily.\n",
      "Introduction of metoprolol (dose not specified).\n",
      "Rationale: Tailoring the diuretic dosage to the patient’s response. Beta-blocker was introduced for additional heart failure management.\n",
      "\n",
      "4.4. Outcomes\n",
      "Marked improvement in symptoms, including reduced dyspnea and leg swelling.\n",
      "Transition from NYHA class III to class II, indicating enhanced functional capacity.\n",
      "The patient expresses subjective well-being, supporting the effectiveness of the therapeutic interventions.\n",
      "Note: The adjustments in the intervention were made based on the patient’s response and the evolving clinical picture.\n",
      "\n",
      "5. Follow-up and outcomes\n",
      "\n",
      "5.1. Clinician-assessed outcomes\n",
      "Day 5 (Registrer’s ward round [RWR]):\n",
      "Reduced symptoms of cough, leg swelling, and orthopnea.\n",
      "Objective improvement in vital signs (pulse rate: 98 b/m, BP: 140/90 mm Hg).\n",
      "The cough subsided, leg swelling markedly reduced, and orthopnea improved.\n",
      "Day 7 (RWR-discharge):\n",
      "Significant improvement in breathlessness and leg swelling.\n",
      "The patient is happier, not pale, with pedal edema up to the distal 1/3 of the tibia.\n",
      "Pulse rate: 87 b/m, NVR, BP: 142/89 mm Hg.\n",
      "\n",
      "5.2. Patient-assessed outcomes\n",
      "Day 5 (RWR):\n",
      "Subjective improvement in cough, leg swelling, and ability to sleep supine.\n",
      "The patient reports reduced overall discomfort and improved exercise tolerance.\n",
      "Day 7 (RWR-discharge):\n",
      "The patient expresses marked improvement in breathlessness and leg swelling.\n",
      "No new complaints were reported, indicating overall satisfaction with the treatment.\n",
      "\n",
      "5.3. Follow-up test results\n",
      "Day 3:\n",
      "Chest X-ray, electrocardiogram, echo, abdominal pelvic ultrasound scan, PCV, urinalysis, and serum electrolytes, urea, and creatinine were performed.\n",
      "Results indicated cardiomegaly, pleural effusion, reduced left ventricular ejection fraction, hepatomegaly, anemia, and proteinuria.\n",
      "\n",
      "5.4. Intervention adherence and tolerability\n",
      "Adherence is assessed through daily nursing care and discussions with the patient.\n",
      "Tolerability is assessed based on the absence of adverse effects and symptom improvement.\n",
      "\n",
      "5.5. Adverse and unanticipated events\n",
      "No adverse events were reported during the follow-up period.\n",
      "The patient exhibited good tolerance to the prescribed medications.\n",
      "\n",
      "5.6. Conclusion\n",
      "Mrs. O.K.O. responded positively to the therapeutic interventions, significantly improving clinician- and patient-assessed outcomes. Adherence was monitored through nursing care, and the absence of adverse events suggests tolerability. Regular follow-up remains crucial to assess the long-term efficacy and compliance with the prescribed regimen.\n",
      "\n",
      "Note: The follow-up and outcomes assessment involved a combination of objective clinical measures, patient-reported experiences, and ongoing monitoring of test results.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "32111713.txt\n",
      "A 32 year-old woman was admitted to our institution with a 2-week history of progressive shortness of breath.\n",
      "\n",
      "She had a significant medical history of end-stage renal failure secondary to chronic pyelonephritis and had undergone a cadaveric renal transplant in 2010. Prior to transplantation, she had undergone haemodialysis through a proximal left radiocephalic arteriovenous fistula. Her renal transplant surgery was complicated by flash pulmonary oedema requiring a stay on intensive care. In 2012, she was investigated for reduced graft function, which was attributed to chronic urinary tract infections. Following this episode, her creatinine stabilised at a baseline of 190–200 µmol/L.\n",
      "\n",
      "No other significant medical history was reported, and the patient’s medication list on admission was as follows; Prograf 4 mg two times per day, mycophenolate 1 g two times per day, amlodipine 5 mg/day, Aranesp 30 ug/week, bisoprolol 5 mg/day, calcium acetate 1 g three times a day with meals, ranitidine 150 mg/day, sodium bicarbonate 2 g two times per day, prednisolone 30 mg/day (reducing regime from general practitioner for wheeze and dyspnoea).\n",
      "\n",
      "The patient presented with shortness of breath, which had started 1 month prior to admission, having initially begun after her general practitioner prescribed a course of flucloxacillin for a paronychia. Her dyspnoea was worse on exertion with an associated wheeze and tightness in the chest. She denied pleuritic chest pain, palpitations, orthopnoea or paroxysmal nocturnal dyspnoea. There were no reports of cough, sputum production, fever or night sweats to suggest an infective or neoplastic cause for her symptoms.\n",
      "\n",
      "Observations on admission demonstrated a respiratory rate within normal limits at 16/min with oxygen saturations of 98% on room air. Blood pressure was raised at 186/105 mm Hg with a heart rate of 115 beats/min. Tympanic temperature was 36.7°C. On auscultation of the praecordium, she was found to have a pansystolic murmur, loudest over the left lower sternal edge, and there was evidence of a raised jugular venous pressure. The combination of these clinical signs was suggestive of tricuspid regurgitation. Respiratory examination was unremarkable and abdominal examination revealed only a mass in the right iliac fossa consistent with the known renal transplant. There was a proximal left radiocephalic arteriovenous fistula in situ.\n",
      "\n",
      "Investigations\n",
      "\n",
      "A number of investigations were requested to investigate the dyspnoea. Preliminary investigations were undertaken including an ECG which demonstrated sinus tachycardia with a normal cardiac axis and no evidence of ischaemia. A chest radiograph was reported as showing minor pulmonary vascular congestion.\n",
      "\n",
      "Routine blood tests revealed a microcytic anaemia with a haemoglobin of 94 g/L (70 g/L at its lowest during admission) with a mean corpuscular volume of 82.5 fL. Her platelet count and white cell count were normal. C-reactive protein was less than 5. Haematinics revealed slightly raised B12 levels at 865 ng/L with a normal folate of 7.5 µg/L. Iron studies revealed a ferritin of 613 µg/L, with iron 10.0 µmol/L, transferrin 1.87 g/L, total iron binding capacity 43 µmol/L and saturation of iron 23%. Renal function was impaired with a sodium of 138 mmol/L, potassium 5.0 mmol/L, bicarbonate 16 mmol/L, urea 21.7 mmol/L, creatinine 381 mmol/L (baseline 201 mmol/L) and estimated glomerular filtration rate 12 mL/min/1.73 m2 (baseline 25 mL/min/1.73 m2). Taken together, these results suggested an anaemia of chronic disease, most likely renal anaemia. Clotting screen was normal. Liver function tests were normal apart from a slightly raised alanine aminotransferase of 44 U/L. Thyroid function tests revealed a euthyroid state. Alpha 1 antitrypsin level was normal, along with normal blood borne virus serology. Rheumatoid factor, antinuclear antibody, anti-liver-kidney microsomal antibody, antimitochondrial antibody, anti-smooth muscle antibody, antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody were all negative.\n",
      "\n",
      "Given the history of exertional dyspnoea with radiographic evidence of pulmonary oedema, the patient underwent a series of cardiac investigations. A transthoracic echocardiogram was performed which showed a normal left ventricle with normal left ventricular systolic function, moderate biatrial enlargement, mild mitral regurgitation and mild to moderate tricuspid regurgitation. There was evidence of an elevated right ventricular systolic pressure of 50–60 mm Hg suggestive of pulmonary hypertension. A trivial pericardial effusion was also noted.\n",
      "\n",
      "\n",
      "Differential diagnosis\n",
      "\n",
      "The finding of pulmonary hypertension was unexpected. A low-dose ventilation/perfusion scan was performed to rule out chronic thromboembolic disease, the results of which were normal. Spirometry and later full pulmonary function testing (PFTs) were performed to investigate for pulmonary causes of secondary pulmonary hypertension. They revealed a pattern in keeping with a mild restrictive defect with minimal small airways obstruction on flow volume loops. After discussion with a respiratory physician, the findings on spirometry and PFTs were deemed most likely due to pulmonary oedema. The patient proceeded to have a CT scan of the thorax with intravenous contrast which did not show any evidence of chronic lung disease. As above, her full autoantibody and connective tissue disease screen was unremarkable.\n",
      "\n",
      "\n",
      "Treatment\n",
      "\n",
      "In light of the right-sided cardiac findings on echocardiography, the patient underwent a doppler ultrasound of her left radiocephalic arteriovenous fistula. The fistula study revealed an anastomosis of 9.2 mm, with an inflow of approximately 2.7 L/min and a reversed outflow of 700 mL/min. Flow within the fistula itself was estimated at 3 L/min, with the upper limit of normal considered to be 2 L/min in our institution. Based on this information, the patient was deemed to have a high output fistula.\n",
      "\n",
      "With the exclusion of other causes of pulmonary hypertension, a diagnosis of high-output cardiac failure secondary to a high-output arteriovenous fistula was hypothesised. A strategy was designed to further investigate our hypothesis with repeat transthoracic echocardiography performed first with a patent fistula and then repeated while the fistula was temporarily occluded. The left-sided radiocephalic fistula was occluded using a simple disposable tourniquet.\n",
      "\n",
      "The preocclusion echocardiogram showed a normal left ventricle with good left ventricular systolic function. There was at least moderate biatrial dilatation. Moderate tricuspid regurgitation was observed with at least moderate pulmonary regurgitation (however this was not reproducible on colour doppler). The right ventricle was reported as normal with evidence of good systolic function. Prior to occlusion of the fistula, the inferior vena cava was dilated at 2 cm with less than 50% collapse on inspiration. The estimated right atrial pressure (RAP) was 10–15 mm Hg and the estimated pulmonary arterial systolic pressure (PASP) was 58–63 mm Hg consistent with moderate pulmonary hypertension. On temporary occlusion of the fistula, the inferior vena cava reduced to 1.7 cm with more than 50% collapse on inspiration, the estimated RAP decreased to 5–10 mm Hg and estimated PASP dropped to 53–58 mm Hg. This reduction in PASP demonstrates the improved haemodynamic status of the patient following fistula occlusion.\n",
      "\n",
      "Our cardiology colleagues were consulted for review of the preocclusion and postocclusion echocardiography findings. They advised further investigation with cardiac MRI to review the cardiac anatomy and to further evaluate for right heart failure. Cardiac MR revealed an ejection fraction of 72% with an end diastolic volume of 97 mL/m2 (reference range 62–98 mL/m2) and end systolic volume of 27 mL/m2 (reference range 13–37 mL/m2). Stroke volume was calculated at 70 mL/m2 (reference range 43–67 mL/m2). Cardiac output was 9.8 L/min. The left and right ventricles were non-dilated with normal systolic function. Moderate tricuspid regurgitation and mild mitral regurgitation were noted again, and there was evidence of biatrial dilatation. Only the left segmental pulmonary artery was visualised, but accounting for this, pulmonary artery distensibility was calculated as normal. There was an incidental finding of bilateral pleural effusions.\n",
      "\n",
      "The case was discussed in the nephrology and renal transplant surgery multidisciplinary team meeting where a decision was made to ligate the left radiocephalic fistula to see if there would be any improvement in the patient’s cardiac function and symptoms. The patient underwent ligation of her left radiocephalic fistula under local anaesthetic without complication. Postoperative transthoracic echocardiography showed a normal left ventricle with normal systolic function, normal diastolic function and a right ventricle with normal size and function. Repeated doppler estimated PASP at 25 mm Hg. The improvements were sustained when transthoracic echocardiography was repeated further 4 months later.\n",
      "\n",
      "\n",
      "Outcome and follow-up\n",
      "\n",
      "The patient reported a marked improvement in her shortness of breath and exercise tolerance in the first few days postoperatively. She remains clinically well and returns regularly for routine nephrology follow-up. The emphasis in this case is on the immediate improvement in PASP from occluding the fistula. The echocardiography preocclusion and postocclusion allowed a definitive management decision to be made. This was justified as the patient had no pulmonary hypertension 6 months later on routine follow-up scans. If left unchecked, these patients go on to develop dilated right hearts and right ventricular failure.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "38545376.txt\n",
      "Patient information\n",
      "The patient was a 16-year-old Spanish adolescent, Caucasian, with no allergies, with mild intermittent extrinsic asthma treated with corticosteroids and aerosols (salmeterol 25 mcg/fluticasone 250 mcg two inhalations twice a day). He has no relevant past interventions and no medical, family or psychosocial history (including genetic) of interest. He presented with general discomfort, asthenia and fever (38°C) for three days and was treated with paracetamol 1g/8 hours and azithromycin 500 mg/24 hours for three days at home. After seven days, he came to the emergency department with persistence of symptoms, shortness of breath, arthromyalgia and diarrhea (two diarrheal stools without pathological products).\n",
      "\n",
      "Clinical findings\n",
      "Physical examination revealed a bad general condition. He was dehydrated (dry mucous membranes), but aware, oriented and collaborative. Blood pressure was 70/30 mmHg, heart rate was 110 bpm, respiratory rate was 18 bpm, SpO 2 98% and axillary temperature was 38.5°C. Lung auscultation found bibasilar crackles and heart auscultation found no murmurs. He had hepatosplenomegaly, oliguria, no edemas, no cutaneous rash and no arthritis. He had diuresis of 170 ml in 12 hours. The results of laboratory testing were: white blood cell count 10200 μL −1 (4000-11500 μL −1), with 8420 (1800-8000 μL −1) neutrophils, hemoglobin 12.5 g.dl −1 (13-17.5 g.dl −1), platelet count 104000 μL −1 (140000-450000 μL −1), serum C-reactive protein level 269.4 mg.l −1 (<5 mg.l −1), alanine aminotransferase level 81 U/L (7-49 U/L), aspartate aminotransferase level 71 U/L (13-40 U/L), total bilirubin level 3.30 mg.dl −1 (0.2-1 mg.dl −1), direct bilirubin level 2.73 mg.dl −1 (<0.3 mg.dl −1), high sensitiviry cardiac troponin I 1135 ng.l −1, blood urea nitrogen 48 mg.dl −1 (20-50 mg.dl −1), creatinine 2.72 mg.dl −1 (0.7-1.3 mg.dl −1), erythrocyte sedimentation rate of 12 mm/h (<15 mm/h), procalcitonin 1.96 ng.ml −1 (<0.1 ng.ml −1), arterial pH 7.32 (7.35-7.45), pCO 2 50.2 mmHg (35-45), pO 2 92 (75-100) mmHg, HCO 3 23 mmol/L (22-26 mmol/L), SpO 2 98% (96-100%), lactic acid 2.2 mmol.l −1 (0.5-2 mmol.l −1), ferritin 655.4 ng.ml −1 (22-322 ng.ml −1), triglycerides 161 mg/dL (22-150 mg/dL), uric acid 11.3 mg/dL (4.4-7.6 mg/dL), prothrombin activity 64.7% (70-130%), international normalized ratio 1.28 (0.8-1.2), activated partial thromboplastin time (aPTT) 28.9 seconds (20.6-31 seconds), aPTT ratio 1.16 (0.8-1.2) and D-dimer 7.500 ng/mL (220-500 ng/mL).\n",
      "\n",
      "Diagnostic assessment\n",
      "A nasopharyngeal swab and reverse transcriptase-polymerase chain reaction (RT-PCR) for COVID-19 (Cepheid-Xpert ® Xpress CoV-2 plus) was negative, but COVID-19 serology was IgM negative and IgG positive. Microbiological screening (urine, blood, sputum and stool culture), serological tests (virus, parasites, fungi and bacteria), and a Mantoux test were carried out. His thoracoabdominal CT scan showed multiple para-aortic and peri-pancreatic lymphadenopathy (compatible with lymphoproliferative syndrome as the most likely diagnosis) and acute respiratory distress syndrome (ARDS). There was no sign of pulmonary thromboembolism, but there were signs of pulmonary hypertension. He was admitted to the ICU and treated with broad spectrum antibiotics (imipenem 1 g/8 h, linezolid 600 mg/12 h) and a low dose of norepinephrine (0.05 mcg/kg/min).\n",
      "\n",
      "An investigation of lymphoproliferative syndrome considering the possibility of MAS secondary to COVID-19 was carried out, including autoimmune tests. Protein electrophoresis showed an inflammatory pattern and a direct Coombs test was negative. A bone marrow biopsy showed reactive cells, without atypical cellularity, discarding lymphoproliferative or MAS. Tests for autoimmune diseases revealed a low level of C3 and positivity for lupus anticoagulant. The rest of the antibody tests were negative.\n",
      "\n",
      "Microbiological screening, serological test and Mantoux were all negative, supporting the theory of an exaggerated systemic inflammatory response due to COVID-19. Septic shock was ruled out, so we decided to withdraw antibiotics. Only a rectal swab was positive for COVID-19.\n",
      "\n",
      "During his time in hospital, the patient presented with acute confusion and agitation. He had no meningeal signs on examination. Cranial CT scan was normal and symptoms remitted within 24 hours.\n",
      "\n",
      "An electrocardiograph showed atrial fibrillation and diffuse T wave inversion. Transthoracic echocardiography (TTE) was performed regularly, due to elevated cardiac enzymes. The first TTE was normal, but on the third day of admission demonstrated moderate biventricular dysfunction that progressed to severe in the following 24 hours, and atrial fibrillation.\n",
      "\n",
      "Therapeutic intervention\n",
      "From the beginning our patient was treated with a nasal cannula at 3 liters/minute for five days and a venturi mask at 40% FiO 2 for four days. Also, broad spectrum antibiotics (at the beginning, 1 g/8 h imipenem and 600 mg/12 h linezolid for six days, and on the third day of admission, 500 mg/24 h daptomycin and 200 mg/24 h fluconazole were added to the regimen) and a low dose of norepinephrine (0.05 mcg/kg/min) were administered.\n",
      "\n",
      "When the possibility of a septic shock was ruled out, antibiotics were withdrawn and 8 mg/24 hours dexamethasone was started to try to contain the cytokine storm. The dose was increased to 12 mg when he suffered with confusion, agitation and heart failure. The patient was treated with adrenalin up to 0.1 mcg/kg/min, 12.5 mg/24 hours levosimendan and 20 mg/8-12 hours furosemide for eight days. A bolus of 150 mg amiodaron followed by an infusion of 600 mg in 24 hours was administered when atrial fibrillation was targeted. He was given enoxaparin 60 mg/24 hours during the first days and then it was increased to 60 mg/12 hours.\n",
      "\n",
      "A new TTE that was performed four hours after levosimendan was initiated showed a moderate improvement in left ventricular function and a slight improvement in right ventricular function. In 12 hours, the cardiac function returned to normal and sinus rhythm was recovered.\n",
      "\n",
      "\n",
      "Outcomes\n",
      "Hemodynamic support therapy was withdrawn, and oxygen therapy, furosemide and dexamethasone were progressively reduced. He didn’t have any adverse events with the medication; it was well tolerated.\n",
      "\n",
      "In a few days, the clinical picture resolved and the patient was discharged to the Internal Medicine ward. The evolution of his condition was very favorable. He was afebrile, hemodynamically stable, with good food tolerance and without other clinical symptoms. Microbiological screening was repeated by Internal Medicine and a stool culture was positive for group B Salmonella species. The patient had no symptoms, but ciprofloxacin was administered for seven days and then he was discharged hemodynamically stable, eupneic and with oxygen saturation of 99% with oxygen supply of 0.28%. Two weeks later he left the hospital.\n",
      "\n",
      "Timeline with information from the current episode of care.\n",
      "Initial patient assessment\t- A 16-year-old Spanish adolescent, Caucasian, no allergies, extrinsic asthma treated with corticosteroids and aerosols occasionally.\n",
      "- No relevant past interventions and no medical, family or psychosocial history (including genetic) of interest.\n",
      "- Blood pressure 70/30 mmHg, heart rate 110 bpm, respiratory rate 18 bpm, axillary temperature 38.5°C.\n",
      "- Lung auscultation: bibasilar crackles.\n",
      "- Heart auscultation without murmurs.\n",
      "- Hepatosplenomegaly, oliguria, no edemas, no cutaneous rash and no arthritis.\n",
      "- Diuresis 170 ml in 12 hours.\n",
      "- General discomfort, asthenia and fever (38°C) for three days.\n",
      "- He was treated with paracetamol and azithromycin at home.\n",
      "- Six days after, he came to the emergency department with persistence of symptoms, shortness of breath, arthromyalgia and diarrhea.\n",
      "Diagnostic evaluation and therapeutic interventions\t- Nasopharyngeal swab RT-PCR and serology of COVID-19.\n",
      "- Blood test, protein electrophoresis.\n",
      "- Thoracoabdominal CT scan.\n",
      "- Microbiological screening and serological test.\n",
      "- Bone marrow biopsy.\n",
      "- Autoimmune test.\n",
      "- Cranial CT scan.\n",
      "- Electrocardiograph, transthoracic echocardiography.\n",
      "- Paracetamol 1 g/8 h and azithromycin 500 mg/24 h for three days.\n",
      "- Broad spectrum antibiotics (imipenem 1 g/8 h, linezolid 600 mg/12 h for six days). Daptomycin 500 mg/24 h and fluconazole 200 mg/24 h were added on the third day of admission.\n",
      "- Nasal cannula 3 liters/minute for five days and then venturi mask at 40% for four days.\n",
      "- Norepinephrine 0.05 μcg/kg/min for four days.\n",
      "- Dexamethasone 8 mg/24 h for three days and later 12 mg/24 h for four days.\n",
      "- Enoxaparin 60 mg/24 h for three days and then 60mg/12h until discharge.\n",
      "- Adrenalin 0.1 μcg/kg/min for two days.\n",
      "- Levosimendan 12.5 mg in 24 hours.\n",
      "- Furosemide 20 mg/8-12 h for eight days.\n",
      "- Bolus of amiodaron 150 mg, followed of an infusion of 600 mg in 24 h.\n",
      "Outcomes and follow-up\t- After a good recovery in ICU, the patient was discharged to the Internal Medicine ward.\n",
      "- He was afebrile, hemodynamically stable, without antibiotics and decreasing dosage of corticosteroids.\n",
      "- A new stool culture was positive for group B Salmonella species.\n",
      "- He had no symptoms, but ciprofloxacin was administered for seven days and then he was discharged.\n",
      "- In a follow-up visit to the Internal Medicine clinic he remained asymptomatic and without sequelae.\n",
      "- Cardiac magnetic resonance imaging was performed, which was normal.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "33858880.txt\n",
      "A 21-year-old man initially presented with shortness of breath and abdominal swelling. He was found to be in renal failure with urinary retention and subsequent imaging confirmed severe bilateral hydronephrosis requiring bilateral nephrostomies. He described a 4-month history of progressive shortness of breath on exertion, orthopnoea, weight loss and general malaise. Three months prior to this he had been treated by his general practitioner with a course of oral antibiotics for a productive cough, fevers and shortness of breath. There was no significant past medical history and family history was not suspicious for cardiomyopathy or sudden cardiac death. He was an ex-smoker, having stopped 3 years earlier. Alcohol and illicit drug use were denied, however there was a history of regular ‘Energy drink’ drink consumption, specifically consuming an average of four 500 mL cans per day for approximately 2 years. Each can contains 160 mg of caffeine in addition to taurine and various other ingredients. Retrospectively, the patient recalls occasional symptoms of dyspepsia, tremor and a racing heartbeat but without seeking medical review. In the 3 months prior to admission he was unable to continue his university studies due to his lethargy and feelings of ill health.\n",
      "\n",
      "Creatinine on presentation was 562 μmol/L, with urea of 47.4 mmol/L. Bilateral nephrostomies were inserted on day 3 of admission, with little subsequent improvement in renal function. He did not require any cardiovascular or respiratory support. On examination he was found to be in decompensated cardiac failure with pitting oedema to his knees and ascites. Clinically, he was not in pulmonary oedema. ECG demonstrated minor non-specific findings. A transthoracic echocardiogram showed a dilated left ventricle (LV) with a severely reduced ejection fraction (EF), biplane EF 11% with no left ventricular hypertrophy (LVH), a dilated right ventricle (RV) with impaired systolic function, bi-atrial dilatation, mild mitral regurgitation, mild tricuspid regurgitation and a small localised pericardial effusion 0.4 cm in size. There were bilateral ventricular thrombi caused by stasis requiring systemic anticoagulation with intravenous unfractionated heparin.\n",
      "\n",
      "The patient was then transferred to a tertiary hospital with access to advanced mechanical circulatory support in the event of deterioration. His admission was complicated by subclinical embolic and hypoperfusion-related cerebral infarcts, uraemic encephalopathy requiring emergency haemodialysis and heparin-induced thrombocytopenia. Haemodialysis was initiated on the intensive care unit on day 9, requiring a small amount of norepinephrine vasopressor support initially (0.04 μg/kg/min) but no inotropic agents were required. At the time there was concern that initiation of dialysis might result in cardiovascular collapse, which fortunately did not occur. This suggests that the low cardiac output was likely to have been chronic over a period of months for such haemodynamic compensation to occur. Given his intracardiac thrombi and renal failure, he initially received anticoagulation with intravenous unfractionated heparin. On day 9 of unfractionated heparin treatment his platelet count was noted to be 70×109/L following a gradual decline over the previous week (lowest platelet count 26×109/L on day 12). A positive heparin-induced thrombocytopenia screen resulted in a switch to argatroban. The patient stabilised on the intensive care unit but remained in cardiac and renal failure requiring regular haemodialysis without improvement in cardiac function and remaining haemodynamically stable off vasopressor support and without any inotrope requirement.\n",
      "\n",
      "He was referred and subsequently transferred for consideration of combined cardiac and renal transplantation. While urological investigations were being carried out to assess the suitability for kidney transplantation, his urine output via nephrostomies and urinary bladder improved with stable renal chemistry and fluid status, allowing a break from dialysis. Invasive assessment of his cardiac output with right heart catheterisation indicated that this was adequate, so imminent cardiac transplantation or mechanical circulatory support was not required at the time.\n",
      "\n",
      "Fifty-eight days after his initial presentation he was discharged home from hospital with ongoing cardiology, renal and urology follow-up with a creatinine of 383 μmol/L. His repeat outpatient cardiac magnetic resonance (CMR) scan after 2 months showed improvement in LVEF to 18% and repeat transthoracic echocardiogram at 9 months post discharge showed further improvement of LVEF to 51% with normal right ventricular function. His CMR indicated that there was no scar, inflammation or oedema.\n",
      "\n",
      "\n",
      "Investigations\n",
      "\n",
      "Admission ECG showed sinus tachycardia with a ventricular rate of 135 bpm, QRS duration of 110 ms and a normal PR interval. There was T-wave inversion in leads I and aVL and left axis deviation.\n",
      "Blood tests.\n",
      "Plain film chest radiograph (5/12/19, day 3 of admission) showed cardiomegaly, no pleural effusions and no pulmonary oedema\n",
      "\n",
      "Transthoracic echocardiogram (1) (5/12/19) showed a dilated LV (LV diameter 7.2 cm) with severely reduced EF (11%). No LVH. Laminated thrombus in LV mid anteroseptal wall extending to apex, dilated left atrium (30 cm2), dilated RV (6.3 cm base) with impaired systolic function. Tricuspid annular plane systolic excursion 14 mm. RV S’ 0.09 m/s, dilated right atrium (24 cm2), small pericardial effusion 0.4 cm atrial side, mild tricuspid regurgitation, RV systolic pressure 32 mmHg+right atrial pressure, mild mitral regurgitation, other valves were normal.\n",
      "CMR imaging (1) (11/12/19): CMR imaging showed a non-ischaemic cardiomyopathy with global severely impaired LV and RV systolic function, with LVEF of 9% and RVEF of 16%, severe bi-atrial dilatation with multiple LV and RV thrombi noted. No myocardial fibrosis, infiltration or infarction.\n",
      "CMR imaging (2) (14/2/20): CMR imaging showed improving but still severely impaired global LV systolic function (LVEF 18%). The mid inferior lateral wall is relatively more hypokinetic and there is improvement in RV function (RVEF 33%). No myocardial oedema and no obvious thrombi although gadolinium was not used on this occasion.\n",
      "Transthoracic echocardiogram (2) (10/6/20) showed a normal LV cavity size (LV diameter 5.7 cm) with global moderate impairment of systolic function (LVEF 38%). Normal RV size and function, normal bi-atrial sizes.\n",
      "Transthoracic echocardiogram (3) (18/8/20) showed a normal LV cavity size with mildly impaired systolic function (LVEF 51%). Normal RV size and function, normal bi-atrial sizes.\n",
      "Right heart catheterisation.\n",
      "MRI brain/spinal cord/lumbar spine (17/12/19): Combination of cardioembolic and hypoperfusion acute infarcts. The extensive bilateral subcortical acute infarcts as described favour a cardioembolic aetiology whereas the bilateral internal border zone acute infarcts suggest a hypoperfusion aetiology. No cauda equina/spinal cord compression, normal spinal cord and lumbar spine.\n",
      "Ultrasound abdomen (6/12/19): Enlarged kidneys with severe hydronephrosis and ureteric dilatation seen bilaterally. Increased echogenicity of the renal cortex and diffuse cortical thinning, appearance suggestive of chronic/longstanding obstruction. The liver is moderately enlarged with mild increased echogenicity of the parenchyma. The IVC in hepatic veins are prominent in size, likely in keeping with cardiac history.\n",
      "Urodynamic studies (1/7/20): Bladder capacity 400 mL. Reflux to upper tracts increasing volume and lowering pressure. Bladder outline highly trabeculated with closed bladder neck. No loss of compliance measured (upper tracts compensating for this).\n",
      "Bladder biopsy (20/08/20): Bladder mucosa shows stromal oedema, moderate chronic inflammation and stromal haemorrhage. No malignancy and no smooth muscle in biopsy samples.\n",
      "\n",
      "\n",
      "Differential diagnosis\n",
      "\n",
      "This was a case of severe biventricular failure with biventricular thrombi of uncertain aetiology. A number of differential diagnoses were considered.\n",
      "\n",
      "First, a stress-induced or ‘Takotsubo’ cardiomyopathy was felt to be less likely in this case given an absence of a preceding emotional or physical stressor, although these stressors may not be present in up to one-third of patients with Takotsubo syndrome.5 The insidious onset, over months prior to admission, was also not typical for Takotsubo syndrome, which classically presents more acutely and left ventricular function often recovers more quickly (usually within 21 days of onset).6 Furthermore, our patient did not fulfil the revised Mayo Clinic criteria7 or the international Takotsubo diagnostic criteria,8 and transthoracic echocardiography did not show any of the characteristic features (transient hypokinesis, akinesis or dyskinesis of the left ventricular mid-segments with or without apical involvement or any regional wall motion abnormalities extending beyond a single epicardial vascular distribution).9 Finally, Takotsubo syndrome predominantly affects postmenopausal women, although there have been case reports of younger male patients.10\n",
      "\n",
      "Heart failure secondary to myocarditis was also considered, however again the insidious clinical course was not typical for acute fulminant myocarditis and the CMR scan did not show the typical myocardial inflammation or fibrosis associated with this condition. Heart failure secondary to metabolic disturbances resulting from chronic renal failure was also considered as a potential differential diagnosis.\n",
      "\n",
      "A tachycardia-related cardiomyopathy was excluded as there was no evidence of arrhythmia throughout the admission, during which the patient remained on cardiac monitoring. Given the history of chronic energy drink consumption, lack of significant past medical or family history, cardiac imaging findings and improvement with ceasing intake, energy drink-induced cardiotoxicity was felt to be the most likely cause.\n",
      "\n",
      "\n",
      "Treatment\n",
      "\n",
      "Initial medical treatment was with intravenous furosemide and antibiotics for a suspected community acquired pneumonia. The patient was anticoagulated with unfractionated heparin, later switched to argatroban and then warfarin due to heparin-induced thrombocytopenia.\n",
      "\n",
      "Bilateral nephrostomies were inserted 3 days after admission, with little subsequent improvement in renal function. He later required temporary haemodialysis and now remains a low clearance patient under renal and urology follow-up with bilateral nephrostomies and ureteric stents.\n",
      "\n",
      "After stabilisation he was discharged on the following medications: warfarin once daily, carvedilol 3.125 mg twice daily, furosemide 20 mg once daily, isosorbide dinitrate 20 mg twice daily, hydralazine 25 mg three times a day, lansoprazole and oral nutritional supplements. Persisting severe renal impairment prevented the introduction of ACE inhibitor or mineralocorticoid receptor antagonist.\n",
      "\n",
      "\n",
      "Outcome and follow-up\n",
      "\n",
      "Post discharge, the patient had a considerable increase in exercise tolerance without any symptoms of heart failure or palpitations (NYHA class I). The patient had maintained euvolaemia and haemodynamic stability. Renal function remained severely impaired (estimated glomerular filtration rate 18 mL/min), and we were able to uptitrate carvedilol to 6.25 mg twice daily during the follow-up period in addition to his other medications. At 9 months post-discharge, a repeat echocardiogram showed that the left ventricular size had normalised with mildly impaired systolic function (LVEF 51%). There was no evidence of the previous intracardiac thrombus.\n",
      "\n",
      "As mentioned previously, poor renal function has largely inhibited the use of best medical therapy for heart failure. However, despite this, the patient has continued to improve and recover ventricular function. This is likely to be due to avoidance of energy drinks. He is no longer under follow-up from the cardiac transplantation team due to his improvement. However, it is difficult to predict the clinical course of recovery or potential for relapse. It is likely that the patient will at some point require renal transplantation. He has undergone urodynamic studies and bladder biopsies, which have not conclusively identified the cause of obstructive uropathy but do indicate that future bladder reconstruction is likely to be required to protect a future renal graft.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "31959653.txt\n",
      "An 18-year-old hispanic male patient with no significant medical history presents to the emergency department (ED) complaining of substernal, non-radiated chest pain, orthopnoea, dry and non-productive cough, and subjective fevers at home, for the last 3–4 days. Family history remarkable for paternal grandfather diagnosed with non-ischaemic cardiomyopathy and a pacemaker at age 86 years old. Patient lives with both parents and denies any smoking, ethanol consumption, recreational drug use, abuse or neglect at home. He worked at auto-part shop and planned to start college soon.\n",
      "\n",
      "\n",
      "Investigations\n",
      "\n",
      "\n",
      "In the ED, serum troponin I levels were found to be elevated and ECG showed diffuse ST-segment elevation. He was admitted to the local hospital and initial workup was remarkable for an enlarged cardiac silhouette and mild pulmonary oedema observed on chest X-ray, a transthoracic echocardiogram (TTE) demonstrating left ventricular ejection fraction (LVEF) of 40%, with severe left ventricular (LV) concentric hypertrophy and mild posterior pericardial effusion. Additionally, the patient was found to have elevated titres for Coxsackie virus A and B. His symptoms initially improved with the initiation of ibuprofen and colchicine. Cardiac catheterisation was performed, which revealed no evidence of coronary artery disease. Repeat TTE showed an LVEF of 40%–45%, hypokinesis of anteroapical and inferolateral wall, with an elevated LV end-diastolic pressure, consistent with diastolic dysfunction. Chest CT angiogram showed evidence of pneumonitis and a pericardial effusion. And at this point, the constellation of symptoms was thought to be secondary to Coxsackie myopericarditis, for which he continued to receive medical treatment as previously mentioned.\n",
      "\n",
      "On the fourth day of admission, the patient became diaphoretic, tachycardic and hypotensive with an undetectable blood pressure. Emergent TTE showed large pericardial effusion with impending cardiac tamponade features, and pericardiocentesis was performed. During the procedure, the patient developed pulseless electrical activity (PEA) cardiac arrest and received advanced cardiovascular support for 30 min. Ultimately patient was intubated, placed on venous-arterial extracorporeal membrane oxygenation (VA ECMO) and started on vasopressor support (norepinephrine 5 mcg/min and vasopressin 0.05 units/min), with numerous transfusions (9 packed red bloodcells, 10 units of platelets, 10 units of cryoprecipitate and 4 units of fresh frozen plasma) due to significant oozing of blood from the ECMO cannula. He was transferred to our hospital where endomyocardial biopsy (EMB) was then obtained due to concern of fulminant myocarditis and to test for other infiltrative cardiomyopathies. Pathology reports showed no signs suggestive of inflammatory or infiltrative process in the endomyocardium. Coxsackie Abs were repeated and were positive for Cox A type 9, Coxsackie B2 and Coxsackie B6, and an elevated Epstein-Barr virus (EBV) DNA quantitative PCR at 133 000 IU/mL. At this point, another TTE was done, which showed a severely decreased ejection fraction (EF) of 10%–15% with previously noted severe LV concentric hypertrophy (1.9 cm septum and 2.2 cm in the inferolateral wall).\n",
      "\n",
      "The patient was started on intravenous immunoglobulin (IVIG) for treatment of Coxsackie myocarditis, and broad-spectrum antibiotics due to worsening leucocytosis, but with no identified infectious focus. Colchicine was discontinued due to concern for rhabdomyolysis, with elevation of serum creatine kinase level to 2874 unit/L. Vasopressors were then discontinued and the patient was extubated. He also developed episode of flushing, fever, dyspnoea and decreasing oxygen saturation, with chest X-ray showing congested lung parenchyma with concerns for ARDS, therefore, IVIG was stopped.\n",
      "\n",
      "Given improvement of cardiac function in another TTE with LVEF of 25%–30%, it was decided to attempt to remove the ECMO, which was unsuccessful. The patient remained on ECMO support and emergent discussion with heart failure team took place to determine best approach. The patient was evaluated for possible left ventricle assist device, however, deemed not a candidate due to significant global concentric LV hypertrophy, and the multidisciplinary team agreed to facilitate emergency listing for heart transplantation, with consideration to transition to another cardiovascular support such as intra-aortic balloon pump, with potential inotrope support.\n",
      "\n",
      "During further evaluation for possible heart transplant, an incisional biopsy of a 1×1 inch palpable, painless, rubbery, mobile mass in the right arm was done and sent for pathology. The patient mentioned he first noticed this lesion approximately 2–3 months before presenting to the ED. Pathology report of the right upper extremity mass showed aggressive EBV (+) NK/T-cell lymphoma with a cytotoxic immunophenotype (positive for CD 2, CD3, CD56, BCL2, granzyme B, TIA1, MUM1 and diffuse coexpression of Epstein-Barr virus-encoded small RNAs by in situ hybridisation), and a modified SMILE (Steroids, Methotrexate with leucovorin, Ifosfamide with mesna, L-asparaginase and Etoposide) chemotherapy regimen was started. In situ hybridisation of the EMB previously obtained were negative for EBV-RNA.\n",
      "\n",
      "Cardiac MRI was obtained, which revealed hypokinesis of the inferolateral and anterolateral wall, as previously described by TTE, delayed enhancement in the subendocardial and transmural distribution in these regions, with relative sparing of the septum. Additionally, avid enhancement and thickening of the pericardium, without a mass identified, and a pocket of pericardial fluid with septations, concerning for loculations, were also noted.\n",
      "\n",
      "\n",
      "Differential diagnosis\n",
      "\n",
      "The constellation of symptoms (shortness of breath, orthopnoea, hypotension and subjective fevers), with findings such as diffuse ST-segment elevation on ECG, leakages of cardiac markers (troponin), elevated Coxsackie virus titres (both of serotype A and B), as well as echocardiographic findings of pericardial effusion; all seemed to correlate with a classic presentation of viral pericarditis clinical due to Coxackie virus. However, despite medical treatment with colchicine, the patient continued to decompensate and eventually required pericardiocentesis due to cardiac tamponade, then developed cardiac arrest and ultimately requires ECMO support, for what seems acute onset heart failure. In this setting, fulminant myocarditis secondary to Coxsackie virus was considered. Cardiotropic RNA virus, such as Coxackie viruses, induce receptor-mediated endocytosis, with viral replication contributing to cellular dysfunction and ultimately apoptosis of the cell.1 When susceptible individuals are infected with highly virulent viral strains, maladaptive immunologic activity can occur, leading to persistent activation of T cells and continued antibody-mediated myocyte destruction, which can ultimately lead to fulminant myocarditis. EBV myocarditis could also explain the rapid deterioration in the setting of a positive EBV PCR, which is a more sensitivity test than traditional serologies for detection of acute infection.2 However, in situ hybridisation was negative for EBV-RNA.\n",
      "\n",
      "Nevertheless, the significant concentric hypertrophy observed on the initial TTEs and the atypical delayed enhancement observed on the cardiac MRI are not explained by this diagnosis. Additionally, the EMB did not show an inflammatory process.\n",
      "\n",
      "Fortuitous finding of EBV (+) NK/T-cell lymphoma by incisional biopsy of the right upper extremity allowed for a more fitting diagnosis for this case. The pericardial effusion, unresponsive to initial medical treatment and new acute heart failure with concentric hypertrophic cardiomyopathy, in the setting of newly diagnosed NK/T-cell lymphoma, raises the possibility of NK/T-cell lymphoma with involvement of the myocardium and pericardium as the most adequate diagnosis in this scenario, which englobes all the features previously mentioned in this case.\n",
      "\n",
      "Other differentials taken into consideration include infiltrative cardiomyopathy such as amyloidosis. However, Congo red staining of the EMB samples failed to demonstrate deposition of amyloid.\n",
      "\n",
      "\n",
      "Treatment\n",
      "\n",
      "Given the diagnosis of extranodal NK/T-cell lymphoma (ENKTCL) with suspected pericardial involvement and no bone marrow involvement, modified SMILE regimen was desired as the first-line chemotherapy regimen. This regimen includes dexamethasone, ifosfamide, mesna and etoposide, and excluded methotrexate, due to evidence of third-spacing and effusions, which could lead to delayed excretion and increased risk of toxicity.\n",
      "\n",
      "However, due to his compromised cardiac function, it was believed that the patient would not tolerate cytotoxic chemotherapy which requires aggressive intravenous, and alternatively, emergent chemotherapy regimen was instituted: carboplatin (day 1–day 3), etoposide (day 1–day 5) and dexamethasone. Peg-asparaginase was later introduced in the regimen (day 7–day 21). This regimen proved effective, as evidenced by rapid recovery of the LV function and overall haemodynamic stability, and decision was made to incorporate a modified SMILE chemotherapy regimen, of which he received two cycles. Then chemotherapy regimen was changed to dexamethasone, gemcitabine, carboplatin and peg-asparaginase (DDGP). The patient received two cycles of DDGP. A full body positron emission tomography (PET) scan was negative for lymphoma. The plan is to continue two more cycles of chemotherapy (to complete six total cycles of chemotherapy). Currently, the patient is considering radiation therapy and possible stem cell transplant, after completion of the chemotherapy regimen. Additionally, the patient is currently on guideline-directed medical therapy for heart failure and has completed cardiac rehabilitation.\n",
      "\n",
      "\n",
      "Outcome and follow-up\n",
      "\n",
      "The patient has completed five out of six chemotherapy sessions with the previously mentioned regimens. After initiation of chemotherapy and optimal medical treatment for heart failure, the patient has recovered much of his cardiac function, as evidenced by an LVEF of 55%, no wall motion abnormalities and normal myocardial wall thickness on his most recent TTE. He continues to be followed by heart failure/cardiology team and oncology team in clinic.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "34603764.txt\n",
      "Patient B., 52 years old, was urgently admitted to the Specialized Cardiosurgical Clinical Hospital named after Academician B.A. Korolev (Nizhny Novgorod, Russia) where he was diagnosed with acute dissection of the thoracic aorta, aortic valve insufficiency, paroxysmal atrial fibrillation, cardiovascular failure IIA, and NYHA functional class III. The patient suddenly became ill 2 days before the admission; he felt a sharp piercing pain behind the sternum radiating into the inter-scapular area and further along the spine. The next day, a paroxysm of atrial fibrillation developed and was stopped with a medication (amiodarone 300 mg). The patient was admitted to the Uren District Hospital (Nizhny Novgorod Region, Russia), where echocardiography revealed an enlargement of the ascending aorta up to 7 cm with the presence of fluid in the pericardial cavity (about 200 ml). The patient was then transferred to the Specialized Cardiosurgical Clinical Hospital named after Academician B.A. Korolev for surgical treatment.\n",
      "\n",
      "On admission: a serious condition, clear consciousness, an active position, skin and visible mucous membranes of a physiological color, normosthenic constitution. In the lungs: breathing with a bronchial component, no wheezing, respiratory rate — 18 per minute. Rhythmic heart sounds with a heart rate of 76 per minute. Auscultation — no heart sound abnormality. BP — 110/50 mm Hg under medication support. The abdomen is soft and painless. The liver is not enlarged. No peripheral edema. Physiological functions are normal.\n",
      "\n",
      "ECG data on admission: sinus regular rhythm with a heart rate of 82 per minute, without signs of myocardial ischemia. Repeated echocardiography revealed an enlarged segment of the ascending aorta up to 70 mm, hemopericardium up to 200 mm.\n",
      "\n",
      "Emergency surgery for vital signs was performed: a Bentall–de Bono procedure (conduit consisting of a MEDINZH-2 mechanical aortic valve with a diameter of 27 mm (MedInzh, Russia) and a Vascutek Gelweave vascular prosthesis (Vascutek Ltd., UK) with a diameter of 30 mm) and distal anastomosis area plastic using the sandwich technique. Normothermic perfusion was maintained for a total of 203 min. Crystalloid cardioplegia with Custodiol solution (4000 ml total) was used for myocardial protection. The aorta was clamped for a total of 164 min.\n",
      "\n",
      "After the restoration of cardiac activity, signs of bleeding appeared; the source was found in the anastomosis to the right coronary artery (RCA). When trying to suture the anastomosis on the beating heart, the rate of bleeding increased. It was decided to extend this anastomosis by using an auto-venous graft. A fragment of the great saphenous vein 5 cm long was taken from the left tibia. The aorta was clamped again. The cardioplegic solution was administered into the root. The previous anastomosis to RCA and the conduit were removed. The RCA orifice was reduced to 5 mm and a distal anastomosis was formed of the auto-vein “end to end” along the axis. Then, a fragment of the auto-vein was replaced to the conduit and a proximal “end to side” anastomosis was applied along the axis directed to 6 o’clock. After the cardiac activity recovered, a pacemaker rhythm was imposed with a heart rate of 80 per minute. Hemodynamics got stabilized. Osteosynthesis of the sternum was performed using wire sutures. Surgical wounds on the chest and right groin were sutured layer-by-layer.\n",
      "\n",
      "After the patient was transferred to the ICU, he experienced progression of acute heart failure, extreme instability of hemodynamics, and hyperenzymemia, which necessitated an increase in cardiotonic support. Since the patient’s heart rhythm was driven with a pacemaker, no ECG record for signs of ischemia was possible. A decision was made to perform an emergency selective coronary angiography: the test showed no filling of the RCA orifice; all subsequent attempts to conduct a coronary guidewire were unsuccessful. Diagnoses of acute coronary syndrome, acute lower Q-wave myocardial infarction, and condition after a Bentall–de Bono procedure were then made.\n",
      "\n",
      "The patient underwent emergency myocardial revascularization by repeating RCA bypass grafting. Peripheral arteriovenous ECMO was initiated. Normothermic perfusion was run for a total of 60 min, while the aorta was clamped for 36 min. Revision of coronary arteries revealed no pulsation of RCA in plastic zone and the following additional auto-venous graft; both vessels looked collapsed.\n",
      "\n",
      "The decision was made to bypass the posterior descending artery accessible to bypassing in its proximal third. A distal “end to side” anastomosis was performed between the posterior descending artery and the auto-vein along the axis, by using a 7-0 prolene without additional sutures. The shunt was connected to the vascular prosthesis. A proximal anastomosis of a venous shunt was formed with an orientation of 5 o’clock. As a result, the shunt showed pulsation and was well drained off. Cardiac activity in the form of ventricular fibrillation and asystole was recorded, a pacemaker was imposed. An attempt was made to slow down the heart-lung machine, which resulted in a decrease in the central hemodynamics indices. It was then decided to connect another ECMO apparatus via peripheral circulation. Thus, the femoral vein was exposed 2 cm below the inguinal fold on the right and cannulated with a 27 Fr cannula according to Seldinger. The ECMO procedure was launched by using a Stockert S3 perfusion system (Sorin Group, Germany) and a Medos HILITE 7000 oxygenator (Medos, Germany). With the help of this additional ECMO, the hemodynamics got stabilized. Decannulation of the right heart was performed, and the wound closed.\n",
      "\n",
      "The patient was transferred to the ICU in critical condition. Arteriovenous ECMO was performed at the following parameters: perfusion flow — 5.21 L/min; perfusion index — 2.4 L/min/m2). Using epinephrine and norepinephrine (VIS — 35 units) for inotropic support, we observed stable hemodynamic parameters: BP of 90–95/70–75 mm Hg. Ultrasound examination showed a sharp decrease in the left ventricular ejection fraction (LVEF) to 30%, the right ventricle — to 22% with diffuse hypokinesis. The myocardial damage markers were creatine phosphokinase-MB (CPK-MB) at 500 ng/ml, troponin I at 200 ng/ml. Hyperenzymemia was also noted: the level of AST increased up to 2331 units, ALT — to 972 units, CPK — to 6145 units, lactate dehydrogenase — to 2633 units. It was then decided to add gaseous nitric oxide to the ECMO circuit. To generate nitric oxide, we used a device (Tianox; RFNC-VNIIEF, Russia) that produced nitric oxide from the ambient air, supplied it into the extracorporeal circuit, and monitoring/regulating NO concentration in the supplying mixture. The average dosage of nitric oxide was 40 ppm; the average NO2 concentration was 0.2–1.1 (0.80±0.06) ppm. The level of methemoglobin (MetHb) at all stages of the procedure did not exceed 1.5%. A session of efferent therapy — prolonged hemodiafiltration (CVVHDF) was started after 3 h.\n",
      "\n",
      "After 8 h, a decrease in myocardial damage markers was noted: CPK-MB — down to 144 ng/ml, troponin I — down to 126 ng/ml. During that time, ECMO was performed with the calculating flow, and stable hemodynamics was maintained by increased doses of epinephrine and norepinephrine (VIS was 55 units). Diffuse hypokinesis of both left and right ventricles was noted and the LVEF decreased to 19%.\n",
      "\n",
      "A significant improvement in the patient’s condition was observed only after 24 h exposure to NO-containing ECMO and ongoing hemodiafiltration. There was a decrease in both the dose of the inotropic drugs administered (VIS — to 7 units) and the concentration of the myocardial damage markers (CPK-MB — to 30.4 ng/ml, troponin I — to 50 ng/ml). The first hemodiafiltration session was completed after 24 h.\n",
      "\n",
      "Fifty-eight hours after starting the procedure, a gradual decrease in ECMO performance was initiated by reducing the perfusion flow (75–50–25% of the total volume rate); during that period, nitric oxide was continuously supplied to the oxygenator. At this stage, an increase in LVEF up to 45% and restoration of contractility of both the left and right ventricles was noted. Myocardial damage markers also decreased: CPK-MB — to 9.2 and 6.9 ng/ml after 48 and 72 h, respectively; troponin I dropped to 38.9 and 5.6 ng/ml after 48 and 72 h, respectively. After 48 h, the VIS was reduced to 6 units, and after 72 h — to 3 units. Twelve hours after the first session, a second portion of renal replacement therapy (RRT) was performed to treat multiple organ failure. During the RRT session, the manifestations of acute heart failure and multiple organ failure almost completely ceased. ECMO was discontinued 82 h later and the patient was decannulated. He showed stable hemodynamic parameters and myocardial contractile function. On day 5 after the operation, the patient was extubated; he maintained clear consciousness, adequate spontaneous breathing, satisfactory acid-base balance, and close to normal parameters of the blood chemistry. In total, he stayed in the ICU for 11 days. The postoperative wound of the sternum healed by primary intention.\n",
      "\n",
      "The patient was discharged from the clinic on day 18 after the operation. At the time of discharge, he had: ECG — with the sinus rhythm and a heart rate of 84 per minute; QRST — with no change; echocardiography — end-diastolic/systolic volume (EDV/ESV) — 161/83 ml; LVEF — 51%; the aortic valve prosthesis function was not impaired; aortic pressure gradient — 9/6 mm Hg; 0–I degree regurgitation; the mean pulmonary artery pressure was 32 mm Hg; 6-minute walk test — 280 m; Rehabilitation Routing Scale score was 4.\n",
      "\n",
      "The work was performed in accordance with the Declaration of Helsinki (2013) and approved by the Ethics Committee of the Specialized Cardiosurgical Clinical Hospital named after Academician B.A. Korolev. The patient signed an informed consent to participate in the study.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "35808997.txt\n",
      "Initial medical examination\n",
      "A 35‐year‐old female, with a medical history of total thyroidectomy due to obstructive goitre and ongoing thyroxine substitution (100 μg O.D.) experienced bilateral dorsal pain above the level of the kidneys, being severe in character and refractory to over‐the‐counter oral analgesics (paracetamol, ibuprofen, and diclofenac) in daily maximum doses. One week after the dorsal pain began, the symptoms worsened and broadened into sharp pain in the epigastric region with persistent nausea, and the patient was admitted to the regional emergency unit (ER). During physical examination, right subcostal and epigastric regions were highly sensitive to pressure, being the point of maximal pain at the gallbladder. No abdominal guarding was present. Abdominal ultrasound ruled out any pathological signs, except for an increased amount of fluid within the posterior cul‐de‐sac. This led to further gynaecological examination by a specialist, but no evident cause was found. Chest X‐ray (CXR) was also performed, without any significant abnormalities. The first laboratory tests showed that the glomerular filtration rate (GFR) was slightly reduced along with elevated C reactive protein (CRP). Urine analysis made with a dipstick was without any positive finding. The patient was discharged the same day and was advised to follow‐up with blood tests in a week, which later showed no significant changes, except for elevated lactate dehydrogenase enzyme. Since the initial examination was performed in April 2020, there was no routine screening available at that time to exclude SARS‐CoV‐2 infection.\n",
      "\n",
      "Deterioration of the patient's general state led to hospitalization\n",
      "After 10 days, the patient was admitted to the same ER with severe generalized weakness, headache, shortness of breath following minimal physical stress, and dry cough, but without any history of fever. Physical examination showed tachypnoea, bilateral crepitation in the lungs with congestion, along with normal heart sounds, diffuse abdominal sensitivity and bilateral peripheral oedema in her lower extremities. Normal values were obtained with blood pressure (BP) measurements on the upper limbs. ECG showed no specific alterations. CXR proved pneumonia and hydrothorax in the right lung. Furthermore, moderately elevated CRP was detected. Taking the symptoms, CXR result, and heightened awareness about the pandemic into consideration, the patient was admitted with high probability of SARS‐CoV‐2 infection. However, real‐time reverse transcriptase‐polymerase chain reaction (RT‐PCR) analysis ruled out an active infection. Therefore, a chest computed tomography (CT) scan was performed to search for potential radiological signs of COVID‐19. A large area of pneumonia involving both lungs with extended pleural effusion was detected, but the specific COVID‐19 characteristics of bilateral, basal peripheral ground‐glass opacities were not found. The contour of the heart was enlarged, but the CT scan evaluation did not suggest any other cardiac abnormality. During examination, the CT scan was extended to the upper abdominal region, where an occluded right renal artery was detected. Because the supplied kidney was atrophic, an acute occlusive event was excluded. An aneurysm in the proximal part of the splenic artery was also noted. Because of the pleural effusion, thoracentesis was performed, where 2000 mL serosanguineous, but lightly clouded fluid was removed, which was confirmed to be a transudate according to Light criteria. Further analysis of the transudate excluded any pathogenic infection or malignancy. The patient's treatment began here with intravenous (i.v.) levofloxacin and pantoprazole, which were administered for 9 days.\n",
      "\n",
      "Transfer to the regional COVID‐19 ward\n",
      "Regardless that SARS‐CoV‐2 infection was excluded, the patient was still moved to a regional COVID‐19 facility at day 5 of hospitalization. Consequently, this decision to transfer unnecessarily elevated her exposure risk to SARS‐CoV‐2. She also experienced severe nausea, and a gastroscopic examination was performed, where gastroesophageal reflux was proven. A new round of RT‐PCR tests again excluded SARS‐CoV‐2 infection. To explore alternative pathologies that could explain her status, transthoracic echocardiographic (TTE) examination was indicated, which showed severely reduced left ventricular ejection fraction (LVEF). On day 6 of hospitalization, HF was first posited as an explanation for the patient's severe status and symptoms. Hypotension was detected following a non‐invasive BP measurement; therefore, mannitol solution together with furosemide and dopamine were administered i.v.\n",
      "\n",
      "At this point, the patient was now in New York Heart Association (NYHA) III functional class, without adequate response to HF therapy, and the patient was transferred to our department's intensive care unit.\n",
      "\n",
      "Admission to the cardiology ICU\n",
      "At the time of admission, the patient's TTE showed a severely reduced LVEF of 18% with diffuse hypokinesis. The structure of the valves was normal aside from mild aortic regurgitation, moderate mitral regurgitation, and moderate tricuspid regurgitation with an elevated right ventricular systolic pressure. The thickness of the left ventricular wall was 10 mm. Around the heart, 10 mm concentric pericardial effusion was visualized. On ECG, sinus rhythm was detected, without any specific signs of ischemia, arrhythmia, peri‐ or myocarditis. NT‐proBNP was measured and found to be significantly elevated as high as 31 460 ng/L. Treatment with i.v. positive inotropic agent (dobutamine) and diuretics (furosemide) was initiated, based on acute HF guidelines. \n",
      "\n",
      "Hypertension was ascertained by invasive measurement during coronary angiography.\n",
      "\n",
      "To establish the aetiology of the patient's acute HF, invasive coronary angiography was performed, but this excluded epicardial coronary artery disease. There was no coronary physiology test performed to assess coronary microcirculation. During examination, the right radial artery access failed, because the diagnostic catheter could not reach the brachiocephalic trunk due to an occluded right subclavian artery. It must be noted here that arterial BP was normal at the level of the occlusion. Switching to the right femoral artery approach, 220/100 mmHg BP was ascertained by invasive measurement. Systolic BPs of lower and upper limbs were compared, where the discrepancy was as high as 110 mmHg systolic.\n",
      "\n",
      "Based on these findings, antihypertensive drug therapy was added to the HF therapy. Doses were titrated to achieve perindopril 5 mg twice a day (BID), indapamide 1.25 mg once daily, amlodipine 5 mg BID, bisoprolol 2.5 mg BID, and spironolactone 25 mg BID. The regimen above was prescribed at hospital discharge as well.\n",
      "\n",
      "Final diagnosis\n",
      "Abdominal‐chest CT angiography was performed, which confirmed bilateral subclavian artery occlusion in addition to the previously described right renal artery occlusion, but with a polar artery still supplying the right kidney. Following from our findings, TA was proposed based on the widely used classification criteria by the American College of Rheumatology. Three major criteria led to our conclusion: (i) age under 40 years; (ii) at least 10 mmHg difference systolic BP between the two arms/extremities; and (iii) occlusion of the aortic branches proven by angiography. To summarize the likely progression of her condition, vascular inflammation from TA caused occlusion of the right renal artery and consequentially led to arterial hypertension, which could not be revealed by non‐invasive BP measurements because of the occluded subclavian arteries. Eventually, the patient's uncontrolled hypertension caused acute HF.\n",
      "\n",
      "Our diagnosis of TA was supported after consultation with an immunologist. Another explanation could have been vasculitis of the small vessels causing myocarditis‐related HF; however, in this patient's case anti‐neutrophil cytoplasmic antibody (ANCA) levels were within the reference range and no small vessels were involved. Instead, either TA or immunoglobulin G4 (IgG4) related vasculitis was the most likely underlying pathology. IgG4‐related disease is a fibro‐inflammatory condition that can affect nearly any organ system with inflammatory aortitis and periaortitis, but it is usually restricted to the aorta. However, the patient's IgG4 values were normal, and the clinical character of the lesions suggested this mechanism was unlikely in her case. A positron emission tomography CT scan would have differentiated between TA‐ and IgG4‐related vasculitis but due to the current Hungarian health system financial environment, it could not have been performed in a timely manner. Considering that the treatment course for both diseases is equivalent, and the patient was in poor condition, the immunologist suggested prompt initiation of methylprednisolone and azathioprine therapy in combination with HF and antihypertensive medication.\n",
      "\n",
      "The patient responded quickly to adequate antihypertensive and HF medical management. After 2 weeks, TTE showed a moderately reduced LVEF of 40%. At 4 weeks, cardiac magnetic resonance imaging was performed and excluded significant structural abnormalities, the LVEF was normal. There was no late gadolinium enhancement with inversion recovery sequence.\n",
      "\n",
      "Myocarditis could not be fully excluded as an explanation in this case. Unfortunately, a troponin measurement was not made during the examination process, a biopsy of the myocardium was not obtained, nor was a cardiac MR performed during hospitalization. It must be acknowledged that the patient also received immunosuppressive therapy indicated by the immunologist. However, the patient's rapid response to antihypertensive and HF pharmacotherapy supports our conclusions regarding the cause of the event.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "30785587.txt\n",
      "A 51-year-old male, hypertensive patient, a former smoker, was transferred for treatment of thoracic aortic dissection and heart failure.\n",
      "\n",
      "After a three-week period with progressively more intense chest pain, accompanied by dyspnea, sweating and vomiting, he was admitted to the Hospital in the city where he lived.\n",
      "\n",
      "At hospital admission, he had high blood pressure and the diagnosis of thoracic aortic dissection was made. He received antihypertensive and beta-blocker medications. On the fifth day, he was transferred to Instituto do Coração for treatment. At that moment, he was asymptomatic.\n",
      "\n",
      "The physical examination (June 14, 2012) showed good general health status, paleness, ++ / 4+, increased jugular venous pressure, heart rate of 80 bpm, blood pressure 80 x 60 mmHg; clear lungs; cardiac auscultation disclosed rhythmic heart sounds and ++++ diastolic murmur on the left sternal border, no abdominal alterations, lower limbs without edema, besides palpable and symmetrical pulses.\n",
      "\n",
      "Laboratory tests (June 14, 2012) showed hemoglobin 15.9 g/dL; hematocrit, 49%; leukocytes, 10,080/mm3 (neutrophils 64%, eosinophils 7%, lymphocytes 21%, and monocytes 8%); platelets 232,000/mm3; CKMB, 1.33 ng/mL; troponin I, 0.106 ng/mL; urea, 38 mg / dL; creatinine, 0.94 mg /dL; sodium, 137 mEq/L; potassium, 4.2 mEq/L; prpthrombin time (PT) (INR), 1.1; APTT time ratio, 0.78; AST, 30 U/L; ALT, 61 U/L; gamma-GT, 116 IU/L; alkaline phosphatase, 81 U/L; and negative serology for hepatitis B, C, and HIV.\n",
      "\n",
      "The electrocardiogram (ECG) performed on June 16, 2012 showed sinus rhythm, left atrial and left ventricular overload with strain pattern.\n",
      "\n",
      "The echocardiogram performed on June 17, 2012, disclosed the following measurements: aorta, 37 mm; left atrium, 48 mm; septal thickness and posterior wall, 9 mm; left ventricle, 87/78 mm; ejection fraction, 22%. The patient showed eccentric hypertrophy with diffuse hypokinesis; moderate mitral regurgitation; marked aortic regurgitation; ascending aortic dissection was observed, with the original intimal tear 25 mm from the valve plane. The aortic measurements at the different levels were: aortic sinus, 37 mm, sinotubular junction, 46 mm, ascending aorta, 67 mm and aortic arch, 34 mm.\n",
      "\n",
      "The posteroanterior chest X-ray performed on June 18, 2012 showed normal lung fields, aorta with an image suggestive of aneurysm, and enlarged cardiac area.\n",
      "\n",
      "The coronary angiography did not show any coronary lesions. The pressures were: aorta: (syst/diast/mean) 100/50/67 mmHg and left ventricular: (Syst/initial diast/end diast) 100/10/20 mmHg. The left ventricle showed diffuse hypokinesis. There was marked aortic regurgitation and an ascending aortic aneurysm, with an image suggestive of dissection.\n",
      "\n",
      "The patient underwent surgery for repair of the ascending aortic dissection, with the interposition of a Dacron tube and aortic valve repair (June 19, 2012). The postoperative period was uneventful, and the patient was discharged on the ninth postoperative day.\n",
      "\n",
      "Almost a month after hospital discharge (July 11, 2012), he sought emergency medical attention for worsening of dyspnea, attributed to non-adherence to the prescribed medication.\n",
      "\n",
      "The physical examination (July 11, 2012) disclosed a heart rate of 60 bpm, blood pressure 80 x 60 mmHg; clear lungs; normal cardiac auscultation, no abdominal alterations; lower limbs without edema and no signs of deep vein thrombosis, with normal pulses.\n",
      "\n",
      "The laboratory tests (July 18, 2012) showed hemoglobin 10.7 g/dL; hematocrit, 32%; leukocytes, 9,750/mm3 (band cells 1%, segmented 69%, eosinophils 8%, basophils 3%, lymphocytes 14%, monocytes 5%), platelets, 443,000/mm3, C-reactive protein, 65.05 mg/L; urea 29 mg/dL; creatinine, 0.90 mg/dL, sodium, 130 mEq/L; potassium, 4.8 mEq/L; magnesium, 1.70 mEq/L, BNP, 1280 pp / mL, venous lactate 21 mg/dL; venous gasometry: pH 7.38, pCO2, 48 mmHg; pO2, 34.9 mmHg, O2 saturation, 53.8%; bicarbonate, 26.5 mEq/L, base excess, 2 mEq/L. Blood, urine and catheter tip cultures were negative.\n",
      "\n",
      "One month after this episode he was again brought to emergency care (August 11, 2012) with dyspnea on minimal exertion, orthopnea and oliguria for two days. He denied coughing, fever, coryza or diarrhea; chest pain or palpitation. He reported correct use of medications and hydrosaline restriction.\n",
      "\n",
      "The physical examination on admission showed blood pressure of 80x60 mmHg, heart rate of 102 bpm, fine pulses and decreased peripheral perfusion; jugular venous pulse was present; rhythmic heart sounds, presence of third heart sound, mitral systolic murmur +++ / 6+, tricuspid systolic murmur +++ / 6+ and aortic systolic murmur ++ / 6+; abdominal assessment - liver palpable at 5 cm from the right costal border; palpable and symmetrical lower-limb pulses.\n",
      "\n",
      "He was started on intravenous dobutamine, vasodilator and diuretic drugs, in addition to the antibiotics vancomycin and meropenem.\n",
      "\n",
      "Laboratory tests (August 11, 2012) showed hemoglobin: 9.2 g/dL, hematocrit: 31%, leukocytes: 12,980/mm3 (neutrophils 74%, eosinophils 1%, basophils 1%, lymphocytes 19%, monocytes 5%), platelets: 395,000/mm³, C-reactive protein: 79.58 mg/dL, urea: 55 mg/dL, creatinine: 1.26 mg/dL, sodium: 135 mEq/L, potassium: 5.1 mEq/L, prothrombin time: (INR) = 1.2, APTT:(rel) = 0.97, venous lactate: 55 mg/dL\n",
      "\n",
      "The chest x-ray showed pulmonary congestion and cardiomegaly.\n",
      "\n",
      "The echocardiogram (August 13, 2012) showed the following measurements: aorta, 41 mm; left atrium, 50 mm; right ventricle, 35 mm; septum, 9 mm; posterior wall, 10 mm; left ventricle, 86 mm; ejection fraction, 20%; hypertrophic left ventricle with diffuse hypokinesis; right ventricle with moderate hypokinesis; severe mitral regurgitation; normal aortic valve; pulmonary valve with indirect signs of pulmonary hypertension; estimated pressure of 43 mmHg and presence of Dacron tube in the aorta.\n",
      "\n",
      "The transesophageal echocardiogram (August 16, 2012) also showed the presence of marked tricuspid regurgitation and no images suggestive of thrombi or vegetations were observed.\n",
      "\n",
      "The laboratory tests performed on August 12 showed hemoglobin decrease to 7.7 g/dL and no evidence of bleeding and, therefore, an upper digestive endoscopy was requested, which did not show any alterations.\n",
      "\n",
      "A Doppler ultrasonography of the lower limbs carried out due to suspicion of pulmonary thromboembolism (recent RV dysfunction) showed no signs of thrombosis. The patient then underwent a chest tomography, which identified a small consolidation on the right side, with right pleural effusion.\n",
      "\n",
      "He developed refractory shock, despite the use of antibiotics. The right pleural effusion was punctured, and the presence of transudate was identified.\n",
      "\n",
      "All blood cultures and urine cultures were negative. He required orotracheal intubation for ventilatory support on August 29, 2012, developing an increasing need for noradrenaline, and the antibiotics were replaced by daptomycin, micafungin, and rifampicin.\n",
      "\n",
      "Laboratory reassessment (September 4, 2012) showed: hemoglobin: 10 g/dL; hematocrit: 33%; leukocytes: 5,450/mm³ (neutrophils 85%, lymphocytes 10% and monocytes 5%); platelets: 313,000/mm³; C-reactive protein: 221.38 mg/L; urea: 44 mg/dL; creatinine: 2.21 mg/dL; phosphorus: 2.2 mg/dL; magnesium: 1.6 mEq/L.\n",
      "\n",
      "The patient remained in shock and died (September 4, 2012).\n",
      "\n",
      "\n",
      "Clinical aspects\n",
      "\n",
      "This was a male patient, who presented with ascending aortic dissection, and who, even after surgery for dissection repair, developed a picture of severe heart failure and died.\n",
      "\n",
      "The International Registry of Acute Aortic Dissection (IRAD) showed that patients with aortic dissection were older than our patient, 61 years; and a majority of males (63%). Regarding the diseases related to the dissection, they were: Marfan syndrome (6.7%), hypertension (69.3%), atherosclerosis (24.4%), previously known aortic aneurysm (12.4%), previous aortic dissection 3.9%) and diabetes mellitus (4.3%). Also, 15.9% had a history of previous cardiac surgery and iatrogenic cause in 4.8% (1.7% coronary angiography and 3.1% after cardiac surgery). The 2015 update of the same registry, with a ten-fold higher number of patients, showed an increase in hypertension (75.5%) and a decrease in the presence of Marfan syndrome (4.5%), (75.5%), atherosclerosis (19.6%) and previous cardiac surgery (10.6%).\n",
      "\n",
      "Genetic tests can be performed in the presence of aortic aneurysm in younger patients. The syndromes related to the presence of aortic aneurysms are Marfan, Loeys-Dietz, Ehler-Danlos syndromes, the cutis laxa or elastolysis and that related to a defect in the transforming growth factor beta (TGFβ).\n",
      "\n",
      "Classically, the genetic alterations found in Marfan syndrome are related to the fibrillin-1 gene. Changes in the physical examination involve ocular (myopia, ectopia lentis, and risk of retinal detachment), skeletal (exaggerated growth and joint laxity, exaggerated growth of the extremities) and cardiovascular alterations (dilation of the aorta at the level of the sinuses of Valsalva, predisposing to dissection). In the present case, we do not have a description of these phenotypic changes that might suggest such diagnosis.\n",
      "\n",
      "Loeys-Dietz syndrome includes several manifestations similar to those of Marfan Syndrome, but they also include hypertelorism, broad or bifid uvula, cleft palate and generalized arterial tortuosity, aneurysms, and arterial dissection. Generally no increase of extremities and ocular alterations are observed.\n",
      "\n",
      "As well as for Marfan syndrome, we do not have evidence in the present case to suggest such a diagnosis.\n",
      "\n",
      "The Ehler-Danlos syndrome is characterized by fragility of the connective tissue and the manifestations occur in the skin (hyperelasticity, atrophic scars and easy ecchymosis), joints (hypermotility, frequent dislocations and arthralgias) and vessels (aneurysms and spontaneous vessel ruptures). The vascular form, in which dissection occurs most frequently, occurs through a mutation in the alpha-1 gene of type III collagen, with a silent substitution that leads to the replacement of glycine in the collagen chain.\n",
      "\n",
      "We also have no clinical evidence of such changes in the present case. A more recent study showed gene panel alterations in 25% of patients with aortic aneurysms.\n",
      "\n",
      "What should be taken into account is that even today the criterion for the indication of surgical treatment for rupture prevention remains the diameter of the aneurysm, 50 mm.\n",
      "\n",
      "In the present case, the patient had arterial hypertension and it must have had an important role in the development of the thoracic aneurysm and its rupture. Biomechanical studies show that for hypertension to lead an aneurysm development, there must be concomitant failure in the composition and maintenance of the extracellular matrix and membrane receptors. Consequently, there is damage to the mechanical stress transduction in the cell-signaling response.\n",
      "\n",
      "Regarding the patient’s unfavorable evolution after the surgery, it is probably due to the long evolution of the aortic aneurysm with aortic valve regurgitation, leading to left ventricular dilation and severe dysfunction, which in the very late states do not undergo regression or relief despite valve replacement surgery and progress to progressive heart failure. The ECG disclosed left ventricular overload with strain and the echocardiogram showed large left ventricular dilation and marked dysfunction.\n",
      "\n",
      "The European Guidelines of Cardiology and Thoracic Surgery recommends valve replacement surgery in patients with aortic dilation or aortic regurgitation accentuated with symptoms. In asymptomatic patients, this recommendation appears if there is reduction in ejection fraction (<50%) or ventricular dilation (diastolic diameter >70 mm or diastolic >50 mm).\n",
      "\n",
      "The patient had degrees of dilation (diastolic diameter, 87 mm and systolic diameter, 78 mm) and ventricular dysfunction (ejection fraction of 22%) well beyond those recommended for the indication of valve replacement surgery.\n",
      "\n",
      "This is the most plausible explanation for the poor evolution. (Dr. Desiderio Favarato)\n",
      "\n",
      "Diagnostic hypotheses: Aneurysm in the thoracic aorta, chronic aortic valve regurgitation, aortic dissection. Etiology: arterial hypertension and extracellular matrix disease of the aorta. Final clinical picture: cardiogenic shock due to valvular heart disease. (Dr. Desiderio Favarato)\n",
      "\n",
      "\n",
      "Necropsy\n",
      "\n",
      "The heart weighed 890g, with marked increase in volume and dilation of all chambers, predominantly the ventricles. The atrioventricular valves showed no abnormalities. The aortic valve showed thickening of the free margins of the semilunar leaflets, with a central non-coaptation aspect, compatible with valve regurgitation. A corrugated tube replaced the ascending aorta and was sutured just above the aortic sinotubular junction. Around the junction area between the ascending aorta and the ventricular mass, we noticed cavitation with irregular margins, partially filled by liquefied material, of a yellowish-brown color. There was also a concave circular lesion of the aortic intima, with 1.5 cm in diameter, just below the emergence of the renal arteries. The lungs showed areas of wine-colored parenchyma condensation, triangular in shape when sectioned. There were signs of generalized visceral congestion, as well as ascites (700 mL) and bilateral pleural effusion (200mL in each hemithorax).\n",
      "\n",
      "\n",
      "Histological examination showed accumulation of mucoid material in the tunica media throughout the aorta, as well as focal rupture of elastic fibers in the cavitary lesion described in the abdominal aorta. The anatomopathological study of the peri-aortic cavitary lesion showed mixed inflammation, with necrotic cellular and polymorphonuclear neutrophil debris, among sutures and other synthetic materials. Bacterial and fungal tests were negative at this site. The aortic valve showed fibrous thickening of the margins. There was chronic passive visceral congestion, with hepatic centrolobular necrosis; the wine-colored lesions in the lungs corresponded to recent infarctions. (Dr. Vera Demarchi Aiello)\n",
      "\n",
      "\n",
      "Anatomopathological diagnoses\n",
      "\n",
      "- Post-surgical correction of acute dissection of the ascending aorta\n",
      "- Peri-aortic cavitary lesion, with mixed inflammatory reaction, without the identification of infectious agents\n",
      "- Intramural dissection located in the abdominal aorta\n",
      "- Aortic valve regurgitation\n",
      "- Recent pulmonary infarctions\n",
      "Cause of death: Congestive heart failure with terminal shock (Dr. Vera Demarchi Aiello)\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "34764091.txt\n",
      "A 50-year-old male with a medical history of hypertension, gastro-oesophageal reflux disease, gout, hypothyroidism and anxiety presented to the emergency department with a 4-month history of progressive New York Heart Association (NYHA) class IV heart failure symptoms including dyspnoea, orthopnoea and paroxysmal nocturnal dyspnoea. He had been previously well, but recovered from a viral prodrome the previous month. He was a lifetime non-smoker, non-alcohol consumer and no other illicit drug use. His family history included an unspecified cardiac septal defect. On examination, the patient was afebrile, appearing comfortable in no distress on 3 L of nasal cannula oxygen, with normal blood oxygen saturations, a blood pressure of 119/79 mm Hg, heart rate of 104 bpm and normal respiratory rate. He had normal S1 and prominent S2 heart sounds with an S3 gallop and his jugular venous pressure (JVP) was elevated to the level of his earlobes, with course crackles in his chest. His abdomen was soft and nontender with no organomegaly and he had pitting oedema in his lower legs.\n",
      "\n",
      "He had multiple episodes of pronounced gait unsteadiness and at times would experience mechanical falls. These symptoms had been there throughout his adolescence and he endorsed he would require more upper limb strength to lift him off a chair and if on the floor he would need to get on his limbs first and push up with his arms. He also mentioned that as a child he would get muscle weakness and cramping during activity and had large calves. His neurological examination yielded a normal cranial nerve examination, reflexes were 2+ and symmetric with downgoing plantars bilaterally. His sensation was also grossly normal. He had atrophy of his quadriceps bilaterally, calf hypertrophy and normal strength in the upper extremities. He had mild weakness in his hip flexors (4/5) and hip abductors (4+/5), quadriceps (4+/5) and hamstrings (4/5) with preserved full distal strength in his lower extremities (graded in MRC muscle power scale). He had a waddling gait.\n",
      "\n",
      "\n",
      "Investigations\n",
      "\n",
      "ECG showed normal sinus rhythm, evidence of left atrial enlargement and left anterior fascicular block, with no signs of acute or chronic ischaemia or infarction. Transthoracic echocardiogram (TTE) showed severe LV dysfunction with moderate secondary mitral regurgitation (MR) with an estimated ejection fraction (EF) of 20% and right ventricular systolic pressure (RVSP) of 74 mm Hg. CT coronary angiogram and pulmonary embolism study (CT-CA) that showed no significant epicardial coronary artery disease and no evidence of pulmonary emboli. He had a negative haemochromatosis workup. His initial telemetry findings showed few runs of asymptomatic non-sustained ventricular tachycardia (NSVT).\n",
      "\n",
      "His 24-hour outpatient Holter was unremarkable. Cardiac MRI showed gross dilation of the LV with an EF of 17%. The LV was thin and hypertrabeculated in the anterior, lateral and inferior segments with delayed enhancement, suggestive of LVNC. His repeat TTE showed severe global reduced LV function with EF of 20%–25%, LV dilation and eccentric hypertrophy with grade II diastolic dysfunction. The RV was hypokinetic with RVSP of 40 mm Hg, restricted mitral leaflets and mild MR and tricuspid regurgitation. The atria were also mildly dilated. Given the findings of new onset heart failure and the delayed enhancement seen on cardiac MRI, a CA was performed, which demonstrated normal coronary arteries and left ventriculogram showing severe global hypokinesis and EF of 15%–20%. Contrast echocardiogram showed features consistent with LVNC.\n",
      "\n",
      "On review, the patient had recurrent syncopal episodes, prompting further risk stratification for sudden cardiac death (SCD), as well as candidacy for an implantable cardiac defibrillator (ICD). An 123I- Meta-iodobenzylguanidine (MIBG) scintigraphy scan showed decreased cardiac 123I-MIBG activity suggestive of moderate to severe cardiac sympathetic denervation, implying high risk for SCD.\n",
      "\n",
      "With regard to his muscular weakness, he had a normal CT brain and normal MRI brain and spine. He subsequently had an electromyogram (EMG) showing features consistent with nonspecific proximal lower extremity predominant myopathy, which led to a left quadriceps muscle biopsy. Histological examination revealed skeletal muscle with increased epimysial and perimysial fibroadipose tissue. An increased range of muscle fibre dimensions was evident, with many hypertrophic fibres measuring up to 150 µm in diameter, along with scattered single and very small collections of muscle fibres. Larger fibres were commonly rounded in appearance while normal and small-sized fibres were found to generally retain their usual polygonal contours. Occasional scattered degenerating or necrotic as well as regenerating fibres were identified, with several associated with collections of lymphocytes and macrophages. Blood vessels were unremarkable, and periodic-acid Schiff (PAS) and Oil Red O (ORO)-stained sections did not exhibit an apparent increase in glycogen or lipid, respectively. Myofibrillar ATPase-reacted sections demonstrated the normal checkerboard-like pattern of types 1 and 2 fibres, with all populations of fibres containing both types 1 and 2 fibres. An immunohistochemistry panel of merosin, beta-dystroglycan, alpha-sarcoglycan, beta-sarcoglycan, delta-sarcoglycan, dystrophin-1, and dystrophin-2 did not identify a definitive pathological abnormality. However, immunohistochemical analysis with dystrophin-3 antibodies demonstrated diminished to absent sarcolemmal positivity in most muscle fibres. Taken together, these findings were consistent with a nonspecific dystrophic/myopathic process with no inflammatory components, no rimmed vacuoles or inclusions noted.\n",
      "\n",
      "Genetic studies were considered and a gene panel for limb girdle muscular dystrophy turned out to be negative. He was found to have a hemizygous pathogenic variant in the DMD gene, which is designated as an in-frame deletion consistent with a diagnosis of BMD (c.5439_8237del, predicted to cause p.Glu2247_Gln2739del signifying deletions in exons 45–53 that results in truncated and dysfunctional dystrophin). He also was heterozygous for a variant of uncertain significance in the MYBPC3 gene that could potentially be responsible for his LVNC.\n",
      "\n",
      "\n",
      "Differential diagnosis\n",
      "\n",
      "In this gentlemen’s presentation of cardiomyopathy, an important distinction needed to be made between ischaemic and non-ischaemic aetiology. Ischaemia was essentially negated with a normal initial CT -CA and normal CA. A question of viral myocarditis as the causative trigger in the initial hospital presentation (given his viral prodrome) was considered, however, his LV systolic function did not improve over time. He subsequently had a cardiac MRI and contrast TTE which showed features consistent with LVNC.\n",
      "\n",
      "With respect to this patient’s weakness and ataxia, there could have been a multifactorial aetiology including a primary structural central nervous system lesion such as a stroke or multiple sclerosis, which was ruled out by a normal CT and MRI of his brain. He did have EMG evidence of lower limb myopathy and the quadriceps biopsy further showed that he had a nonspecific dystrophic process. Thus, he had a symmetric limb-girdle distribution myopathy. He had no contractures, militating a diagnosis of Emery-Dreifuss syndrome. Inclusion body myositis was ruled out as the biopsy showed no inflammatory features, no rimmed vacuoles and no inclusions. Danon disease was considered given the dyad of cardiomyopathy and skeletal myopathy, however, given the lack of any evidence suggesting cognitive dysfunction and no LAMP2 gene mutations, it made it less likely. Further genetic workup yielded a pathogenic variant in the DMD gene consistent with BMD.\n",
      "\n",
      "\n",
      "Treatment\n",
      "\n",
      "This patient was optimised medically and switched to sacubitril/valsartan with good response. He was deemed high risk for SCD and was booked for an elective primary prevention ICD. Unfortunately he experienced an out-of-hospital cardiac arrest from pulseless VT. He was successfully resuscitated and subsequently received a dual chamber ICD for secondary prevention. He was concomitantly placed on amiodarone as an antiarrhythmic for shock suppression therapy and subsequently switched to sotalol due to amiodarone intolerance. The patient went on to have recurrent syncopal VT episodes requiring multiple hospital admissions. His Interagency Registry for Mechanically Assisted Circulatory Support score was 2–3, which prompted an urgent referral for a LV assist device (LVAD) and he had a HeartMate 3 LVAD implanted.\n",
      "\n",
      "With regard to his BMD, the patient had no specific pharmacotherapy, however, he did attend regular follow-ups with neurology, physiatry, as well as speech pathology to monitor for any neurological and functional complications. This therapy formed an important aspect in preparing him for an eventual cardiac transplantation.\n",
      "\n",
      "His cardiac medications are as follows: sotalol, warfarin, sertraline, aspirin, metoprolol, furosemide, spironolactone and sacubitril/valsartan.\n",
      "\n",
      "\n",
      "Outcome and follow-up\n",
      "\n",
      "This patient follows up regularly with both the heart function clinics. He thinks his management of his activities of daily living are slowly improving. He will have occasional orthostatic light-headedness but denies any syncopal events. He states that he is limited more by leg weakness than any dyspnoea. He denies any ICD shocks or LVAD alarms.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "long_docs = df[df[\"n_words\"] > 1500]\n",
    "\n",
    "for i, row in long_docs.iterrows():\n",
    "    print(row[\"filename\"])\n",
    "    print(row[\"text\"])\n",
    "    print(\"\\n\\n\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Metadata exploration"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total number of MeSH terms: (10592, 2)\n",
      "\n",
      "Top 20 most frequent terms\n",
      "| terms                      |   count |\n",
      "|:---------------------------|--------:|\n",
      "| Humans                     |     996 |\n",
      "| Male                       |     505 |\n",
      "| Female                     |     413 |\n",
      "| Middle Aged                |     298 |\n",
      "| Aged                       |     257 |\n",
      "| Adult                      |     227 |\n",
      "| Treatment Outcome          |     216 |\n",
      "| Echocardiography           |      99 |\n",
      "| *Heart-Assist Devices      |      94 |\n",
      "| *Heart Failure             |      89 |\n",
      "| Stroke Volume              |      74 |\n",
      "| Aged, 80 and over          |      71 |\n",
      "| Diagnosis, Differential    |      63 |\n",
      "| Fatal Outcome              |      61 |\n",
      "| Electrocardiography        |      55 |\n",
      "| Ventricular Function, Left |      50 |\n",
      "| Pregnancy                  |      49 |\n",
      "| *Heart Failure/etiology    |      45 |\n",
      "| SARS-CoV-2                 |      45 |\n",
      "| Acute Disease              |      44 |\n"
     ]
    }
   ],
   "source": [
    "metadata_path = \"data/1_original/metadata\"\n",
    "df_meta = files_to_df(metadata_path)\n",
    "df_meta[\"terms\"] = df_meta[\"text\"].str.split(\"\\n\")\n",
    "df_meta = df_meta.explode(\"terms\")\n",
    "df_meta[\"terms\"] = df_meta[\"terms\"].str.replace(\"MH  - \", \"\")\n",
    "df_meta.drop(columns=\"text\", inplace=True)\n",
    "\n",
    "print(f\"Total number of MeSH terms: {df_meta.shape}\")\n",
    "print(\"\\nTop 20 most frequent terms\")\n",
    "print(df_meta.terms.value_counts().sort_values(ascending=False).head(20).to_markdown())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>filename</th>\n",
       "      <th>terms</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>33175723_1.txt</td>\n",
       "      <td>*Amyloidosis/diagnosis/diagnostic imaging</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>33175723_1.txt</td>\n",
       "      <td>*Cardiomyopathies/diagnostic imaging</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>33175723_1.txt</td>\n",
       "      <td>Diagnostic Imaging</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>33175723_1.txt</td>\n",
       "      <td>*Heart Failure/diagnostic imaging/etiology</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>33175723_1.txt</td>\n",
       "      <td>Prealbumin</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         filename                                       terms\n",
       "0  33175723_1.txt   *Amyloidosis/diagnosis/diagnostic imaging\n",
       "0  33175723_1.txt        *Cardiomyopathies/diagnostic imaging\n",
       "0  33175723_1.txt                          Diagnostic Imaging\n",
       "0  33175723_1.txt  *Heart Failure/diagnostic imaging/etiology\n",
       "0  33175723_1.txt                                  Prealbumin"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "age_mesh = [\"Aged\", \"Middle Aged\", \"Young Adult\", \"Adult\", \"Aged, 80 and over\", \"Infant, Newborn\", \"Infant\", \"Child, Preschool\", \"Child\", \"Adolescent\", \"Young Adult\", \"Adult\"]\n",
    "human_mesh = [\"Humans\", \"Male\", \"Female\"]\n",
    "\n",
    "df_meta_medic = df_meta[~df_meta[\"terms\"].isin(age_mesh + human_mesh)]\n",
    "df_meta_medic.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Medical MeSH terms"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1500x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df_meta_medic.terms.value_counts().sort_values(ascending=True).tail(20).plot(kind=\"barh\", figsize=(15, 6), title=\"Top 20 MeSH terms\")\n",
    "plt.tight_layout()\n",
    "plt.savefig(\"img/data_analysis/mesh_terms_medic.png\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Gender and age"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Gender"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "       filename                                         mesh_terms  \\\n",
      "0  25350173.txt  [Cardiac Surgical Procedures/*methods, Female,...   \n",
      "1  25531204.txt  [Adult, Anti-Inflammatory Agents, Non-Steroida...   \n",
      "2  25654384.txt  [Animals, *Black Widow Spider, Female, Greece,...   \n",
      "3  25679083.txt  [Acute Disease, Aged, Cardiovascular Agents/*t...   \n",
      "4  25725033.txt  [Acute Disease, Aged, 80 and over, Constrictio...   \n",
      "\n",
      "                                                text  \n",
      "0  A 64-year-old female lifelong smoker with no p...  \n",
      "1  A 28-year-old man presented to the Emergency D...  \n",
      "2  A 64-year-old female patient with a history of...  \n",
      "3  Josephine was a 70-year-old white woman measur...  \n",
      "4  An 85-year-old woman reported sudden onset dys...  \n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "gender\n",
       "Male       562\n",
       "Female     424\n",
       "Unknown     14\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_meta_list = df_meta.groupby(\"filename\").apply(lambda x: x[\"terms\"].tolist(), include_groups=False).reset_index().rename(columns={0: \"mesh_terms\"})\n",
    "df_meta_list = df_meta_list.merge(df, on=\"filename\")\n",
    "print(df_meta_list.head())\n",
    "\n",
    "import re\n",
    "df_meta_list[\"male\"] = df_meta_list[\"mesh_terms\"].apply(lambda x: \"Male\" in x)\n",
    "df_meta_list[\"female\"] = df_meta_list[\"mesh_terms\"].apply(lambda x: \"Female\" in x)\n",
    "\n",
    "mask_gender_null = (df_meta_list[\"male\"].astype(int) + df_meta_list[\"female\"].astype(int)) != 1\n",
    "\n",
    "pattern_male = r\"\\b[mM]ale\\b|\\b[mM]an\\b|\\b[bB]oy\\b|\\b[mM]en\\b|\\b[gG]entleman\\b\"\n",
    "pattern_female = r\"\\b[Ff]emale\\b|\\b[wW]oman\\b|\\b[gG]irl\\b|\\b[lL]ady\\b|\\b[wW]omen\\b\"\n",
    "\n",
    "df_meta_list[\"first_match\"] = df_meta_list[\"text\"].apply(lambda x: re.findall(pattern_male + \"|\" + pattern_female, x))\n",
    "df_meta_list[\"first_match\"] = df_meta_list[\"first_match\"].apply(lambda x: x[0] if len(x) > 0 else None)\n",
    "\n",
    "df_meta_list.loc[mask_gender_null, \"male\"] = df_meta_list.loc[mask_gender_null, \"first_match\"].apply(lambda x: bool(re.match(pattern_male, x)) if x is not None else False)\n",
    "df_meta_list.loc[mask_gender_null, \"female\"] = df_meta_list.loc[mask_gender_null, \"first_match\"].apply(lambda x: bool(re.match(pattern_female, x)) if x is not None else False) \n",
    "\n",
    "# df_meta_list.loc[~ (df_meta_list[\"male\"] | df_meta_list[\"female\"])]\n",
    "def get_gender(x):\n",
    "    if x[\"male\"] & (not x[\"female\"]):\n",
    "        return \"Male\"\n",
    "    elif x[\"female\"] & (not x[\"male\"]):\n",
    "        return \"Female\"\n",
    "    else:\n",
    "        return \"Unknown\"\n",
    "    \n",
    "df_meta_list[\"gender\"] = df_meta_list.apply(get_gender, axis=1)\n",
    "\n",
    "df_meta_list = df_meta_list.drop(columns=[\"male\", \"female\", \"first_match\"])\n",
    "\n",
    "df_meta_list[\"gender\"].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>filename</th>\n",
       "      <th>mesh_terms</th>\n",
       "      <th>text</th>\n",
       "      <th>gender</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>403</th>\n",
       "      <td>32470181.txt</td>\n",
       "      <td>[*Betacoronavirus, COVID-19, Coronavirus Infec...</td>\n",
       "      <td>Briefly, the patient was admitted on January 2...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>435</th>\n",
       "      <td>32729665.txt</td>\n",
       "      <td>[Aortic Valve/diagnostic imaging/surgery, *Hea...</td>\n",
       "      <td>During this period, 11 (11%) patients received...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>569</th>\n",
       "      <td>33862215.txt</td>\n",
       "      <td>[COVID-19/*complications, Heart Failure/etiolo...</td>\n",
       "      <td>A 50-year-old patient, six years post-heart tr...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>582</th>\n",
       "      <td>34035020.txt</td>\n",
       "      <td>[*Heart Failure, Humans, Infant, *Ventricular ...</td>\n",
       "      <td>A 5-month-old infant with poor weight gain was...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>641</th>\n",
       "      <td>34624371.txt</td>\n",
       "      <td>[Child, *Heart Failure/complications, Humans, ...</td>\n",
       "      <td>This 6-year-old child was admitted to the hosp...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>681</th>\n",
       "      <td>34962097_2.txt</td>\n",
       "      <td>[*Heart Failure/complications/drug therapy, Hu...</td>\n",
       "      <td>A 50‐year‐old patient was admitted to the ICCU...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>697</th>\n",
       "      <td>35075099.txt</td>\n",
       "      <td>[Activities of Daily Living, *Cardiomyopathies...</td>\n",
       "      <td>A 53-year-old previously healthy patient witho...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>764</th>\n",
       "      <td>35818131.txt</td>\n",
       "      <td>[Infant, Humans, *Aortic Coarctation/complicat...</td>\n",
       "      <td>The 11‐month‐old infant was admitted to our ho...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>815</th>\n",
       "      <td>36345681.txt</td>\n",
       "      <td>[Humans, *Heart-Assist Devices/adverse effects...</td>\n",
       "      <td>A 53‐year‐old African American with Class 1 ob...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>874</th>\n",
       "      <td>37186429.txt</td>\n",
       "      <td>[Humans, *Barth Syndrome/genetics/pathology, *...</td>\n",
       "      <td>The patient was born via spontaneous delivery ...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>910</th>\n",
       "      <td>37701668.txt</td>\n",
       "      <td>[Humans, Cats, Animals, Dogs, Furosemide/adver...</td>\n",
       "      <td>A 2-year-old domestic shorthair cat was presen...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>917</th>\n",
       "      <td>37738714.txt</td>\n",
       "      <td>[Humans, Electrocardiography/methods, Bundle o...</td>\n",
       "      <td>A 72-year-old patient with sinus node disease,...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>926</th>\n",
       "      <td>37840126_1.txt</td>\n",
       "      <td>[Humans, Infant, Newborn, Simendan/pharmacolog...</td>\n",
       "      <td>Patient 1 (P1) had a prenatal diagnosis of sus...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>927</th>\n",
       "      <td>37840126_2.txt</td>\n",
       "      <td>[Humans, Infant, Newborn, Simendan/pharmacolog...</td>\n",
       "      <td>Patient 2 (P2) received no prenatal diagnosis ...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "           filename                                         mesh_terms  \\\n",
       "403    32470181.txt  [*Betacoronavirus, COVID-19, Coronavirus Infec...   \n",
       "435    32729665.txt  [Aortic Valve/diagnostic imaging/surgery, *Hea...   \n",
       "569    33862215.txt  [COVID-19/*complications, Heart Failure/etiolo...   \n",
       "582    34035020.txt  [*Heart Failure, Humans, Infant, *Ventricular ...   \n",
       "641    34624371.txt  [Child, *Heart Failure/complications, Humans, ...   \n",
       "681  34962097_2.txt  [*Heart Failure/complications/drug therapy, Hu...   \n",
       "697    35075099.txt  [Activities of Daily Living, *Cardiomyopathies...   \n",
       "764    35818131.txt  [Infant, Humans, *Aortic Coarctation/complicat...   \n",
       "815    36345681.txt  [Humans, *Heart-Assist Devices/adverse effects...   \n",
       "874    37186429.txt  [Humans, *Barth Syndrome/genetics/pathology, *...   \n",
       "910    37701668.txt  [Humans, Cats, Animals, Dogs, Furosemide/adver...   \n",
       "917    37738714.txt  [Humans, Electrocardiography/methods, Bundle o...   \n",
       "926  37840126_1.txt  [Humans, Infant, Newborn, Simendan/pharmacolog...   \n",
       "927  37840126_2.txt  [Humans, Infant, Newborn, Simendan/pharmacolog...   \n",
       "\n",
       "                                                  text   gender  \n",
       "403  Briefly, the patient was admitted on January 2...  Unknown  \n",
       "435  During this period, 11 (11%) patients received...  Unknown  \n",
       "569  A 50-year-old patient, six years post-heart tr...  Unknown  \n",
       "582  A 5-month-old infant with poor weight gain was...  Unknown  \n",
       "641  This 6-year-old child was admitted to the hosp...  Unknown  \n",
       "681  A 50‐year‐old patient was admitted to the ICCU...  Unknown  \n",
       "697  A 53-year-old previously healthy patient witho...  Unknown  \n",
       "764  The 11‐month‐old infant was admitted to our ho...  Unknown  \n",
       "815  A 53‐year‐old African American with Class 1 ob...  Unknown  \n",
       "874  The patient was born via spontaneous delivery ...  Unknown  \n",
       "910  A 2-year-old domestic shorthair cat was presen...  Unknown  \n",
       "917  A 72-year-old patient with sinus node disease,...  Unknown  \n",
       "926  Patient 1 (P1) had a prenatal diagnosis of sus...  Unknown  \n",
       "927  Patient 2 (P2) received no prenatal diagnosis ...  Unknown  "
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_meta_list[df_meta_list.gender == \"Unknown\"]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Age"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "age_group\n",
       "G - 45-64 years    322\n",
       "H - 65+ years      241\n",
       "F - 19-44 years    211\n",
       "I - 80+ years       73\n",
       "E - 19-24 years     44\n",
       "D - 13-18 years     32\n",
       "C - 6-12 years      27\n",
       "A - 1 year          20\n",
       "B - 2-5 years       16\n",
       "Unknown             14\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "d_ages = {\n",
    "            \"Newborn\": \"birth-1 month\",\n",
    "            \"Infant\": \"A - 1 year\",\n",
    "            \"Preschool Child\": \"B - 2-5 years\",\n",
    "            \"Child\": \"C - 6-12 years\",\n",
    "            \"Adolescent\": \"D - 13-18 years\",\n",
    "            \"Young Adult\": \"E - 19-24 years\",\n",
    "            \"Adult\": \"F - 19-44 years\",\n",
    "            \"Middle Aged\": \"G - 45-64 years\",\n",
    "            \"Aged\": \"H - 65+ years\",\n",
    "            \"Aged, 80 and over\": \"I - 80+ years\"}\n",
    "\n",
    "\n",
    "def filter_preferences(ls_ages):\n",
    "    for i in range(len(d_ages)):\n",
    "        if list(d_ages.keys())[i] in ls_ages:\n",
    "            return [list(d_ages.keys())[i]]\n",
    "    return []\n",
    "\n",
    "def bucket_age(x):\n",
    "    if x is None:\n",
    "        return None\n",
    "    x = int(x)\n",
    "    if x < 1:\n",
    "        return \"Newborn\"\n",
    "    elif x < 2:\n",
    "        return \"Infant\"\n",
    "    elif x < 6:\n",
    "        return \"Preschool Child\"\n",
    "    elif x < 13:\n",
    "        return \"Child\"\n",
    "    elif x < 19:\n",
    "        return \"Adolescent\"\n",
    "    elif x < 25:\n",
    "        return \"Young Adult\"\n",
    "    elif x < 45:\n",
    "        return \"Adult\"\n",
    "    elif x < 65:\n",
    "        return \"Middle Aged\"\n",
    "    elif x < 80:\n",
    "        return \"Aged\"\n",
    "    else:\n",
    "        return \"Aged, 80 and over\"\n",
    "\n",
    "df_meta_list.loc[:, \"age\"] = df_meta_list.loc[:, \"text\"].apply(lambda x: re.findall(r\"(\\d+)\\W+year|(\\d+).year.old\", x)).apply(lambda x: x[0][0] if len(x) > 0 else None).values\n",
    "\n",
    "df_meta_list[\"age_desc\"] = df_meta_list[\"mesh_terms\"].apply(filter_preferences)\n",
    "df_meta_list[\"desc_len\"] = df_meta_list[\"age_desc\"].str.len()\n",
    "\n",
    "df_meta_list[\"age_group\"] = df_meta_list[\"age\"].apply(bucket_age)\n",
    "df_meta_list.loc[df_meta_list[\"age_group\"].isnull(), \"age_group\"] = df_meta_list.loc[df_meta_list[\"age_group\"].isnull(), \"age_desc\"].apply(lambda x: x[0] if len(x) > 0 else \"Unknown\")\n",
    "\n",
    "df_meta_list[\"age_group\"] = df_meta_list[\"age_group\"].map(d_ages).fillna(\"Unknown\")\n",
    "\n",
    "df_meta_list[\"age_group\"].value_counts()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th>gender</th>\n",
       "      <th>Female</th>\n",
       "      <th>Male</th>\n",
       "      <th>Unknown</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>age_group</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1 year</th>\n",
       "      <td>5.0</td>\n",
       "      <td>13.0</td>\n",
       "      <td>2.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2-5 years</th>\n",
       "      <td>10.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>2.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6-12 years</th>\n",
       "      <td>11.0</td>\n",
       "      <td>15.0</td>\n",
       "      <td>1.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13-18 years</th>\n",
       "      <td>13.0</td>\n",
       "      <td>19.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19-24 years</th>\n",
       "      <td>21.0</td>\n",
       "      <td>23.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19-44 years</th>\n",
       "      <td>109.0</td>\n",
       "      <td>102.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45-64 years</th>\n",
       "      <td>129.0</td>\n",
       "      <td>189.0</td>\n",
       "      <td>4.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65+ years</th>\n",
       "      <td>89.0</td>\n",
       "      <td>151.0</td>\n",
       "      <td>1.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>80+ years</th>\n",
       "      <td>32.0</td>\n",
       "      <td>41.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Unknown</th>\n",
       "      <td>5.0</td>\n",
       "      <td>5.0</td>\n",
       "      <td>4.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "gender       Female   Male  Unknown\n",
       "age_group                          \n",
       "1 year          5.0   13.0      2.0\n",
       "2-5 years      10.0    4.0      2.0\n",
       "6-12 years     11.0   15.0      1.0\n",
       "13-18 years    13.0   19.0      0.0\n",
       "19-24 years    21.0   23.0      0.0\n",
       "19-44 years   109.0  102.0      0.0\n",
       "45-64 years   129.0  189.0      4.0\n",
       "65+ years      89.0  151.0      1.0\n",
       "80+ years      32.0   41.0      0.0\n",
       "Unknown         5.0    5.0      4.0"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_plot_gender = df_meta_list.groupby(\"gender\")[\"age_group\"].value_counts().unstack().T.sort_index(ascending=True).fillna(0)\n",
    "df_plot_gender.index = df_plot_gender.index.str.split(\" - \").str[1].fillna(\"Unknown\")\n",
    "df_plot_gender"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1500x600 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import numpy as np\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "\n",
    "# Use a predefined Seaborn palette\n",
    "# sns.set_palette(\"deep\")\n",
    "# Increase font size\n",
    "# sns.set(font_scale=1.5)\n",
    "\n",
    "plt.rcParams.update({'font.size': 15})\n",
    "\n",
    "fig, ax = plt.subplots(1, 2, figsize=(15, 6))\n",
    "\n",
    "# Create the bar plot for age group distribution by gender\n",
    "bar_plot = df_plot_gender.plot(kind=\"bar\", stacked=False, \n",
    "                               title=\"Age group distribution by sex\", ax=ax[0])\n",
    "ax[0].set_xticklabels(ax[0].get_xticklabels(), rotation=45)\n",
    "ax[0].set_xlabel(\"Age\")\n",
    "ax[0].set_ylabel(\"Count\")\n",
    "\n",
    "# Annotate each bar with its absolute value\n",
    "# for container in ax[0].containers:\n",
    "#     ax[0].bar_label(container, label_type='edge')  # This will display the numeric value on top of each bar\n",
    "\n",
    "# For the pie chart, define a custom function to show absolute counts\n",
    "totals = df_plot_gender.sum()\n",
    "\n",
    "def absolute_value_autopct(pct):\n",
    "    total = totals.sum()\n",
    "    absolute = int(round(pct/100. * total))\n",
    "    return f\"{absolute}\\n{pct:.2f}%\"\n",
    "\n",
    "totals.plot(kind=\"pie\", autopct=absolute_value_autopct, \n",
    "            title=\"Sex distribution\", ax=ax[1], startangle=90, shadow=True, radius=1)\n",
    "\n",
    "\n",
    "plt.tight_layout()\n",
    "plt.savefig(\"img/data_analysis/group-gender.png\")\n",
    "plt.show()\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
